WO2021009713A1 - Process of incorporation of functional molecules within freeze-dried dressing - Google Patents
Process of incorporation of functional molecules within freeze-dried dressing Download PDFInfo
- Publication number
- WO2021009713A1 WO2021009713A1 PCT/IB2020/056710 IB2020056710W WO2021009713A1 WO 2021009713 A1 WO2021009713 A1 WO 2021009713A1 IB 2020056710 W IB2020056710 W IB 2020056710W WO 2021009713 A1 WO2021009713 A1 WO 2021009713A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- growth factor
- layer
- wound dressing
- fibroblast growth
- wound
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 123
- 230000008569 process Effects 0.000 title claims description 10
- 238000010348 incorporation Methods 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 279
- 102000008186 Collagen Human genes 0.000 claims abstract description 120
- 108010035532 Collagen Proteins 0.000 claims abstract description 120
- 229920001436 collagen Polymers 0.000 claims abstract description 120
- 229920002201 Oxidized cellulose Polymers 0.000 claims abstract description 53
- 229940107304 oxidized cellulose Drugs 0.000 claims abstract description 53
- 206010052428 Wound Diseases 0.000 claims description 249
- 208000027418 Wounds and injury Diseases 0.000 claims description 249
- 238000009472 formulation Methods 0.000 claims description 131
- -1 silk Polymers 0.000 claims description 56
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
- 239000011248 coating agent Substances 0.000 claims description 29
- 238000000576 coating method Methods 0.000 claims description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 21
- 238000004108 freeze drying Methods 0.000 claims description 18
- 239000004014 plasticizer Substances 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 15
- 239000013543 active substance Substances 0.000 claims description 14
- 239000004627 regenerated cellulose Substances 0.000 claims description 13
- 241000283690 Bos taurus Species 0.000 claims description 12
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 12
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 12
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 claims description 12
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims description 12
- 239000003086 colorant Substances 0.000 claims description 12
- 239000011230 binding agent Substances 0.000 claims description 11
- 239000002781 deodorant agent Substances 0.000 claims description 11
- 238000000151 deposition Methods 0.000 claims description 11
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 11
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 10
- 239000004599 antimicrobial Substances 0.000 claims description 10
- HDDLVZWGOPWKFW-UHFFFAOYSA-N trimethyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound COC(=O)CC(O)(C(=O)OC)CC(=O)OC HDDLVZWGOPWKFW-UHFFFAOYSA-N 0.000 claims description 10
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims description 9
- 239000001913 cellulose Substances 0.000 claims description 9
- 229920002678 cellulose Polymers 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 239000003102 growth factor Substances 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 239000001069 triethyl citrate Substances 0.000 claims description 9
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims description 9
- 235000013769 triethyl citrate Nutrition 0.000 claims description 9
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 8
- 229920001661 Chitosan Polymers 0.000 claims description 8
- 102000001187 Collagen Type III Human genes 0.000 claims description 8
- 108010069502 Collagen Type III Proteins 0.000 claims description 8
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 8
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 8
- 102000004042 Fibroblast Growth Factor-23 Human genes 0.000 claims description 8
- 108090000569 Fibroblast Growth Factor-23 Proteins 0.000 claims description 8
- 102000004864 Fibroblast growth factor 10 Human genes 0.000 claims description 8
- 108090001047 Fibroblast growth factor 10 Proteins 0.000 claims description 8
- 102000014252 Fibroblast growth factor 11 Human genes 0.000 claims description 8
- 108050003237 Fibroblast growth factor 11 Proteins 0.000 claims description 8
- 102000014250 Fibroblast growth factor 12 Human genes 0.000 claims description 8
- 108050003239 Fibroblast growth factor 12 Proteins 0.000 claims description 8
- 102000003685 Fibroblast growth factor 14 Human genes 0.000 claims description 8
- 108090000046 Fibroblast growth factor 14 Proteins 0.000 claims description 8
- 101710153363 Fibroblast growth factor 15 Proteins 0.000 claims description 8
- 102000012570 Fibroblast growth factor 16 Human genes 0.000 claims description 8
- 108050002072 Fibroblast growth factor 16 Proteins 0.000 claims description 8
- 102000012565 Fibroblast growth factor 17 Human genes 0.000 claims description 8
- 108050002074 Fibroblast growth factor 17 Proteins 0.000 claims description 8
- 102100031734 Fibroblast growth factor 19 Human genes 0.000 claims description 8
- 101710153349 Fibroblast growth factor 19 Proteins 0.000 claims description 8
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 8
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 8
- 102000012558 Fibroblast growth factor 20 Human genes 0.000 claims description 8
- 108050002085 Fibroblast growth factor 20 Proteins 0.000 claims description 8
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims description 8
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims description 8
- 102000012548 Fibroblast growth factor 22 Human genes 0.000 claims description 8
- 108050002062 Fibroblast growth factor 22 Proteins 0.000 claims description 8
- 102000003975 Fibroblast growth factor 3 Human genes 0.000 claims description 8
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 claims description 8
- 102000003969 Fibroblast growth factor 4 Human genes 0.000 claims description 8
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 claims description 8
- 102000003967 Fibroblast growth factor 5 Human genes 0.000 claims description 8
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 8
- 102000003968 Fibroblast growth factor 6 Human genes 0.000 claims description 8
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 claims description 8
- 102000003956 Fibroblast growth factor 8 Human genes 0.000 claims description 8
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 claims description 8
- 102000003957 Fibroblast growth factor 9 Human genes 0.000 claims description 8
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 claims description 8
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 claims description 8
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 8
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 8
- 229920002125 Sokalan® Polymers 0.000 claims description 8
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
- 229920001222 biopolymer Polymers 0.000 claims description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 8
- 102000003684 fibroblast growth factor 13 Human genes 0.000 claims description 8
- 108090000047 fibroblast growth factor 13 Proteins 0.000 claims description 8
- 102000003977 fibroblast growth factor 18 Human genes 0.000 claims description 8
- 108090000370 fibroblast growth factor 18 Proteins 0.000 claims description 8
- 229940029303 fibroblast growth factor-1 Drugs 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 229940014259 gelatin Drugs 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 8
- 229920002674 hyaluronan Polymers 0.000 claims description 8
- 229960003160 hyaluronic acid Drugs 0.000 claims description 8
- 238000009581 negative-pressure wound therapy Methods 0.000 claims description 8
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 206010048038 Wound infection Diseases 0.000 claims description 7
- 229960000583 acetic acid Drugs 0.000 claims description 7
- 235000011054 acetic acid Nutrition 0.000 claims description 7
- 230000008021 deposition Effects 0.000 claims description 7
- 229920001610 polycaprolactone Polymers 0.000 claims description 7
- 239000004632 polycaprolactone Substances 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 7
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 6
- 229920000153 Povidone-iodine Polymers 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 230000035876 healing Effects 0.000 claims description 6
- 229960001621 povidone-iodine Drugs 0.000 claims description 6
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 5
- BSXJTDJJVULBTQ-UHFFFAOYSA-N 2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononan-1-ol Chemical compound OCC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F BSXJTDJJVULBTQ-UHFFFAOYSA-N 0.000 claims description 5
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical compound CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims description 5
- 239000004804 Butyryltrihexylcitrate Substances 0.000 claims description 5
- 102000012422 Collagen Type I Human genes 0.000 claims description 5
- 108010022452 Collagen Type I Proteins 0.000 claims description 5
- XKGDWZQXVZSXAO-ADYSOMBNSA-N Ricinoleic Acid methyl ester Chemical compound CCCCCC[C@@H](O)C\C=C/CCCCCCCC(=O)OC XKGDWZQXVZSXAO-ADYSOMBNSA-N 0.000 claims description 5
- XKGDWZQXVZSXAO-SFHVURJKSA-N Ricinolsaeure-methylester Natural products CCCCCC[C@H](O)CC=CCCCCCCCC(=O)OC XKGDWZQXVZSXAO-SFHVURJKSA-N 0.000 claims description 5
- 235000010208 anthocyanin Nutrition 0.000 claims description 5
- 239000004410 anthocyanin Substances 0.000 claims description 5
- 229930002877 anthocyanin Natural products 0.000 claims description 5
- 150000004636 anthocyanins Chemical class 0.000 claims description 5
- 239000003125 aqueous solvent Substances 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
- XKGDWZQXVZSXAO-UHFFFAOYSA-N ricinoleic acid methyl ester Natural products CCCCCCC(O)CC=CCCCCCCCC(=O)OC XKGDWZQXVZSXAO-UHFFFAOYSA-N 0.000 claims description 5
- WEAPVABOECTMGR-UHFFFAOYSA-N triethyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCOC(=O)CC(C(=O)OCC)(OC(C)=O)CC(=O)OCC WEAPVABOECTMGR-UHFFFAOYSA-N 0.000 claims description 5
- TUUQISRYLMFKOG-UHFFFAOYSA-N trihexyl 2-acetyloxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCOC(=O)CC(C(=O)OCCCCCC)(OC(C)=O)CC(=O)OCCCCCC TUUQISRYLMFKOG-UHFFFAOYSA-N 0.000 claims description 5
- AMMPRZCMKXDUNE-UHFFFAOYSA-N trihexyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCOC(=O)CC(O)(C(=O)OCCCCCC)CC(=O)OCCCCCC AMMPRZCMKXDUNE-UHFFFAOYSA-N 0.000 claims description 5
- APVVRLGIFCYZHJ-UHFFFAOYSA-N trioctyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound CCCCCCCCOC(=O)CC(O)(C(=O)OCCCCCCCC)CC(=O)OCCCCCCCC APVVRLGIFCYZHJ-UHFFFAOYSA-N 0.000 claims description 5
- VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 claims description 4
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 4
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 4
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 229920000936 Agarose Polymers 0.000 claims description 4
- CEZCCHQBSQPRMU-LLIZZRELSA-L Allura red AC Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1\N=N\C1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-LLIZZRELSA-L 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- 239000005995 Aluminium silicate Substances 0.000 claims description 4
- 240000005528 Arctium lappa Species 0.000 claims description 4
- 235000003130 Arctium lappa Nutrition 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 4
- 244000017106 Bixa orellana Species 0.000 claims description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 4
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 4
- 235000014375 Curcuma Nutrition 0.000 claims description 4
- 108010002069 Defensins Proteins 0.000 claims description 4
- 102000000541 Defensins Human genes 0.000 claims description 4
- 229920002307 Dextran Polymers 0.000 claims description 4
- 102000009123 Fibrin Human genes 0.000 claims description 4
- 108010073385 Fibrin Proteins 0.000 claims description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 4
- 108010049003 Fibrinogen Proteins 0.000 claims description 4
- 102000008946 Fibrinogen Human genes 0.000 claims description 4
- 102100028412 Fibroblast growth factor 10 Human genes 0.000 claims description 4
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 4
- 102000006492 Histatins Human genes 0.000 claims description 4
- 108010019494 Histatins Proteins 0.000 claims description 4
- 101000917237 Homo sapiens Fibroblast growth factor 10 Proteins 0.000 claims description 4
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 claims description 4
- 244000025221 Humulus lupulus Species 0.000 claims description 4
- 235000008694 Humulus lupulus Nutrition 0.000 claims description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 4
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 240000003183 Manihot esculenta Species 0.000 claims description 4
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 claims description 4
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 claims description 4
- 108010053775 Nisin Proteins 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 4
- 229920002413 Polyhexanide Polymers 0.000 claims description 4
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 claims description 4
- 241000235070 Saccharomyces Species 0.000 claims description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 4
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 240000002657 Thymus vulgaris Species 0.000 claims description 4
- 235000007303 Thymus vulgaris Nutrition 0.000 claims description 4
- 150000001252 acrylic acid derivatives Chemical class 0.000 claims description 4
- 229940072056 alginate Drugs 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000012741 allura red AC Nutrition 0.000 claims description 4
- 239000004191 allura red AC Substances 0.000 claims description 4
- 235000012211 aluminium silicate Nutrition 0.000 claims description 4
- 235000012665 annatto Nutrition 0.000 claims description 4
- 239000010362 annatto Substances 0.000 claims description 4
- 235000010233 benzoic acid Nutrition 0.000 claims description 4
- 229960004365 benzoic acid Drugs 0.000 claims description 4
- 229920001400 block copolymer Polymers 0.000 claims description 4
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 claims description 4
- 229960001631 carbomer Drugs 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 4
- 239000000679 carrageenan Substances 0.000 claims description 4
- 229920001525 carrageenan Polymers 0.000 claims description 4
- 235000010418 carrageenan Nutrition 0.000 claims description 4
- 229940113118 carrageenan Drugs 0.000 claims description 4
- POIUWJQBRNEFGX-XAMSXPGMSA-N cathelicidin Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(C)C)C1=CC=CC=C1 POIUWJQBRNEFGX-XAMSXPGMSA-N 0.000 claims description 4
- 229940045110 chitosan Drugs 0.000 claims description 4
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 4
- 235000015165 citric acid Nutrition 0.000 claims description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 4
- IINNWAYUJNWZRM-UHFFFAOYSA-L erythrosin B Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(I)C(=O)C(I)=C2OC2=C(I)C([O-])=C(I)C=C21 IINNWAYUJNWZRM-UHFFFAOYSA-L 0.000 claims description 4
- 235000012732 erythrosine Nutrition 0.000 claims description 4
- 239000004174 erythrosine Substances 0.000 claims description 4
- 229940011411 erythrosine Drugs 0.000 claims description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 4
- 229950003499 fibrin Drugs 0.000 claims description 4
- 229940012952 fibrinogen Drugs 0.000 claims description 4
- 229940098448 fibroblast growth factor 7 Drugs 0.000 claims description 4
- 239000000576 food coloring agent Substances 0.000 claims description 4
- 229920000669 heparin Polymers 0.000 claims description 4
- 229960002897 heparin Drugs 0.000 claims description 4
- 235000012907 honey Nutrition 0.000 claims description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 4
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 239000010445 mica Substances 0.000 claims description 4
- 229910052618 mica group Inorganic materials 0.000 claims description 4
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 4
- 239000004311 natamycin Substances 0.000 claims description 4
- 235000010298 natamycin Nutrition 0.000 claims description 4
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 claims description 4
- 229960003255 natamycin Drugs 0.000 claims description 4
- 239000004309 nisin Substances 0.000 claims description 4
- 235000010297 nisin Nutrition 0.000 claims description 4
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 4
- 239000004584 polyacrylic acid Substances 0.000 claims description 4
- 239000004633 polyglycolic acid Substances 0.000 claims description 4
- 235000019260 propionic acid Nutrition 0.000 claims description 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 4
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 4
- 235000010199 sorbic acid Nutrition 0.000 claims description 4
- 239000004334 sorbic acid Substances 0.000 claims description 4
- 229940075582 sorbic acid Drugs 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims description 4
- 235000012756 tartrazine Nutrition 0.000 claims description 4
- 239000004149 tartrazine Substances 0.000 claims description 4
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 claims description 4
- 229960000943 tartrazine Drugs 0.000 claims description 4
- 239000001585 thymus vulgaris Substances 0.000 claims description 4
- 239000004408 titanium dioxide Substances 0.000 claims description 4
- 229950003937 tolonium Drugs 0.000 claims description 4
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 claims description 4
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 claims description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 4
- GAWWVVGZMLGEIW-GNNYBVKZSA-L zinc ricinoleate Chemical compound [Zn+2].CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O.CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O GAWWVVGZMLGEIW-GNNYBVKZSA-L 0.000 claims description 4
- 229940100530 zinc ricinoleate Drugs 0.000 claims description 4
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 3
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 3
- 229920002627 poly(phosphazenes) Polymers 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 244000164439 Curcuma angustifolia Species 0.000 claims 2
- 108700022109 ropocamptide Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 description 57
- 210000004027 cell Anatomy 0.000 description 10
- 239000002002 slurry Substances 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 230000000670 limiting effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 239000000835 fiber Substances 0.000 description 7
- 239000004332 silver Substances 0.000 description 7
- 229910052709 silver Inorganic materials 0.000 description 7
- 229940100890 silver compound Drugs 0.000 description 7
- 150000003379 silver compounds Chemical class 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 238000007710 freezing Methods 0.000 description 6
- 230000008014 freezing Effects 0.000 description 6
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000004365 Protease Substances 0.000 description 5
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000002354 daily effect Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 230000037373 wrinkle formation Effects 0.000 description 5
- 208000025865 Ulcer Diseases 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- XMOCLSLCDHWDHP-IUODEOHRSA-N epi-Gallocatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-IUODEOHRSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000000503 Collagen Type II Human genes 0.000 description 2
- 108010041390 Collagen Type II Proteins 0.000 description 2
- 244000163122 Curcuma domestica Species 0.000 description 2
- 206010056340 Diabetic ulcer Diseases 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 2
- XMOCLSLCDHWDHP-UHFFFAOYSA-N L-Epigallocatechin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C1=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000000558 Varicose Ulcer Diseases 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940096423 bovine collagen type i Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- VEVZSMAEJFVWIL-UHFFFAOYSA-O cyanidin cation Chemical compound [O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC=C(O)C(O)=C1 VEVZSMAEJFVWIL-UHFFFAOYSA-O 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- WFPZPJSADLPSON-UHFFFAOYSA-N dinitrogen tetraoxide Chemical compound [O-][N+](=O)[N+]([O-])=O WFPZPJSADLPSON-UHFFFAOYSA-N 0.000 description 2
- DZYNKLUGCOSVKS-UHFFFAOYSA-N epigallocatechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3cc(O)c(O)c(O)c3 DZYNKLUGCOSVKS-UHFFFAOYSA-N 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000007421 fluorometric assay Methods 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- KZMACGJDUUWFCH-UHFFFAOYSA-O malvidin Chemical compound COC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 KZMACGJDUUWFCH-UHFFFAOYSA-O 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 150000003378 silver Chemical class 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- XMOCLSLCDHWDHP-SWLSCSKDSA-N (+)-Epigallocatechin Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC(O)=C(O)C(O)=C1 XMOCLSLCDHWDHP-SWLSCSKDSA-N 0.000 description 1
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 description 1
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- FTVWIRXFELQLPI-CYBMUJFWSA-N (R)-naringenin Chemical compound C1=CC(O)=CC=C1[C@@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-CYBMUJFWSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 1
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- WFOMQSXGCDVIEY-UHFFFAOYSA-N 4-aminobenzoic acid;silver Chemical compound [Ag].NC1=CC=C(C(O)=O)C=C1 WFOMQSXGCDVIEY-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- YAMJITULHOEKMI-UHFFFAOYSA-N B([O-])([O-])[O-].[Ag+3] Chemical compound B([O-])([O-])[O-].[Ag+3] YAMJITULHOEKMI-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- YDDGKXBLOXEEMN-IABMMNSOSA-L Chicoric acid Natural products C1=C(O)C(O)=CC=C1\C=C\C(=O)O[C@@H](C([O-])=O)[C@H](C([O-])=O)OC(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-L 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- GCPYCNBGGPHOBD-UHFFFAOYSA-N Delphinidin Natural products OC1=Cc2c(O)cc(O)cc2OC1=C3C=C(O)C(=O)C(=C3)O GCPYCNBGGPHOBD-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- YDDGKXBLOXEEMN-UHFFFAOYSA-N Di-E-caffeoyl-meso-tartaric acid Natural products C=1C=C(O)C(O)=CC=1C=CC(=O)OC(C(O)=O)C(C(=O)O)OC(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-UHFFFAOYSA-N 0.000 description 1
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 description 1
- 229920002079 Ellagic acid Polymers 0.000 description 1
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 1
- GQODBWLKUWYOFX-UHFFFAOYSA-N Isorhamnetin Natural products C1=C(O)C(C)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 GQODBWLKUWYOFX-UHFFFAOYSA-N 0.000 description 1
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 1
- MZSGWZGPESCJAN-MOBFUUNNSA-N Melitric acid A Natural products O([C@@H](C(=O)O)Cc1cc(O)c(O)cc1)C(=O)/C=C/c1cc(O)c(O/C(/C(=O)O)=C/c2cc(O)c(O)cc2)cc1 MZSGWZGPESCJAN-MOBFUUNNSA-N 0.000 description 1
- IKMDFBPHZNJCSN-UHFFFAOYSA-N Myricetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC(O)=C(O)C(O)=C1 IKMDFBPHZNJCSN-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 102100033174 Neutrophil elastase Human genes 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 229910021612 Silver iodide Inorganic materials 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- SBGJVZHTWCTWBJ-UHFFFAOYSA-N [Ag+]=O Chemical compound [Ag+]=O SBGJVZHTWCTWBJ-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 108010045569 atelocollagen Proteins 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 102000014509 cathelicidin Human genes 0.000 description 1
- 108060001132 cathelicidin Proteins 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- YDDGKXBLOXEEMN-IABMMNSOSA-N chicoric acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)\C=C\C1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-IABMMNSOSA-N 0.000 description 1
- 150000003841 chloride salts Chemical class 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229930016920 cichoric acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920002770 condensed tannin Polymers 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000007336 cyanidin Nutrition 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 235000007242 delphinidin Nutrition 0.000 description 1
- FFNDMZIBVDSQFI-UHFFFAOYSA-N delphinidin chloride Chemical compound [Cl-].[O+]=1C2=CC(O)=CC(O)=C2C=C(O)C=1C1=CC(O)=C(O)C(O)=C1 FFNDMZIBVDSQFI-UHFFFAOYSA-N 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-M deoxycholate Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-M 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- YDDGKXBLOXEEMN-PMACEKPBSA-N dicaffeoyl-D-tartaric acid Natural products O([C@H](C(=O)O)[C@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-PMACEKPBSA-N 0.000 description 1
- YDDGKXBLOXEEMN-WOJBJXKFSA-N dicaffeoyl-L-tartaric acid Natural products O([C@@H](C(=O)O)[C@@H](OC(=O)C=CC=1C=C(O)C(O)=CC=1)C(O)=O)C(=O)C=CC1=CC=C(O)C(O)=C1 YDDGKXBLOXEEMN-WOJBJXKFSA-N 0.000 description 1
- OJKANDGLELGDHV-UHFFFAOYSA-N disilver;dioxido(dioxo)chromium Chemical compound [Ag+].[Ag+].[O-][Cr]([O-])(=O)=O OJKANDGLELGDHV-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229960002852 ellagic acid Drugs 0.000 description 1
- 235000004132 ellagic acid Nutrition 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- 235000012734 epicatechin Nutrition 0.000 description 1
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 description 1
- TUJPOVKMHCLXEL-UHFFFAOYSA-N eriodictyol Natural products C1C(=O)C2=CC(O)=CC(O)=C2OC1C1=CC=C(O)C(O)=C1 TUJPOVKMHCLXEL-UHFFFAOYSA-N 0.000 description 1
- 235000011797 eriodictyol Nutrition 0.000 description 1
- SBHXYTNGIZCORC-ZDUSSCGKSA-N eriodictyol Chemical compound C1([C@@H]2CC(=O)C3=C(O)C=C(C=C3O2)O)=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-ZDUSSCGKSA-N 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- SBHXYTNGIZCORC-UHFFFAOYSA-N eriodyctiol Natural products O1C2=CC(O)=CC(O)=C2C(=O)CC1C1=CC=C(O)C(O)=C1 SBHXYTNGIZCORC-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ANQVKHGDALCPFZ-UHFFFAOYSA-N ethyl 2-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]acetate Chemical compound C1=C2NC(CC(=O)OCC)=NC2=CC=C1N1CCN(C)CC1 ANQVKHGDALCPFZ-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 235000011987 flavanols Nutrition 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 229920002824 gallotannin Polymers 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 235000008466 glycitein Nutrition 0.000 description 1
- DXYUAIFZCFRPTH-UHFFFAOYSA-N glycitein Chemical compound C1=C(O)C(OC)=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 DXYUAIFZCFRPTH-UHFFFAOYSA-N 0.000 description 1
- NNUVCMKMNCKPKN-UHFFFAOYSA-N glycitein Natural products COc1c(O)ccc2OC=C(C(=O)c12)c3ccc(O)cc3 NNUVCMKMNCKPKN-UHFFFAOYSA-N 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 102000052502 human ELANE Human genes 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 235000008800 isorhamnetin Nutrition 0.000 description 1
- IZQSVPBOUDKVDZ-UHFFFAOYSA-N isorhamnetin Chemical compound C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 IZQSVPBOUDKVDZ-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 235000009584 malvidin Nutrition 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- PCOBUQBNVYZTBU-UHFFFAOYSA-N myricetin Natural products OC1=C(O)C(O)=CC(C=2OC3=CC(O)=C(O)C(O)=C3C(=O)C=2)=C1 PCOBUQBNVYZTBU-UHFFFAOYSA-N 0.000 description 1
- 235000007743 myricetin Nutrition 0.000 description 1
- 229940116852 myricetin Drugs 0.000 description 1
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 1
- 235000007625 naringenin Nutrition 0.000 description 1
- 229940117954 naringenin Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- HKUHOPQRJKPJCJ-UHFFFAOYSA-N pelargonidin Natural products OC1=Cc2c(O)cc(O)cc2OC1c1ccc(O)cc1 HKUHOPQRJKPJCJ-UHFFFAOYSA-N 0.000 description 1
- 235000006251 pelargonidin Nutrition 0.000 description 1
- YPVZJXMTXCOTJN-UHFFFAOYSA-N pelargonidin chloride Chemical compound [Cl-].C1=CC(O)=CC=C1C(C(=C1)O)=[O+]C2=C1C(O)=CC(O)=C2 YPVZJXMTXCOTJN-UHFFFAOYSA-N 0.000 description 1
- 229930015721 peonidin Natural products 0.000 description 1
- 235000006404 peonidin Nutrition 0.000 description 1
- OGBSHLKSHNAPEW-UHFFFAOYSA-N peonidin chloride Chemical compound [Cl-].C1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 OGBSHLKSHNAPEW-UHFFFAOYSA-N 0.000 description 1
- 229930015717 petunidin Natural products 0.000 description 1
- 235000006384 petunidin Nutrition 0.000 description 1
- QULMBDNPZCFSPR-UHFFFAOYSA-N petunidin chloride Chemical compound [Cl-].OC1=C(O)C(OC)=CC(C=2C(=CC=3C(O)=CC(O)=CC=3[O+]=2)O)=C1 QULMBDNPZCFSPR-UHFFFAOYSA-N 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 125000000075 primary alcohol group Chemical group 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- VLEUZFDZJKSGMX-ONEGZZNKSA-N pterostilbene Chemical compound COC1=CC(OC)=CC(\C=C\C=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-ONEGZZNKSA-N 0.000 description 1
- VLEUZFDZJKSGMX-UHFFFAOYSA-N pterostilbene Natural products COC1=CC(OC)=CC(C=CC=2C=CC(O)=CC=2)=C1 VLEUZFDZJKSGMX-UHFFFAOYSA-N 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000003385 ring cleavage reaction Methods 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- NBYLLBXLDOPANK-UHFFFAOYSA-M silver 2-carboxyphenolate hydrate Chemical compound C1=CC=C(C(=C1)C(=O)O)[O-].O.[Ag+] NBYLLBXLDOPANK-UHFFFAOYSA-M 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- ADZWSOLPGZMUMY-UHFFFAOYSA-M silver bromide Chemical compound [Ag]Br ADZWSOLPGZMUMY-UHFFFAOYSA-M 0.000 description 1
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 1
- 229910001958 silver carbonate Inorganic materials 0.000 description 1
- 229940071575 silver citrate Drugs 0.000 description 1
- 229940045105 silver iodide Drugs 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 1
- 229910000367 silver sulfate Inorganic materials 0.000 description 1
- LMEWRZSPCQHBOB-UHFFFAOYSA-M silver;2-hydroxypropanoate Chemical compound [Ag+].CC(O)C([O-])=O LMEWRZSPCQHBOB-UHFFFAOYSA-M 0.000 description 1
- OABJRIZQBSJBGD-UHFFFAOYSA-M silver;5-amino-2-carboxyphenolate Chemical compound [Ag+].NC1=CC=C(C([O-])=O)C(O)=C1 OABJRIZQBSJBGD-UHFFFAOYSA-M 0.000 description 1
- MNMYRUHURLPFQW-UHFFFAOYSA-M silver;dodecanoate Chemical compound [Ag+].CCCCCCCCCCCC([O-])=O MNMYRUHURLPFQW-UHFFFAOYSA-M 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 235000008603 tangeritin Nutrition 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- 229940026509 theaflavin Drugs 0.000 description 1
- 235000008118 thearubigins Nutrition 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- QUTYHQJYVDNJJA-UHFFFAOYSA-K trisilver;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ag+].[Ag+].[Ag+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QUTYHQJYVDNJJA-UHFFFAOYSA-K 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00987—Apparatus or processes for manufacturing non-adhesive dressings or bandages
- A61F13/00991—Apparatus or processes for manufacturing non-adhesive dressings or bandages for treating webs, e.g. for moisturising, coating, impregnating or applying powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/01—Non-adhesive bandages or dressings
- A61F13/01008—Non-adhesive bandages or dressings characterised by the material
- A61F13/01012—Non-adhesive bandages or dressings characterised by the material being made of natural material, e.g. cellulose-, protein-, collagen-based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/225—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/425—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
Definitions
- the present technology relates generally to wound dressing compositions including a mixture of a collagen and an oxidized cellulose and including a coating comprising functional molecules that is disposed adjacent to a wound-facing surface. Methods of manufacture and use as well as kits regarding the same are also provided.
- the intricate process of wound healing involves the activation of numerous biological pathways that work in concert to regenerate a tissue microenvironment consisting of cells and extracellular matrix (ECM) with enzymes, cytokines, and growth factors.
- ECM extracellular matrix
- the wound healing process may be divided into the following sequential phases: hemostasis (clotting to stop bleeding), inflammatory response (removal of bacteria and tissue debris from the site of damage), proliferation (cell division to regenerate the tissue, angiogenesis, and matrix deposition), and remodeling (cellular apoptosis and matrix realignment in the newly generated tissue).
- the present disclosure provides a wound dressing composition
- a wound dressing composition comprising a freeze-dried layer with a wound-facing surface and an environmental-facing surface; wherein the freeze-dried layer comprises a first layer comprising a combination of collagen and an oxidized cellulose; and a coating forming a coated layer on the first layer, the coated layer comprising a formulation comprising an effective amount of at least one biologically active agent wherein the wound dressing composition does not visually appear to be wrinkled.
- the formulation is applied to the first layer before freeze drying the first layer.
- the coated layer has an average thickness of about 0.01 mih, about 0.03 mih, about 0.1 mih, about 0.3 mih, about 0.6 mih, about 1 mih, about 2 mih, about 5 mih, about 10 mih, about 15 mih, about 30 mih, about 50 mih, about 75 mm, about 100 mih, about 150 mih, about 200 mm, about 300 mih, about 400 mm, about 500 mih, about 600 mih, about 800 mm, or about 1,000 mih, or any range including and/or in between any two of these values.
- the coated layer has an average thickness of about 0.1 mih to about 1 mih, about 0.3 mih to about 3 mih, about 1 mih to about 10 mih, about 3 mih to about 30 mih, about 10 mih to about 100 mih, about 30 mih to about 300 mih, or about 100 mih to about 1000 mih.
- the wound dressing is resistant to structural changes compared to a control dressing that includes a collagen and an oxidized cellulose that has been freeze-dried and has been coated with the same formulation.
- the control dressing is coated with the formulation via spray coating or coating with a brush.
- the oxidized cellulose may be oxidized regenerated cellulose (ORC).
- the formulation is applied at a temperature of about 40 °C, about 45 °C, about 50 °C, about 55 °C, about 60 °C, about 65 °C, about 70 °C, about 75 °C, about 80 °C, or any range including and/or in between any two of these values.
- the formulation is applied at a temperature of about 40 °C to about 50 °C, about 45 °C to about 55 °C, about 50 °C to about 60 °C, about 55 °C to about 65 °C, about 60 °C to about 70 °C, about 65 °C to about 75 °C, about 70 °C to about 80 °C, or any range including and/or in between any two of these values.
- the first layer is frozen at a temperature between about 0 °C to about -80 °C before application of the formula.
- the first layer is frozen at a temperature of about 0 °C, about -5 °C, about -10 °C, about -15 °C, about -20 °C, about -30 °C, about -40 °C, about -50 °C, about -60 °C, about -70 °C, about -80 °C, or any range including and/or in between any two of these values.
- the first layer is frozen at a temperature between about 0 °C to about -20 °C, about -10 °C to about -30 °C, about -20 °C to about -40 °C, about -30 °C to about -50 °C, about -40 °C to about -60 °C, about -50 °C to about -70 °C, about -60 °C to about -80 °C, or any range including and/or in between any two of these values.
- the first layer may include about 30 wt.% to about 70 wt.% oxidized cellulose.
- the first layer may include oxidized cellulose at about 30 wt.%, about 35 wt.%, about 40 wt.%, about 45 wt.%, about 50 wt.%, about 55 wt.%, about 60 wt.%, about 65 wt.%, about 70 wt.%, or any range including and/or in between any two of the preceding values.
- the first layer may include about 30 wt.% to about 40 wt.%, about 35 wt.% to about 45 wt.%, about 40 wt.% to about 50 wt.%, about 45 wt.% to about 55 wt.%, about 50 wt.% to about 60 wt.%, about 55 wt.% to about 65 wt.%, about 60 wt.% to about 70 wt.% oxidized cellulose, or any range including and/or in between any two of these values.
- the oxidized cellulose may have a weight-average molecular weight of about 50,000 to about 1,000,000. Additionally or alternatively, in some embodiments, the oxidized cellulose may have a weight-average molecular weight of about 50,000, about 60,000, about 75,000, about 100,000, about 150,000, about 200,000, about 250,000, about 300,000, about 400,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, about 1,000,000, or any range including and/or in between any two of the preceding values.
- the oxidized cellulose may have a weight-average molecular weight of about 50,000 to about 200,000, about 100,000 to about 250,000, about 200,000 to about 400,000, about 300,000 to about 500,000, about 400,000 to about 800,000, about 600,000 to about 1,000,000, or any range including and/or in between any two of these values.
- the collagen may be recombinant or naturally occurring. Additionally or alternatively, in some embodiments, the collagen may be a mammalian collagen. Additionally or alternatively, in some embodiments, the mammalian collagen may be a bovine collagen, a human collagen, or any combination thereof. Additionally or alternatively, in some embodiments, the collagen may comprise one or more of type I human recombinant collagen, type III human recombinant collagen, type I bovine collagen, type III bovine collagen, or any combination thereof.
- the first layer may include about 30 wt.% to about 95 wt.% collagen. Additionally or alternatively, in some embodiments, the first layer may include collagen at about 30 wt.%, about 35 wt.%, about 40 wt.%, about 45 wt.%, about 50 wt.%, about 55 wt.%, about 60 wt.%, about 65 wt.%, about 70 wt.%, about 75 wt.%, about 80 wt.%, about 85 wt.%, about 90 wt.%, about 95 wt.% collagen, or any range including and/or in between any two of the preceding values.
- the first layer may include about 30 wt.% to about 45 wt.%, about 40 wt.% to about 55 wt.%, about 50 wt.% to about 65 wt.%, about 60 wt.% to about 75 wt.%, about 70 wt.% to about 85 wt.%, about 80 wt.% to about 95 wt.% collagen, or any range including and/or in between any two of the preceding values.
- the collagen may have a weight-average molecular weight of about 5,000 to about 100,000. Additionally or alternatively, in some embodiments, the collagen may have a weight-average molecular weight of about 5,000, about 6,000, about 7,500, about 10,000, about 15,000, about 20,000, about 25,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, about 100,000, or any range including and/or in between any two of the preceding values.
- the collagen may have a weight- average molecular weight of about 5,000 to about 20,000, about 10,000 to about 25,000, about 20,000 to about 40,000, about 30,000 to about 50,000, about 40,000 to about 80,000, about 60,000 to about 100,000, or any range including and/or in between any two of these values.
- the formulation may include a solvent and an effective amount of at least one agent selected from the group consisting of a growth factor, an antimicrobial agent, a peptide, a biopolymer, and any combination thereof.
- the solvent may be an aqueous solvent or an organic solvent (e.g., water, citric acid, acetic acid etc.).
- the at least one agent may be included at about 0.01 wt.% to about 40 wt.%, or about 0.5 wt.% to about 5 wt.% in the formulation. Additionally or alternatively, in some embodiments, the at least one agent may be included at about 0.01 wt.%, about 0.025 wt.%, about 0.05 wt.%, about 0.1 wt.%, about 0.25 wt.%, about 0.5 wt.%, about 1 wt.%, about 5 wt.%, about 10 wt.%, about 15 wt.%, about 20 wt.%, about 25 wt.%, about 30 wt.%, about 35 wt.%, about 40 wt.% of the formulation, or any range including and/or in between any two of these values.
- the at least one agent may be included about 0.01 wt.% to about 0.1 wt.%, about 0.05 wt.% to about 0.5 wt.%, about 0.1 wt.% to about 1 wt.%, about 0.5 wt.% to about 5 wt.%, about 1 wt.% to about 10 wt.%, about 5 wt.% to about 25 wt.%, about 10 wt.% to about 40 wt.% of the formulation, or any range including and/or in between any two of these values.
- the formulation may include one or more of a binder, a colorant, a deodorant agent, a fdler, a plasticizer, a viscosity modifier, an anti microbial, or any combination thereof.
- the binder may include one or more of hyaluronic acid, chitosan, heparin, alginate, cellulose, fibrin, gelatin, chondroitin sulfate, agarose, dextran, carrageenan, silk, polyethylene glycol), poly(vinyl alcohol), polycaprolactone, polyphophazene, polyglycolic acid, rosin, lactose, sucrose, tapioca starch, polyvinylpyrrolidone, or any combination thereof.
- the colorant comprises one or more of direct red 80, bromophenol blue, toluidine blue, a food coloring, Allura Red AC, Erythrosine, Tartrazine 5, Anthocyanins, Curcuma, Annatto, or any combination thereof.
- the deodorant agent comprises one or more of zinc ricinoleate, triethyl citrate, Saccharomyces ferment, Arctium lappa root extract, Humulus lupulus extract, Thymus vulgaris, or any combination thereof.
- the filler comprises one or more of amorphous silica, mica, kaolin, titanium dioxide, or any combination thereof.
- the plasticizer may include one or more of an acetylated monoglyceride, an alkyl citrate, methyl ricinoleate, glycerol, or any combination thereof.
- the alkyl citrate may be one or more of triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, trioctyl citrate, acetyl trioctyl citrate, trihexyl citrate, acetyl trihexyl citrate, butyryl trihexyl citrate, trimethyl citrate, or any combination thereof.
- the viscosity modifier may include one or more of sodium polyacrylate, acrylates/alkyl methacrylate block copolymers, polyacrylic acid, cellulose gum, hydroxyethylcellulose, stearyl alcohol, carbomer, or any combination thereof.
- the growth factor may include one or more of epidermal growth factor (EGF), hepatocyte growth factor (HGF), fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), or any combination thereof.
- the fibroblast growth factors comprise one or more of fibroblast growth factor 1 (FGF1), fibroblast growth factor 2 (FGF2), fibroblast growth factor 3 (FGF3), fibroblast growth factor 4 (FGF4), fibroblast growth factor 5 (FGF5), fibroblast growth factor 6 (FGF6), fibroblast growth factor 7 / keratinocyte growth factor (FGF7/KGF), fibroblast growth factor 8 (FGF8), fibroblast growth factor 9 (FGF9), fibroblast growth factor 10 / keratinocyte growth factor 2 (FGF10/KGF2), fibroblast growth factor 11 (FGF11), fibroblast growth factor 12 (FGF12), fibroblast growth factor 13 (FGF13), fibroblast growth factor 10 (FGF11), fibroblast growth factor 12 (F
- the antimicrobial agent may include one or more of polyhexamethylene biguanide, acetic acid, benzoic acid, povidone iodine, natamycin, nisin, citric acid, sorbic acid, propionic acid, honey, sulfites, or any combination thereof.
- the peptide may include one or more of defensins, histatins, cathebcidin LL-37, or any combination thereof.
- the biopolymer may include one or more of hyaluronic acid, fibrinogen, a chitosan, a polysaccharide, a gelatin, a collagen, an oxidized cellulose, an oxidized regenerated cellulose (ORC), or any combination thereof.
- the present disclosure provides a method for making a wound dressing composition of any embodiment disclosed herein, the method comprising, heating a formulation to about 40 °C to about 80 °C, depositing the formulation onto a layer comprising a collagen and an oxidized cellulose to form a coated layer, and freezing the coated layer, wherein the coated layer has an average thickness of about 0.1 pm to about 1,000 pm. Additionally or alternatively, in some embodiments, the method further comprises drying the coated layer.
- the coated layer has an average thickness of about 0.1 pm, about 0.3 pm, about 0.6 pm, about 1 pm, about 2 pm, about 5 pm, about 10 pm, about 15 pm, about 30 pm, about 50 pm, about 75 pm, about 100 pm, about 150 pm, about 200 pm, about 300 pm, about 400 pm, about 500 pm, about 600 pm, about 800 pm, or about 1,000 pm, or any range including and/or in between any two of these values.
- the coated layer has an average thickness of about 0.1 pm to about 1 pm, about 0.3 pm to about 3 pm, about 1 pm to about 10 pm, about 3 pm to about 30 pm, about 10 pm to about 100 pm, about 30 pm to about 300 pm, or about 100 pm to about 1000 pm.
- the method comprises heating the formulation to about 40 °C, about 45 °C, about 50 °C, about 55 °C, about 60 °C, about 65 °C, about 70 °C, about 75 °C, about 80 °C, or any range including and/or in between any two of these values.
- the method comprises heating the formulation to about 40 °C to about 50 °C, about 45 °C to about 55 °C, about 50 °C to about 60 °C, about 55 °C to about 65 °C, about 60 °C to about 70 °C, about 65 °C to about 75 °C, about 70 °C to about 80 °C, or any range including and/or in between any two of these values.
- the formulation is heated for a period between about 0.5 min to about 240 min. Additionally or alternatively, in some embodiments, the formulation is heated for a period between about 0.5 min, about 1 min, about 2.5 min, about 5 min, about 7.5 min, about 10 min, about 15 min, about 30 min, about 45 min, about 60 min, about 90 min, about 120 min, about 150 min, about 180 min, about 210 min, about 240 min, or any range including and/or in between any two of these values.
- the formulation is heated for a period between about 0.5 min to about 5 min, about 2 min to about 20 min, about 5 min to about 50 min, about 20 min to about 90 min, about 45 min to about 180 min, about 60 min to about 240 min, or any range including and/or in between any two of these values.
- the first layer may be frozen to form a frozen layer prior to deposition of the formulation, wherein the frozen layer optionally comprises a first surface.
- the first surface of the frozen layer may be melted prior to deposition of the formulation.
- the formulation may be deposited by a spray process or a thin layer application. Additionally or alternatively, in some embodiments, the thin layer application may be carried out by means of a brush.
- the coated layer is frozen at a temperature between about 0 °C to about -80 °C. Additionally or alternatively, in some embodiments, the coated layer is frozen at a temperature of about 0 °C, about -5 °C, about -10 °C, about -15 °C, about -20 °C, about -30 °C, about -40 °C, about -50 °C, about -60 °C, about -70 °C, about -80 °C, or any range including and/or in between any two of these values.
- the coated layer is frozen at a temperature between about 0 °C to about -20 °C, about -10 °C to about -30 °C, about -20 °C to about -40 °C, about -30 °C to about -50 °C, about -40 °C to about -60 °C, about -50 °C to about -70 °C, about -60 °C to about -80 °C, or any range including and/or in between any two of these values.
- the coated layer may be frozen and/or freeze-dried for a period between about 0.1 min to about 10,000 min. Additionally or alternatively, in some embodiments, the coated layer may be frozen and/or freeze-dried for a period between about 0.1 min, about 0.5 min, about 1 min, about 5 min, about 15 min, about 30 min, about 60 min, about 90 min, about 120 min, about 200 min, about 500 min, about 750 min, about 1000 min, about 2000 min, about 4000 min, about 6000 min, about 8000 min, about 10,000 min, or any range including and/or in between any two of these values.
- the coated layer may be frozen and/or freeze-dried for a period between about 0.1 min to about 1 min, about 0.5 min to about 5 min, about 2 min to about 20 min, about 5 min to about 50 min, about 20 min to about 200 min, about 50 min to about 500 min, about 200 min to about 2000 min, about 500 min to about 5000 min, about 1000 min to about 10000 min, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the coated layer may be frozen and/or freeze-dried for at least 30 minutes.
- the present disclosure provides for a wound dressing composition generated by any method disclosed herein.
- the present disclosure provides a method for treating a wound in a subject in need thereof, the method including administering to the wound a wound dressing composition of any embodiment disclosed herein. Additionally or alternatively in some embodiments, the wound dressing composition induces, enhances, or promotes healing in the subject. Additionally or alternatively, in some embodiments, the subject is human.
- the present disclosure provides a method for preventing or reducing the risk of wound infection in a subject in need thereof, the method including administering to the wound a wound dressing composition of any embodiment disclosed herein. Additionally or alternatively in some embodiments, the wound dressing composition induces, enhances, or promotes healing in the subject. Additionally or alternatively, in some embodiments, the subject is human. Additionally or alternatively, in some embodiments, the method further comprises performing negative pressure wound therapy to the wound prior to, concurrently with or after applying the wound dressing.
- kits comprising the wound dressing compositions of any embodiment described herein and instructions for use. Additionally or alternatively, in some embodiments, the kit, further comprises negative pressure wound therapy device.
- the present disclosure provides an apparatus comprising a layer with a wound facing surface and an environmental-facing surface, wherein the freeze-dried layer comprises a first layer comprising a combination of collagen and an oxidized cellulose; and a coating forming a coated layer on the first layer, the coated layer comprising a formulation comprising an effective amount of at least one biologically active agent wherein the wound dressing composition does not visually appear to be wrinkled.
- the formulation is applied to the first layer before freeze drying the first layer.
- the coated layer has an average thickness of about 0.1 pm to about 1,000 pm.
- the formulation is applied at a temperature of about 40 °C to about 80 °C. Additionally or alternatively, in some embodiments, the apparatus is resistant to structural changes compared to a control apparatus that includes a collagen and an oxidized cellulose that has been freeze- dried before coating with the same formulation.
- the present disclosure provides a device for the treatment of wound comprising a layer a layer with a wound-facing surface and an environmental-facing surface, wherein the freeze-dried layer comprises a first layer comprising a combination of collagen and an oxidized cellulose; and a coating forming a coated layer on the first layer, the coated layer comprising a formulation comprising an effective amount of at least one biologically active agent wherein the wound dressing composition does not visually appear to be wrinkled.
- the formulation is applied to the first layer before freeze drying the first layer.
- the coated layer has an average thickness of about 0.1 pm to about 1,000 pm.
- the formulation is applied at a temperature of about 40 °C to about 80 °C. Additionally or alternatively, in some embodiments, the device is resistant to structural changes compared to a device dressing that includes a collagen and an oxidized cellulose that has been freeze-dried before coating with the same formulation.
- the present disclosure provides a method of the treatment of a wound in a subject in need thereof, the method comprising administering to the subject the apparatus disclosed herein or the device for the treatment of wound of any embodiment. Additionally or alternatively, in some embodiments, the method further comprises performing negative pressure wound therapy to the wound prior to, concurrently with or after applying the wound dressing.
- the present disclosure provides a method for preventing or reducing the risk of wound infection in a subject in need thereof, the method comprising administering to the subject the apparatus disclosed herein or the device for the treatment of wound of any embodiment.
- FIG. l shows a flow diagram of exemplary methods to manufacture the wound dressing compositions of the present technology.
- FIG. 2 shows non-limiting representations of specific embodiments of a wound dressing composition of the present technology.
- FIG. 3 shows decreased wrinkle formation in the wound dressing composition of the present technology (right panel), compared to a wound dressing composition that has been initially freeze-dried prior to applying the citric acid coating (left panel).
- the present disclosure is directed to wound dressing compositions which have been coated with a formulation to incorporate functional molecules onto the surface of the wound dressing compositions, and methods for making the same.
- the wound dressing compositions of the present technology do not comprise any wrinkles after coating with the formulation, which can be beneficial for ease of use, product packaging and handling, and can decrease the rate of degradation of the wound dressing upon application to a wound (see Kharkar, P.M. et al. Chemical Society Reviews 42:7335-7372 (2013)).
- the present disclosure provides a wound dressing composition
- a wound dressing composition comprising a freeze-dried layer with a wound-facing surface and an environmental-facing surface; wherein the freeze-dried layer comprises a first layer comprising a combination of collagen and an oxidized cellulose; and a coating forming a coated layer on the first layer, the coated layer comprising a formulation comprising an effective amount of at least one biologically active agent wherein the wound dressing composition does not visually appear to be wrinkled.
- the formulation the formulation is applied at a temperature of about 40 °C to about 80 °C. Additionally or alternatively, in some embodiments, the formulation is applied to the first layer before freeze drying the first layer.
- the formulation the coated layer has an average thickness of about 0.1 pm to about 1,000 pm. Additionally or alternatively, in some embodiments, the formulation the wound dressing is resistant to structural changes compared to a control dressing that includes a collagen and an oxidized cellulose that has been freeze-dried and has been coated with the same formulation. In some embodiments, the control dressing is coated with the formulation via spray coating or continuous coating with a brush.
- the present disclosure is directed to methods for making a wound dressing composition, the method comprising, heating a formulation to about 40 °C to about 80 °C, depositing the formulation onto a layer comprising a collagen and an oxidized cellulose to form a coated layer, and freezing the coated layer; wherein the coated layer has an average thickness of about 0.1 pm to about 1,000 pm.
- FIG. 1 provides a representative, non-limiting flow diagram of an exemplary method for making the wound dressing compositions of the present technology.
- FIG. 2 provides representative, non-limiting illustrations of embodiments of the wound dressing compositions of the present technology.
- FIG. 3 demonstrates that the wound dressing compositions of the present technology feature decreased wrinkle formation compared to the wound dressing compositions which undergo freeze-drying prior to the application of the coating.
- the“administration” of a wound dressing composition to a subject includes any route of introducing or delivering to a subject a wound dressing composition to perform its intended function. Administration can be carried out by any suitable route, including but not limited to, topical administration. Administration includes self-administration and the administration by another.
- the term“effective amount” refers to a quantity sufficient to achieve a desired therapeutic effect and/or prophylactic effect, e.g., an amount which results in the decrease in a wound described herein or one or more signs or symptoms associated with a wound described herein.
- the wound dressing composition administered to the subject will vary depending on the composition, the degree, type, and severity of the wound and on the characteristics of the individual.
- the terms“individual”,“patient”, or“subject” can be an individual organism, a vertebrate, a mammal, or a human. In some embodiments, the individual, patient or subject is a human.
- “molecular weight” is a dimensionless quantity that can be converted to molar mass by multiplying by 1 gram/mole - for example, collagen with a weight-average molecular weight of 5,000 has a weight- average molar mass of 5,000 g/mol.
- solid content refers to the density of a material and/or fdm of the wound dressing composition of the present technology, which is its mass per unit volume.
- Treating” or“treatment” as used herein covers the treatment of a wound described herein, in a subject, such as a human, and includes: (i) inhibiting a wound, i.e., arresting its development; (ii) relieving a wound, i.e., causing regression of the wound; (iii) slowing progression of the wound; and/or (iv) inhibiting, relieving, or slowing progression of one or more symptoms of the wound.
- treatment means that the symptoms associated with the wound are, e.g., alleviated, reduced, cured, or placed in a state of remission.
- % w/v refers to the percent of weight of the solution in the total volume of the solution, i.e., the number of grams of solute in 100 mL of solution.
- the various modes of treatment of wounds as described herein are intended to mean“substantial,” which includes total but also less than total treatment, and wherein some biologically or medically relevant result is achieved.
- the treatment may be a continuous prolonged treatment for a chronic wound or a single, or several administrations for the treatment of an acute wound.
- the present disclosure provides a wound dressing composition
- a wound dressing composition comprising a layer with a wound-facing surface and an environmental-facing surface, wherein the first layer comprises a collagen and an oxidized cellulose, and wherein the first layer is coated with a formulation on the wound-facing surface to form a coated layer on the first layer; wherein the coated layer has an average thickness of about 0.1 pm to about 1,000 pm, the formulation is applied at a temperature of about 40 °C to about 80 °C, and the wound dressing is resistant to structural changes compared to a control dressing that includes a collagen and an oxidized cellulose, and has been freeze-dried and then coated with the same formulation.
- the method further comprises drying the coated layer.
- the coated layer has an average thickness of about 0.1 pm, about 0.3 pm, about 0.6 pm, about 1 pm, about 2 pm, about 5 pm, about 10 pm, about 15 pm, about 30 pm, about 50 pm, about 75 pm, about 100 pm, about 150 pm, about 200 pm, about 300 pm, about 400 pm, about 500 pm, about 600 pm, about 800 pm, or about 1,000 pm, or any range including and/or in between any two of these values.
- the coated layer has an average thickness of about 0.1 pm to about 1 pm, about 0.3 pm to about 3 pm, about 1 pm to about 10 pm, about 3 pm to about 30 pm, about 10 pm to about 100 pm, about 30 pm to about 300 pm, or about 100 pm to about 1000 pm.
- the formulation is applied at a temperature of about 40 °C to about 80 °C. In any embodiment disclosed herein, the formulation is applied at a temperature of about 40 °C, about 45 °C, about 50 °C, about 55 °C, about 60 °C, about 65 °C, about 70 °C, about 75 °C, about 80 °C, or any range including and/or in between any two of these values.
- the formulation is applied at a temperature of about 40 °C to about 50 °C, about 45 °C to about 55 °C, about 50 °C to about 60 °C, about 55 °C to about 65 °C, about 60 °C to about 70 °C, about 65 °C to about 75 °C, about 70 °C to about 80 °C, or any range including and/or in between any two of these values.
- the collagen may be recombinant or naturally occurring. Additionally or alternatively, in some embodiments, the collagen may be a mammalian collagen, an avian collagen, a reptilian collagen, an amphibian collagen, or any combination thereof.
- the collagen may be mammalian collagen. Additionally or alternatively, in some embodiments, the collagen may be a human collagen. Additionally or alternatively, in some embodiments, the human collagen may be human collagen type I, human collagen type III, or any combination thereof. Additionally or alternatively, in some embodiments, the collagen may be a bovine collagen. Additionally or alternatively, in some embodiments, the collagen may be bovine collagen type I, bovine collagen type II, bovine collagen type III, bovine collagen type IV, or any combination thereof. Additionally or alternatively, in some embodiments, the collagen may be bovine collagen type I and bovine collagen type III.
- the collagen may be provided by any manner known in the art. Additionally or alternatively, in some embodiments, the collagen may be provided by a tissue sample or recombinantly manufactured. Additionally or alternatively, in some embodiments, mammalian recombinant collagen may be provided by any suitable method known in the art. Additionally or alternatively, in some embodiments, human recombinant collagen may be provided by any suitable method known in the art. For example, the step of providing human recombinant collagen may comprise following the protocol described in U.S. Pat. No. 5,962,648, the entire content of which is incorporated herein by reference. Further recombinant processes are set forth in U.S. Pat. No.
- collagen will be recombinantly manufactured by culturing a cell which has been transfected with at least one gene encoding a polypeptide comprising collagen and genes encoding oxidized cellulose and subunits of the post-translational enzyme prolyl 4-hydroxylase, and purifying the resultant collagen monomer therefrom.
- collagen will be recombinantly manufactured by a plant (e.g., CollPlant, CollPlant Holdings Ltd., Ness Ziona, Israel) such as tobacco, or in yeast.
- the human recombinant collagen solution may be subsequently subjected to polymerization or cross-linking conditions to produce an insoluble fibrous collagen.
- the collagen may be a type I collagen, a type II collagen, or a type III collagen. Additionally or alternatively, in some embodiments, the collagen may be obtained from any natural source, may be chemically-modified collagen (e.g., an atelocollagen obtained by removing the immunogenic telopeptides from natural collagen), or may be any combination thereof.
- the collagen may include collagen obtained from bovine corium that has been rendered largely free of non-collagenous components, for example, including fat, non-collagenous proteins, polysaccharides, and other carbohydrates, such as by procedures described in U.S. Pat. Nos. 4,614,794 and 4,320,201, the entire contents of which are incorporated by reference.
- the first layer may include about 1 wt.% to about 95 wt.% collagen. Additionally or alternatively, in some embodiments, the first layer may include about 1 wt.%, about 2 wt.%, about 5 wt.%, about 10 wt.%, about 15 wt.%, about 20 wt.%, about 25 wt.% about 30 wt.%, about 35 wt.%, about 40 wt.%, about 45 wt.%, about 50 wt.%, about 55 wt.%, about 60 wt.%, about 65 wt.%, about 70 wt.%, about 75 wt.%, about 80 wt.%, about 85 wt.%, about 90 wt.%, about 95 wt.%, or any range including and/or in between any two of the preceding values, of collagen.
- the first layer may include about 1 wt.% to about 10 wt.%, about 5 wt.% to about 20 wt.%, 10 wt.% to about 40 wt.%, about 30 wt.% to about 45 wt.%, about 40 wt.% to about 55 wt.%, about 50 wt.% to about 65 wt.%, about 60 wt.% to about 75 wt.%, about 70 wt.% to about 85 wt.%, about 80 wt.% to about 95 wt.% collagen, or any range including and/or in between any two of the preceding values.
- the collagen may have a weight-average molecular weight of about 5,000 to about 100,000. Additionally or alternatively, in some embodiments, the collagen may have a weight-average molecular weight of about 5,000, about 6,000, about 7,500, about 10,000, about 15,000, about 20,000, about 25,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, about 100,000, or any range including and/or in between any two of the preceding values.
- the collagen may have a weight-average molecular weight of about 5,000 to about 20,000, about 10,000 to about 25,000, about 20,000 to about 40,000, about 30,000 to about 50,000, about 40,000 to about 80,000, about 60,000 to about 100,000, or any range including and/or in between any two of these values.
- the oxidized cellulose comprises cellulose or a modified form of cellulose such as oxidized regenerated cellulose (ORC). Additionally or alternatively in some embodiments, the oxidized cellulose comprises ORC.
- ORC may be produced by the oxidation of cellulose, for example with dinitrogen tetroxide and/or as described in U.S. Pat. No. 3,122,479 (incorporated herein by reference). Without wishing to be bound by theory, it is believed that this process may convert primary alcohol groups on the saccharide residues of the cellulose to carboxylic acid groups, for example, forming uronic acid residues within the cellulose chain.
- oxidation need not proceed with complete selectivity, and as a result hydroxyl groups on carbons 2 and 3 of the saccharide residue may be converted to the keto form.
- ketone units may introduce an alkali labile link, which at pH 7 or higher initiates the decomposition of the polymer via formation of a lactone and sugar ring cleavage.
- alkali labile link which at pH 7 or higher initiates the decomposition of the polymer via formation of a lactone and sugar ring cleavage.
- oxidized regenerated cellulose is biodegradable and bioresorbable under physiological conditions.
- ORC is available with a variety of degrees of oxidation and hence rates of degradation.
- the first layer may include about 30 wt.% to about 70 wt.% oxidized cellulose. In any embodiment disclosed herein, the first layer may include about 30 wt.%, about 35 wt.%, about 40 wt.%, about 45 wt.%, about 50 wt.%, about 55 wt.%, about 60 wt.%, about 65 wt.%, about 70 wt.%, or any range including and/or in between any two of the preceding values, of oxidized cellulose.
- the first layer may include about 30 wt.% to about 40 wt.%, about 35 wt.% to about 45 wt.%, about 40 wt.% to about 50 wt.%, about 45 wt.% to about 55 wt.%, about 50 wt.% to about 60 wt.%, about 55 wt.% to about 65 wt.%, about 60 wt.% to about 70 wt.% oxidized cellulose, or any range including and/or in between any two of these values.
- the oxidized cellulose and/or ORC may comprise a weight-average molecular weight of about 50,000 to about 1,000,000. Additionally or alternatively, in some embodiments, the oxidized cellulose may have a weight-average molecular weight of about 50,000, about 60,000, about 75,000, about 100,000, about 150,000, about 200,000, about 250,000, about 300,000, about 400,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, about 1,000,000, or any range including and/or in between any two of the preceding values.
- the oxidized cellulose may have a weight-average molecular weight of about 50,000 to about 200,000, about 100,000 to about 250,000, about 200,000 to about 400,000, about 300,000 to about 500,000, about 400,000 to about 800,000, about 600,000 to about 1,000,000, or any range including and/or in between any two of these values.
- the ORC may include particles, fibers, or both; in any embodiment disclosed herein, the ORC may be in the form of particles, such as fiber particles or powder particles.
- the ORC fibers may have a volume fraction such that at least 80% of the fibers have lengths in the range from about 5 pm to about 1,000 pm.
- the ORC may include fiber lengths of about 5 pm, about 10 pm, about 20 pm, about 50 pm, about 75 pm, about 100 pm, about 150 pm, about 200 pm, about 300 pm, about 400 pm, about 500 pm, about 600 pm, about 800 pm, about 1,000 pm, or any range including and/or in between any two of the preceding values.
- the ORC may include fiber lengths of about 5 pm to about 50 pm, about 10 pm to about 100 pm, about 50 pm to about 250 pm, about 100 pm to about 500 pm, about 200 pm to about 600 pm, about 500 pm to about 1000 pm, or any range including and/or in between any two of the preceding values.
- the wound dressing compositions of the present technology may comprise about 30 wt.% to about 90 wt.% of the mixture of collagen and oxidized cellulose. Additionally or alternatively, in some embodiments, the collagen and oxidized cellulose mixture may be comprised at about 30 wt.%, about 40 wt.%, about 50 wt.%, about 60 wt.%, about 70 wt.%, about 80 wt.%, about 90 wt.%, or any range including and/or in between any two of the preceding values.
- the mixture of collagen and oxidized cellulose can be included within the wound dressing compositions of the present technology at about 30 wt.% to about 40 wt.%, about 35 wt.% to about 45 wt.%, about 40 wt.% to about 50 wt.%, about 45 wt.% to about 55 wt.%, about 50 wt.% to about 60 wt.%, about 55 wt.% to about 65 wt.%, about 60 wt.% to about 70 wt.% about 65 wt.% to about 75 wt.%, about 70 wt.% to about 80 wt.%, about 75 wt.% to about 85 wt.%, about 80 wt.% to about 90 wt.%, or any range including and/or in between any two of these values.
- the first layer may be frozen at a temperature between about 0 °C to about -80 °C. Additionally or alternatively, in some embodiments, the first layer is frozen at a temperature of about 0 °C, about -5 °C, about -10 °C, about -15 °C, about -20 °C, about -30 °C, about -40 °C, about -50 °C, about -60 °C, about -70 °C, about -80 °C, or any range including and/or in between any two of these values.
- the first layer is frozen at a temperature between about 0 °C to about -20 °C, about -10 °C to about -30 °C, about -20 °C to about -40 °C, about -30 °C to about -50 °C, about -40 °C to about -60 °C, about -50 °C to about -70 °C, about -60 °C to about -80 °C, or any range including and/or in between any two of these values.
- the formulation may include a solvent and an effective amount of at least one agent selected from the group consisting of a growth factor, an antimicrobial agent, a peptide, a biopolymer, and any combination thereof.
- the solvent may be an aqueous solvent or an organic solvent.
- the aqueous solvent may include a dilute organic acid, for example, acetic acid, citric acid, or a combination thereof.
- the formulation may include one or more of a binder, a colorant, a deodorant agent, a filler, a plasticizer, a viscosity modifier, an anti-microbial, or any combination thereof.
- the binder may be one or more of hyaluronic acid, chitosan, heparin, alginate, cellulose, fibrin, gelatin, chondroitin sulfate, agarose, dextran, carrageenan, silk, poly(ethylene glycol), poly(vinyl alcohol), polycaprolactone, polyphosphazene, polyglycolic acid, rosin, lactose, sucrose, tapioca starch, polyvinylpyrrolidone, or any combination thereof.
- the formulation may include about 1 % w/v to about 10 % w/v of the binder.
- the formulation may include about 1.0 % w/v, about 2.0 % w/v, about 3.0 % w/v, about 4.0 % w/v, about 5.0 % w/v, about 6.0 % w/v, about 7.0 % w/v, about 8.0 % w/v, about 9.0 % w/v, about 10 % w/v, or any range including and/or in between any two of the preceding values, of the binder.
- the formulation may include about 1.0 % w/v to about 2.5 % w/v, about 2.0 % w/v to about 4 % w/v, 3.0 % w/v to about 5.0 % w/v, about 4.0 % w/v to about 6 % w/v, 5.0 % w/v to about 7.0 % w/v, about 6.0 % w/v to about 8 % w/v, 7.0 % w/v to about 9.0 % w/v, about 8.0 % w/v to about 10 % w/v, or any range including and/or in between any two of the preceding values, of the binder.
- the colorant may be one or more of direct red 80, bromophenol blue, toluidine blue, a food coloring, Allura Red AC, Erythrosine, Tartrazine 5, Anthocyanins, Curcuma, Annatto, or any combination thereof. Additionally or alternatively, in some embodiments, the formulation may include about 0.1 % w/v to about 5 % w/v of the colorant. Additionally or alternatively, in some embodiments, the formulation may include about 1 % w/v to about 10 % w/v of the colorant.
- the formulation may include about 0.1 % w/v, about 0.15 % w/v, about 0.20 % w/v, about 0.30 % w/v, about 0.50 % w/v, about 0.75 % w/v, about 1.0 % w/v, about 2.0 % w/v, about 2.5 % w/v, about 3.0 % w/v, about 4.0 % w/v, about 5.0 % w/v, or any range including and/or in between any two of the preceding values, of the colorant.
- the formulation may include about 0.1 % w/v to about 0.5 % w/v, about 0.25 % w/v to about 1.25 % w/v, about 1 % w/v to about 3 % w/v, about 2.0 % w/v to about 4.0 % w/v, about 2.5 % w/v to about 5.0 % w/v, or any range including and/or in between any two of the preceding values, of the colorant.
- the deodorant agent may be one or more of zinc ricinoleate, triethyl citrate, Saccharomyces ferment, Arctium lappa root extract, Humulus lupulus extract, Thymus vulgaris, or any combination thereof. Additionally or alternatively, in some embodiments, the formulation may include about 0.01 % w/v to about 5 % w/v of the deodorant agent.
- the formulation may include about 0.01 % w/v, about 0.025 % w/v, about 0.05 % w/v, about 0.075 % w/v, 0.1 % w/v, about 0.20 % w/v, about 0.30 % w/v, about 0.50 % w/v, about 0.75 % w/v, about 1.0 % w/v, about 2.0 % w/v, about 2.5 % w/v, about 3.0 % w/v, about 4.0 % w/v, about 5.0 % w/v, or any range including and/or in between any two of the preceding values, of the deodorant agent.
- the formulation may include about 0.01 % w/v to about 0.05 % w/v, about 0.025 % w/v to about 0.125 % w/v, 0.1 % w/v to about 0.5 % w/v, about 0.25 % w/v to about 1.25 % w/v, about 1 % w/v to about 3 % w/v, about 2.0 % w/v to about 4.0 % w/v, about 2.5 % w/v to about 5.0 % w/v, or any range including and/or in between any two of the preceding values, of the deodorant agent.
- the fdler may be one or more of amorphous silica, mica, kaolin, titanium dioxide, or any combination thereof. Additionally or alternatively, in some embodiments, the formulation may include about 0.01 % w/v to about 10 % w/v of the fdler.
- the formulation may include about 0.01 % w/v, about 0.025 % w/v, about 0.05 % w/v, about 0.075 % w/v, 0.1 % w/v, about 0.20 % w/v, about 0.30 % w/v, about 0.50 % w/v, about 0.75 % w/v, about 1.0 % w/v, about 2.0 % w/v, about 2.5 % w/v, about 3.0 % w/v, about 4.0 % w/v, about 5.0 % w/v, about 6.0 % w/v, about 7.0 % w/v, about 8.0 % w/v, about 9.0 % w/v, about 10.0 % w/v, or any range including and/or in between any two of the preceding values, of the fdler.
- the formulation may include about 0.01 % w/v to about 0.05 % w/v, about 0.025 % w/v to about 0.125 % w/v, 0.1 % w/v to about 0.5 % w/v, about 0.25 % w/v to about 1.25 % w/v, about 1 % w/v to about 3 % w/v, about 2.0 % w/v to about 4.0 % w/v, about 2.5 % w/v to about 7.5 % w/v, about 3.0 % w/v to about 10.0 % w/v, or any range including and/or in between any two of the preceding values, of the fdler.
- the plasticizer may include at least one component selected from the group consisting of an acetylated monoglyceride, an alkyl citrate, methyl ricinoleate, and glycerol.
- the alkyl citrate may be triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, trioctyl citrate, acetyl trioctyl citrate, trihexyl citrate, acetyl trihexyl citrate, butyryl trihexyl citrate, trimethyl citrate, or any combination thereof.
- the formulation may include about 1 % w/v to about 10 % w/v of the at least one plasticizer.
- the at least one plasticizer may be included in an amount of about 0.01 % w/v, about 0.025 % w/v, about 0.05 % w/v, about 0.075 % w/v, 0.1 % w/v, about 0.20 % w/v, about 0.30 % w/v, about 0.50 % w/v, about 0.75 % w/v, about 1.0 % w/v, about 2.0 % w/v, about 2.5 % w/v, about 3.0 % w/v, about 4.0 % w/v, about 5.0 % w/v, about 6.0 % w/v, about 7.0 % w/v, about 8.0 % w/v, about 9.0 % w/v, about 10.0 % w/v, or any
- the formulation may include about 0.01 % w/v to about 0.05 % w/v, about 0.025 % w/v to about 0.125 % w/v, 0.1 % w/v to about 0.5 % w/v, about 0.25 % w/v to about 1.25 % w/v, about 1 % w/v to about 3 % w/v, about 2.0 % w/v to about 4.0 % w/v, about 2.5 % w/v to about 7.5 % w/v, about 3.0 % w/v to about 10.0 % w/v, or any range including and/or in between any two of the preceding values, of at least one plasticizer.
- the viscosity modifier may be one or more of sodium polyacrylate, acrylates/alkyl methacrylate block copolymers, polyacrylic acid, cellulose gum, hydroxyethylcellulose, stearyl alcohol, carbomer, or any combination thereof. Additionally or alternatively, in some embodiments, the formulation may include about 0.1 % w/v to about 10 % w/v of the viscosity modifier.
- the formulation may include an amount of about 0.01 % w/v, about 0.025 % w/v, about 0.05 % w/v, about 0.075 % w/v, 0.1 % w/v, about 0.20 % w/v, about 0.30 % w/v, about 0.50 % w/v, about 0.75 % w/v, about 1.0 % w/v, about 2.0 % w/v, about 2.5 % w/v, about 3.0 % w/v, about 4.0 % w/v, about 5.0 % w/v, about 6.0 % w/v, about 7.0 % w/v, about 8.0 % w/v, about 9.0 % w/v, about 10.0 % w/v, or any range including and/or in between any two of the preceding values, of the viscosity modifier.
- the formulation may include about 0.01 % w/v to about 0.05 % w/v, about 0.025 % w/v to about 0.125 % w/v, 0.1 % w/v to about 0.5 % w/v, about 0.25 % w/v to about 1.25 % w/v, about 1 % w/v to about 3 % w/v, about 2.0 % w/v to about 4.0 % w/v, about 2.5 % w/v to about 7.5 % w/v, about 3.0 % w/v to about 10.0 % w/v, or any range including and/or in between any two of the preceding values, of the viscosity modifier.
- the formulation may include about 0.01 wt.% to about 40 wt.%, or about 0.5 wt.% to about 5 wt.% of the at least one agent. Additionally or alternatively, in some embodiments, the formulation may include at least one agent at about 0.01 wt.%, about 0.025 wt.%, about 0.05 wt.%, about 0.1 wt.%, about 0.25 wt.%, about 0.5 wt.%, about 1 wt.%, about 5 wt.%, about 10 wt.%, about 15 wt.%, about 20 wt.%, about 25 wt.%, about 30 wt.%, about 35 wt.%, about 40 wt.%, or any range including and/or in between any two of these values.
- the at least one agent may be included at about 0.01 wt.% to about 0.1 wt.%, about 0.05 wt.% to about 0.5 wt.%, about 0.1 wt.% to about 1 wt.%, about 0.5 wt.% to about 5 wt.%, about 1 wt.% to about 10 wt.%, about 5 wt.% to about 25 wt.%, about 10 wt.% to about 40 wt.% of the formulation, or any range including and/or in between any two of these values.
- the growth factor may include one or more of epidermal growth factor (EGF), hepatocyte growth factor (HGF), fibroblast growth factors (FGFs), or platelet-derived growth factor (PDGF). Additionally or alternatively, in some embodiments, the fibroblast growth factors comprise one or more of fibroblast growth factor 1 (FGF1), fibroblast growth factor 2 (FGF2), fibroblast growth factor 3 (FGF3), fibroblast growth factor 4 (FGF4), fibroblast growth factor 5 (FGF5), fibroblast growth factor 6 (FGF6), fibroblast growth factor 7 / keratinocyte growth factor (FGF7/KGF), fibroblast growth factor 8 (FGF8), fibroblast growth factor 9 (FGF9), fibroblast growth factor 10 / keratinocyte growth factor 2 (FGF10/KGF2), fibroblast growth factor 11 (FGF11), fibroblast growth factor 12 (FGF12), fibroblast growth factor 13 (FGF13), fibroblast growth factor
- the antimicrobial agent may include one or more of polyhexamethylene biguanide, povidone-iodine, acetic acid, benzoic acid, povidone iodine, natamycin, nisin, citric acid, sorbic acid, propionic acid, honey, a silver compound, sulfites, or any combination thereof.
- the peptide may be one or more of defensins, histatins, cathelicidin FF-37, or any combination thereof.
- the biopolymer may be one or more of hyaluronic acid, fibrinogen, a chitosan, a polysaccharide, a gelatin, an oxidized cellulose, an oxidized regenerated cellulose (ORC), or any combination thereof.
- the wound dressing composition of the present technology may include one or more synthetic polymers including, but not limited to, polyethylene glycol), poly(lactic acid), poly(vinyl alcohol) and polycaprolactone .
- the first layer has a thickness of about 1 mm to about 15 mm, or about 3 mm to about 8 mm. Additionally or alternatively, in some embodiments of the wound dressing disclosed herein, the first layer may have a thickness of about 1 mm, about 1.5 mm, about 2 mm, about 2.5 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 9 mm, about 10 mm, about 11 mm, about 12 mm, about 13 mm, about 14 mm, about 15 mm, or any range including and/or in between any two of the preceding values.
- the first layer may have a thickness of about 1 mm to about 3 mm, about 2 mm to about 4 mm, about 3 mm to about 5 mm, about 4 mm to about 6 mm, about 5 mm to about 7 mm, about 6 mm to about 8 mm, about 7 mm to about 9 mm, about 8 mm to about 10 mm, about 9 mm to about 11 mm, about 10 mm to about 13 mm, about 12 mm to about 15 mm, or any range including and/or in between any two of the preceding values.
- the first layer and/or coated layer may optionally include a silver compound. Additionally or alternatively, in some embodiments, the first layer and/or coated layer may comprise about 0.1 wt.% to about 3 wt.% of a silver compound. Additionally or alternatively, in some embodiments, the first layer and/or coated layer may comprise about 0.1 wt.%, about 0. 25 wt.%, about 0.5 wt.%, about 0.75 wt.%, about 1 wt.%, about 1.5 wt.%, about 2 wt.%, about 2.5 wt.%, about 3 wt.%, or any range including and/or in between any two of the preceding values, of the silver compound.
- the first layer and/or coated layer may comprise 0.1 wt.%, to about 0.3 wt.%, about 0.25 wt.% to about 0.75 wt.%, about 0.5 wt.% to about 1.5 wt.%, about 1 wt.% to about 2 wt.%, about 1.5 wt.% to about 3 wt.%, or any range including and/or in between any two of the preceding values, of the silver compound.
- the silver compound of the first and/or coated layer may include one or more pharmaceutically acceptable silver salts.
- exemplary sources of the one or more pharmaceutically acceptable silver salts include, but are not limited to, silver oxide, silver chromate, silver allantoinate, silver borate, silver glycerolate, silver nitrate, silver acetate, silver chloride, silver sulfate, silver lactate, silver bromide, silver iodide, silver carbonate, silver citrate, silver laurate, silver deoxycholate, silver salicylate, silver p-aminobenzoate, silver p-aminosalicylate, nanocrystalline silver, any pharmaceutically acceptable salt thereof, or any combination thereof.
- the silver compound comprises a silver (II) oxide, silver (III) oxide, a silver oxy-salt, or any combination thereof.
- the silver oxy-salt may comprise a general formula of Ag(Ag30a)X, wherein X can include, but is not limited to, one or more acid anions such as sulfates, chlorides, phosphates, carbonates, citrates, tartrates, or oxalates; and wherein a is at least two.
- the first layer may include about 1 wt.% to about 15 wt.% of at least one plasticizer. Additionally or alternatively, in some embodiments, the at least one plasticizer of the first layer may be include at about 1 wt.%, about 2 wt.%, about 3 wt.%, about 4 wt.%, about 5 wt.%, about 6 wt.%, about 8 wt.%, about 10 wt.%, about 12.5 wt.%, about 15 wt.%, or any range including and/or in between any two of the preceding values.
- the at least one plasticizer of the first layer may be include at about 1 wt.% to about 3 wt.%, about 2 wt.% to about 4 wt.%, about 3 wt.% to about 5 wt.%, about 4 wt.% to about 6 wt.%, about 5 wt. % to about 10 wt. %, about 8 wt. % to about 15 wt. %, or any range including and/or in between any two of the preceding values.
- the at least one plasticizer may be an acetylated monoglyceride, an alkyl citrate, methyl ricinoleate, glycerol, polyvinylpyrrolidone, and any combination thereof.
- the alkyl citrate may be triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, trioctyl citrate, acetyl trioctyl citrate, trihexyl citrate, acetyl trihexyl citrate, butyryl trihexyl citrate, trimethyl citrate, and any combination thereof.
- the anthocyanins are selected from the group consisting of cyanidin, delphinidin, malvidin, pelargonidin, peonidin, petunidin, and mixtures thereof.
- the flavanols are selected from the group consisting of catechin, epicatechin, theaflavin, thearubigins, gallocatechin, epigallocatechin, or any gallate ester thereof, and mixtures thereof.
- the flavanones are selected from the group consisting of eriodictyol, hesperetin, naringenin, and mixtures thereof.
- the flavones are selected from the group consisting of apigenin, luteolin, tangeritin, and mixtures thereof.
- the flavonols are selected from the group consisting of isorhamnetin, kaempferol, myricetin, proanthocyanidins, quercetin, rutin, and mixtures thereof.
- the isoflavone phytoestrogens are selected from the group consisting of daidzein, genistein, glycitein, and any combination thereof.
- the phenolic acids are selected from the group consisting of chicoric acid, chlorogenic acid, cinnamic acid, ellagic acid, ellagitannins, gallic acid, gallotannins, rosmarinic acid, salicylic acid, or any ester thereof, and any combination thereof.
- the stillbenoids are selected from the group consisting of resveratrol, pterostilbene, and any combination thereof.
- the solid content of the first layer may be comprised at about 0.1 wt.%to about 10 wt.%. Additionally or alternatively, in some embodiments, the solid content of the first layer may be comprised at about 0.1 wt.%, about 0. 25 wt.%, about 0.5 wt.%, about 0.75 wt.%, about 1 wt.%, about 1.5 wt.%, about 2 wt.%, about 2.5 wt.%, about 3 wt.%, about 5 wt.%, about 7.5 wt.%, about 10 wt.%, or any range including and/or in between any two of the preceding values.
- the solid content of the first layer may be comprised at about 0.1 wt.%, to about 0.3 wt.%, about 0.25 wt.% to about 0.75 wt.%, about 0.5 wt.% to about 1.5 wt.%, about 1 wt.% to about 3 wt.%, about 2 wt.% to about 6 wt.%, about 3 wt.% to about 10 wt.%, or any range including and/or in between any two of the preceding values.
- the present disclosure provides an apparatus comprising a layer with a wound facing surface and an environmental-facing surface, wherein the freeze-dried layer comprises a first layer comprising a combination of collagen and an oxidized cellulose; and a coating forming a coated layer on the first layer, the coated layer comprising a formulation comprising an effective amount of at least one biologically active agent wherein the wound dressing composition does not visually appear to be wrinkled.
- the formulation is applied to the first layer before freeze drying the first layer.
- the coated layer has an average thickness of about 0.1 pm to about 1,000 pm.
- the formulation is applied at a temperature of about 40 °C to about 80 °C. Additionally or alternatively, in some embodiments, the apparatus is resistant to structural changes compared to a control apparatus dressing that includes a collagen and an oxidized cellulose that has been freeze-dried before coating with the same formulation.
- the present disclosure provides a device for the treatment of wound comprising a layer a layer with a wound-facing surface and an environmental-facing surface, wherein the freeze-dried layer comprises a first layer comprising a combination of collagen and an oxidized cellulose; and a coating forming a coated layer on the first layer, the coated layer comprising a formulation comprising an effective amount of at least one biologically active agent wherein the wound dressing composition does not visually appear to be wrinkled.
- the formulation is applied to the first layer before freeze drying the first layer.
- the coated layer has an average thickness of about 0.1 pm to about 1,000 pm.
- the formulation is applied at a temperature of about 40 °C to about 80 °C. Additionally or alternatively, in some embodiments, the device is resistant to structural changes compared to a control device that includes a collagen and an oxidized cellulose that has been freeze-dried before coating with the same formulation.
- the present disclosure provides a method for treating a wound in a subject in need thereof, the method including administering to the wound a wound dressing composition, apparatus, device, and/or layer of any embodiment disclosed herein. Additionally or alternatively in some embodiments, the wound dressing composition, apparatus, device, and/or layer induces, enhances, or promotes healing in the subject. Additionally or alternatively, in some embodiments, the subject is human.
- the present disclosure provides a method for preventing or reducing the risk of wound infection in a subject in need thereof, the method including administering to the wound a wound dressing composition, apparatus, device, and/or layer of any embodiment disclosed herein. Additionally or alternatively in some embodiments, the wound dressing composition, apparatus, device, and/or layer induces, enhances, or promotes healing in the subject. Additionally or alternatively, in some embodiments, the subject is human.
- the wound is an acute wound selected from the group consisting of bums, skin grafts, and dehisced surgical wounds. Additionally or alternatively, in some embodiments of the methods disclosed herein, the wound is a chronic wound selected from the group consisting of infectious wounds, venous ulcers, arterial ulcers, decubitis ulcers and diabetic ulcers. [00107] Any method known to those in the art for administering a wound dressing composition, apparatus, device, and/or layer to an acute wound or a chronic wound disclosed herein may be employed. Suitable methods include in vitro or in vivo methods.
- In vivo methods typically include the administration of one or more wound dressing compositions, apparatuses, devices, and/or layers to a subject in need thereof, suitably a human.
- the wound dressing composition, apparatus, device, and/or layer is applied directly to the wound.
- the one or more wound dressing compositions, apparatus, device, and/or layer described herein are administered to the subject in effective amounts (i.e., amounts that have desired therapeutic effect).
- the dose and dosage regimen will depend upon the state of the wound of the subject, and the characteristics of the particular wound dressing, apparatus, device, and/or layer used.
- the effective amount may be determined during pre-clinical trials and clinical trials by methods familiar to physicians and clinicians.
- An effective amount of one or more wound dressing compositions, apparatus, device, and/or layer useful in the methods may be administered to a subject in need thereof by any number of well-known methods for administering wound dressings, apparatuses, devices, and/or layers.
- the wound dressing compositions, apparatuses, devices, and/or layers are administered daily for 1 hour or more, for 2 hours or more, for 3 hours or more, for 4 hours or more, for 5 hours or more, for 6 hours or more, for 12 hours or more. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered one, two, three, four, or five times per day. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered daily for one, two, three, four or five weeks. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered daily for less than 6 weeks.
- the wound dressing compositions, apparatuses, devices, and/or layers are administered daily for 6 weeks or more. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered daily for 12 weeks or more. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered every day, every other day, every third day, every fourth day, every fifth day, or every sixth day. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered weekly, bi-weekly, tri-weekly, or monthly.
- the wound dressing compositions, apparatuses, devices, and/or layers are administered for a period of one, two, three, four, or five weeks. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered for six weeks or more. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered for twelve weeks or more. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered for a period of less than one year. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered for a period of more than one year.
- the wound dressing compositions apparatuses, devices, and/or layers can be changed for a chronic wound as appropriate.
- the wound is a chronic wound selected from the group consisting of infectious wounds, venous ulcers, arterial ulcers, decubitis ulcers and diabetic ulcers.
- the present disclosure provides a method of the treatment of a wound in a subject in need thereof, the method comprising administering to the subject the apparatus, wound dressings, device, and/or layer disclosed herein of any embodiment disclosed herein.
- the present disclosure provides a method for preventing or reducing the risk of wound infection in a subject in need thereof, the method comprising administering to the subject the apparatus any embodiment disclosed herein.
- the present disclosure provides a method for making a wound dressing composition, apparatus, and/or device of any embodiment disclosed herein, the method comprising, heating a formulation to about 40 °C to about 80 °C, depositing the formulation onto a first layer comprising a collagen and an oxidized cellulose to form a coated layer on the first layer, and freezing the coated layer; wherein the coated layer has an average thickness of about 0.1 pm to about 1,000 pm. Additionally or alternatively, in some embodiments, the method further comprises drying the coated layer, wound dressing composition, apparatus, and/or device.
- the method comprises heating the formulation to about 40 °C, about 45 °C, about 50 °C, about 55 °C, about 60 °C, about 65 °C, about 70 °C, about 75 °C, about 80 °C, or any range including and/or in between any two of these values.
- the method comprises heating the formulation to about 40 °C to about 50 °C, about 45 °C to about 55 °C, about 50 °C to about 60 °C, about 55 °C to about 65 °C, about 60 °C to about 70 °C, about 65 °C to about 75 °C, about 70 °C to about 80 °C, or any range including and/or in between any two of these values.
- the formulation is heated for a period of time between about 0.5 min to about 240 min. Additionally or alternatively, in some embodiments, the formulation is heated for a period between about 0.5 min, about 1 min, about 2.5 min, about 5 min, about 7.5 min, about 10 min, about 15 min, about 30 min, about 45 min, about 60 min, about 90 min, about 120 min, about 150 min, about 180 min, about 210 min, about 240 min, or any range including and/or in between any two of these values.
- the formulation is heated for a period between about 0.5 min to about 5 min, about 2 min to about 20 min, about 5 min to about 50 min, about 20 min to about 90 min, about 45 min to about 180 min, about 60 min to about 240 min, or any range including and/or in between any two of these values.
- the first layer may be frozen to form a frozen layer prior to deposition of the formulation, wherein the frozen layer optionally comprises a first surface. Additionally or alternatively, in some embodiments, the first surface of the frozen layer may be melted prior to deposition of the formulation.
- the first layer may be frozen at a temperature between about 0 °C to about -80 °C. Additionally or alternatively, in some embodiments, the first layer is frozen at a temperature of about 0 °C, about -5 °C, about -10 °C, about -15 °C, about -20 °C, about -30 °C, about -40 °C, about -50 °C, about -60 °C, about -70 °C, about -80 °C, or any range including and/or in between any two of these values.
- the first layer is frozen at a temperature between about 0 °C to about -20 °C, about -10 °C to about -30 °C, about -20 °C to about -40 °C, about -30 °C to about -50 °C, about -40 °C to about -60 °C, about -50 °C to about -70 °C, about -60 °C to about -80 °C, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the first layer may be frozen at a temperature lower than -80 °C. Additionally or alternatively, in some embodiments, the first layer may be frozen at or below the freezing temp of the mixture.
- the formulation may be deposited by a spray process or a thin layer application. Additionally or alternatively, in some embodiments, the thin layer application may be carried out by means of a brush.
- the coated layer may be frozen and/or freeze-dried for a period between about 0.1 min to about 10,000 min. Additionally or alternatively, in some embodiments, the coated layer may be frozen and/or freeze-dried for a period between about 0.1 min, about 0.5 min, about 1 min, about 5 min, about 15 min, about 30 min, about 60 min, about 90 min, about 120 min, about 200 min, about 500 min, about 750 min, about 1000 min, about 2000 min, about 4000 min, about 6000 min, about 8000 min, about 10,000 min, or any range including and/or in between any two of these values.
- the coated layer may be frozen and/or freeze-dried for a period between about 0.1 min to about 1 min, about 0.5 min to about 5 min, about 2 min to about 20 min, about 5 min to about 50 min, about 20 min to about 200 min, about 50 min to about 500 min, about 200 min to about 2000 min, about 500 min to about 5000 min, about 1000 min to about 10000 min, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the coated layer may be frozen and/or freeze-dried for at least 30 minutes. Additionally or alternatively, in some embodiments, the coated layer may be frozen and/or freeze-dried for at least 30 minutes.
- the coated layer is further dried and/or freeze-dried at a temperature above the temperature of the first drying and/or freeze drying of the coated fertilizer to facilitate removal of water.
- the coated layer is freeze-dried for at least 30 min., 1 hour, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 20 hours, or 24 hours.
- the first layer may include a combination of a collagen and an oxidized regenerated cellulose (ORC) in a ratio of about 70 wt.%:30 wt.%, about 65 wt.%:35 wt.%, about 60 wt.%:40 wt.%, about 55 wt.%:45 wt.%, about 50 wt.%:50 wt.%, about 45 wt.%:55 wt.%, about 40 wt.%:60 wt.%, about 35 wt.%:65 wt.%, about 30 wt.%:70 wt.%, or any range including and/or in between any two of these values.
- ORC oxidized regenerated cellulose
- the first layer may include a combination of a collagen and an oxidized regenerated cellulose (ORC) in a ratio of about 55 wt.%: 45 wt.%.
- the first layer may be produced by adding a collagen (either in paste or powder form) to an acidic solution e.g., in order to swell the collagen.
- suitable acid solutions include, but are not limited to acetic acid and/or ascorbic acid.
- the collagen may be contacted with the acid solution prior to forming an intermediate slurry with the ORC or an ORC- silver complex.
- a slurry material may be generated with a solid content of about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 8%, about 10%, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, a slurry material may be generated with a solid content of about 0.1% to about 0.5%, about 0.4% to about 2%, about 1% to about 4%, about 3% to about 6%, about 4% to about 10%, or any range including and/or in between any two of these values. The resulting slurry is then frozen.
- the resulting slurry may be flash frozen in a freezer at a temperature between about 0 °C, about -1 °C, about -5 °C, about -10 °C, about -15 °C, about -20 °C, about -30 °C, about -40 °C, about -50 °C, about -60 °C, about -70 °C, about -80 °C, or any range including and/or in between any two of these values.
- the resulting slurry may be flash frozen in a freezer at a temperature between about 0 °C to about -10 °C, about -5 °C to about - 20 °C, about -10 °C to about -30 °C, about -20 °C to about -40 °C, about -30 °C to about -60 °C, about -50 °C to about -80 °C, or any range including and/or in between any two of these values.
- the first layer can then be coated with a thin layer application of a formulation at a temperature of about 40 °C, about 45 °C, about 50 °C, about 55 °C, about 60 °C, about 65 °C, about 70 °C, about 75 °C, about 80 °C, or any range including a temperature and/or range in between any two of these values. Additionally or alternatively, in some embodiments, the formulation may be applied at a temperature of about 40 °C to about 60 °C, about 50 °C to about 70 °C, about 60 °C to about 80 °C, or any range including a temperature and/or range in between any two of these values.
- the coated layer will then be freeze- dried at a reduced pressure to produce a wound dressing of the present technology.
- the present disclosure provides a method of the treatment of a wound in a subject in need thereof, the method comprising administering to the subject the device for the treatment of wound of any embodiment.
- the present disclosure provides a method for preventing or reducing the risk of wound infection in a subject in need thereof, the method comprising administering to the subject the device for the treatment of wound of any embodiment. Additionally or alternatively, in some embodiments, the method further comprises performing negative pressure wound therapy to the wound prior to, concurrently with or after applying the wound dressing.
- kits that include a wound dressing composition of any embodiment described herein and instructions for use.
- the kits of the present technology may also include instructions for treating a wound in a subject in need thereof.
- the kit may optionally comprise components such as antiseptic wipes, ointment, adhesive tape, tweezers, or scissors.
- the kit further comprises negative pressure wound therapy device.
- the kit includes a patch, the patch comprising: a patch layer configured to prevent leaks, the patch layer comprising an opening, a patch backing layer adhered to the patch layer, and a patch delivery layer adhered to the patch layer, wherein the patch delivery layer comprises a slit, wherein the slit extends between an opening in the patch delivery layer and an exterior edge of the patch delivery layer; wherein placing the patch comprises positioning the opening in the patch layer over a vacuum port in the dressing layer and securing the patch layer to the dressing layer; and removing the patch delivery layer from the patch layer, wherein the slit permits the patch delivery layer to be removed when a fluid conduit is coupled to the vacuum port.
- the present technology is further illustrated by the following Example, which should not be construed as limiting in any way.
- the examples herein are provided to illustrate advantages of the present technology and to further assist a person of ordinary skill in the art with preparing or using the compositions and systems of the present technology.
- the examples should in no way be construed as limiting the scope of the present technology, as defined by the appended claims.
- the examples can include or incorporate any of the variations, aspects, or embodiments of the present technology described above.
- the variations, aspects, or embodiments described above may also further each include or incorporate the variations of any or all other variations, aspects or embodiments of the present technology.
- FIG. 1 provides a flow chart for making a wound dressing composition, device, layer, and/or apparatus, of the present technology.
- a wound dressing composition, device, layer, and/or apparatus, of the present technology is made by freezing a slurry comprising collagen and oxidized regenerated cellulose (ORC), coating with a functional molecule, followed by freeze-drying (FIG. 1).
- ORC oxidized regenerated cellulose
- the wound dressing composition, device, layer, and/or apparatus of the present technology may comprise a layer with a wound-facing surface and an environmental-facing surface, wherein the first layer comprises a collagen and an oxidized cellulose, and is coated with a formulation on the wound facing surface to form a coated layer on the first layer; wherein the coated layer has an average thickness of about 0.1 pm to about 1,000 pm, and wherein the formulation is applied at a temperature of about 40 °C to about 80 °C (FIG. 1), and wherein the wound dressing, device, layer, and/or apparatus is resistant to structural changes compared to a control dressing, device, layer, and/or apparatus that includes a collagen and an oxidized cellulose, and has been freeze-dried and then coated with the same formulation (FIGs. 1 and 3).
- the first layer comprises a combination of a collagen and an oxidized regenerated cellulose (ORC) at a ratio of 55 wt.%:45 wt.%.
- ORC oxidized regenerated cellulose
- the first layer was produced by adding and homogenising oxidized regenerated cellulose (ORC), and collagen (either in paste or powder form) to an acidic solution (e.g., in order to swell the collagen), resulting in a slurry with 0.55 g solid collagen weight per 100 mL acid solution and 0.45 g ORC per 100 mL slurry. The slurry was then degassed and flash frozen in at -80°C in a freezer to form a block.
- FIG. 2 shows two non-limiting examples of wound dressings, devices, layers, and/or apparatuses made by this method (left panel shows a uniform coating of citric acid, right panel shows povidone -iodine dots coated on the first layer). The panels also show that surprisingly there is no visually apparent wrinkling of the surface due to the application of the formulation when compared to the uncoated area.
- Example 2 Decreased Wrinkle Formation in the Wound Dressing Compositions of the Present Technology
- the following two wound dressing compositions were prepared and compared with each other.
- the first wound dressing composition which is shown in FIG. 3 (left panel)
- the first layer was initially freeze-dried prior to applying a coating of a citric acid formulation.
- the second wound dressing composition which is shown FIG. 3 (right panel)
- the first layer was first coated with the citric acid formulation and then subjected to freeze- drying.
- the first wound dressing composition exhibited wrinkle formation and distortion.
- the second wound dressing composition exhibited no visually detectable wrinkle formation or distortion, compared to the first wound dressing composition (FIG.
- the second wound dressing is desirable because it allows close contact of the formulation with skin and/ or wound surface, ease of handling, ease of packaging, and a uniform dissolution rate.
- the methods of making the wound dressing compositions of the present technology allow either uniform coating of formulations, or dotted/ patterned coating of formulations.
- the methods of making the wound dressing compositions of the present technology are amenable to coating the dressing with a formulation using processes such as soaking, imbibition, layering using an applicator, spray coating or continuous coating with a brush prior to freeze drying the wound dressing composition.
- This versatility enables coating of the wound dressing compositions of the present technology with a wider variety of formulations, including liquid, powder, semisolid or paste formulations.
- aqueous or non-aqueous formulations can be easily applied.
- wound dressing compositions of the present technology are more versatile to make, and are thus useful in the methods disclosed herein.
- Example 3 Improved Collagen Synthesis Upon Application of the Wound Dressing .
- a collagen synthesis assay with dermal fibroblasts is performed. This is a standard assay which shows the amount of collagen synthesized by fibroblasts after stimulation with the active agents in the wound dressing compositions, devices, layers, and/or apparatuses of the present technology. Briefly, 8.4* 104 human fibroblasts (per well) are plated into 24-well plates, and then incubated at 37° C, 5% C02, in 10% FBS-DMEM. Once the cells are confluent (within 24 hours of plating), the 10% FBS-DMEM is removed, and the cells are washed 3 c with serum-free DMEM (SF-DMEM), before the test samples of the present technology or a collagen/ORC alone dressing is added to the cells.
- SF-DMEM serum-free DMEM
- CICP Type- 1 Collagen
- the collagen synthesis assay with dermal fibroblasts is performed with the wound dressing compositions devices, layers, and/or apparatuses of the present technology as well as a conventional coated wound dressing (e.g., a wound dressing that includes a collagen and an oxidized cellulose that has been freeze-dried first and then has been coated with the same formulation).
- a conventional coated wound dressing e.g., a wound dressing that includes a collagen and an oxidized cellulose that has been freeze-dried first and then has been coated with the same formulation.
- the dressings, devices, layers, and/or apparatuses of the present technology are useful in methods for treating a wound in a subject in need thereof, wherein the method comprises administering to the wound a dressing, device, layer, and/or apparatuse of any embodiment disclosed herein.
- Example 4 Wound Dressing .
- Compositions of the Present Technology Decrease Protease Activity
- a fluorometric assay is utilized to determine residual protease activities after incubation with the test wound dressing, device, layer, and/or apparatuse samples. Briefly, samples of the present technology, a standard collagen/ORC dressing, or a conventional coated wound dressing are incubated either in a solution of simulated wound fluid (SWF) containing human neutrophil elastase (HNE, 273 mU/mL) for 24 hours at 37° C, or in a solution of SWF containing matrix metalloproteinase-9 (MMP- 9, 1 pg/mL) for 2 hours at 37° C.
- SWF simulated wound fluid
- HNE human neutrophil elastase
- MMP- 9, 1 pg/mL matrix metalloproteinase-9
- wound dressing compositions, devices, layers, and/or apparatuses of the present technology exhibit reduced protease levels and improved wound healing of chronic or acute wounds compared to standard collagen/ORC dressings and/or conventional coated wound dressings (e.g., a wound dressing that includes a collagen and an oxidized cellulose that has been freeze-dried first and then has been coated with the same formulation).
- the wound dressing compositions, devices, layers, and/or apparatuses of the present technology are useful in methods for treating a wound in a subject in need thereof, wherein the method comprises administering to the wound a dressing, device, layer, and/or apparatus of any embodiment disclosed herein.
- a range includes each individual member.
- a group having 1-3 cells refers to groups having 1, 2, or 3 cells.
- a group having 1-5 cells refers to groups having 1, 2, 3, 4, or 5 cells, and so forth.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Manufacturing & Machinery (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
The present disclosure relates generally to wound dressing compositions including a mixture of a collagen and an oxidized cellulose with a coated layer of functional molecules disposed therein. Also disclosed herein are methods of use for and manufacturing of such wound dressing compositions as well as kits including such wound dressing compositions, and instructions for use.
Description
PROCESS OF INCORPORATION OF FUNCTIONAU MOUECUUES WITHIN FREEZE-
DRIED DRESSING
CROSS-REFERENCE TO REUATED APPUICATIONS
[0001] This application claims the benefit of priority to U.S. Provisional Application No. 62/875,670, filed on July 18, 2019, which is incorporated herein by reference in its entirety.
TECHNICAU FIEUD
[0002] The present technology relates generally to wound dressing compositions including a mixture of a collagen and an oxidized cellulose and including a coating comprising functional molecules that is disposed adjacent to a wound-facing surface. Methods of manufacture and use as well as kits regarding the same are also provided.
BACKGROUND
[0003] The following description of the background of the present technology is provided simply as an aid in understanding the present technology and is not admitted to describe or constitute prior art to the present technology.
[0004] The intricate process of wound healing involves the activation of numerous biological pathways that work in concert to regenerate a tissue microenvironment consisting of cells and extracellular matrix (ECM) with enzymes, cytokines, and growth factors. The wound healing process may be divided into the following sequential phases: hemostasis (clotting to stop bleeding), inflammatory response (removal of bacteria and tissue debris from the site of damage), proliferation (cell division to regenerate the tissue, angiogenesis, and matrix deposition), and remodeling (cellular apoptosis and matrix realignment in the newly generated tissue). These responses can be enhanced or accelerated by the delivery of functional molecules to the wound site, for example by coating a wound dressing with the desired functional molecules.
SUMMARY OF THE PRESENT TECHNOUOGY
[0005] In one aspect, the present disclosure provides a wound dressing composition comprising a freeze-dried layer with a wound-facing surface and an environmental-facing surface; wherein the freeze-dried layer comprises a first layer comprising a combination of collagen and an oxidized cellulose; and a coating forming a coated layer on the first layer, the coated layer comprising a formulation comprising an effective amount of at least one biologically active agent wherein the wound dressing composition does not visually appear to be wrinkled. Additionally or alternatively, in some embodiments, the formulation is applied to the first layer before freeze drying the first layer.
[0006] Additionally or alternatively, in some embodiments, the coated layer has an average thickness of about 0.01 mih, about 0.03 mih, about 0.1 mih, about 0.3 mih, about 0.6 mih, about 1 mih, about 2 mih, about 5 mih, about 10 mih, about 15 mih, about 30 mih, about 50 mih, about 75 mm, about 100 mih, about 150 mih, about 200 mm, about 300 mih, about 400 mm, about 500 mih, about 600 mih, about 800 mm, or about 1,000 mih, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the coated layer has an average thickness of about 0.1 mih to about 1 mih, about 0.3 mih to about 3 mih, about 1 mih to about 10 mih, about 3 mih to about 30 mih, about 10 mih to about 100 mih, about 30 mih to about 300 mih, or about 100 mih to about 1000 mih. Additionally or alternatively, in some embodiments, the wound dressing is resistant to structural changes compared to a control dressing that includes a collagen and an oxidized cellulose that has been freeze-dried and has been coated with the same formulation. In some embodiments, the control dressing is coated with the formulation via spray coating or coating with a brush.
[0007] In some embodiments, the oxidized cellulose may be oxidized regenerated cellulose (ORC).
[0008] Additionally or alternatively, in some embodiments, the formulation is applied at a temperature of about 40 °C, about 45 °C, about 50 °C, about 55 °C, about 60 °C, about 65 °C, about 70 °C, about 75 °C, about 80 °C, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the formulation is applied at a temperature of about 40 °C to about 50 °C, about 45 °C to about 55 °C, about 50 °C to about 60 °C, about 55 °C to about 65 °C, about 60 °C to about 70 °C, about 65 °C to about 75 °C, about 70 °C to about 80 °C, or any range including and/or in between any two of these values.
[0009] Additionally or alternatively, in certain embodiments, the first layer is frozen at a temperature between about 0 °C to about -80 °C before application of the formula. In some embodiments, the first layer is frozen at a temperature of about 0 °C, about -5 °C, about -10 °C, about -15 °C, about -20 °C, about -30 °C, about -40 °C, about -50 °C, about -60 °C, about -70 °C, about -80 °C, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the first layer is frozen at a temperature between about 0 °C to about -20 °C, about -10 °C to about -30 °C, about -20 °C to about -40 °C, about -30 °C to about -50 °C, about -40 °C to about -60 °C, about -50 °C to about -70 °C, about -60 °C to about -80 °C, or any range including and/or in between any two of these values.
[0010] Additionally or alternatively, in some embodiments, the first layer may include about 30 wt.% to about 70 wt.% oxidized cellulose. In some embodiments, the first layer may include oxidized cellulose at about 30 wt.%, about 35 wt.%, about 40 wt.%, about 45 wt.%, about 50 wt.%, about 55 wt.%, about 60 wt.%, about 65 wt.%, about 70 wt.%, or any range including and/or in between any two of the preceding values. Additionally or alternatively, in some embodiments, the first layer may include about 30 wt.% to about 40 wt.%, about 35 wt.% to about 45 wt.%, about 40 wt.% to about 50 wt.%, about 45 wt.% to about 55 wt.%, about 50 wt.% to about 60 wt.%, about 55 wt.% to about 65 wt.%,
about 60 wt.% to about 70 wt.% oxidized cellulose, or any range including and/or in between any two of these values.
[0011] In certain embodiments, the oxidized cellulose may have a weight-average molecular weight of about 50,000 to about 1,000,000. Additionally or alternatively, in some embodiments, the oxidized cellulose may have a weight-average molecular weight of about 50,000, about 60,000, about 75,000, about 100,000, about 150,000, about 200,000, about 250,000, about 300,000, about 400,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, about 1,000,000, or any range including and/or in between any two of the preceding values. Additionally or alternatively, in some embodiments, the oxidized cellulose may have a weight-average molecular weight of about 50,000 to about 200,000, about 100,000 to about 250,000, about 200,000 to about 400,000, about 300,000 to about 500,000, about 400,000 to about 800,000, about 600,000 to about 1,000,000, or any range including and/or in between any two of these values.
[0012] In some embodiments, the collagen may be recombinant or naturally occurring. Additionally or alternatively, in some embodiments, the collagen may be a mammalian collagen. Additionally or alternatively, in some embodiments, the mammalian collagen may be a bovine collagen, a human collagen, or any combination thereof. Additionally or alternatively, in some embodiments, the collagen may comprise one or more of type I human recombinant collagen, type III human recombinant collagen, type I bovine collagen, type III bovine collagen, or any combination thereof.
[0013] In some embodiments, the first layer may include about 30 wt.% to about 95 wt.% collagen. Additionally or alternatively, in some embodiments, the first layer may include collagen at about 30 wt.%, about 35 wt.%, about 40 wt.%, about 45 wt.%, about 50 wt.%, about 55 wt.%, about 60 wt.%, about 65 wt.%, about 70 wt.%, about 75 wt.%, about 80 wt.%, about 85 wt.%, about 90 wt.%, about 95 wt.% collagen, or any range including and/or in between any two of the preceding values. Additionally or alternatively, in some embodiments, the first layer may include about 30 wt.% to about 45 wt.%, about 40 wt.% to about 55 wt.%, about 50 wt.% to about 65 wt.%, about 60 wt.% to about 75 wt.%, about 70 wt.% to about 85 wt.%, about 80 wt.% to about 95 wt.% collagen, or any range including and/or in between any two of the preceding values.
[0014] In some embodiments, the collagen may have a weight-average molecular weight of about 5,000 to about 100,000. Additionally or alternatively, in some embodiments, the collagen may have a weight-average molecular weight of about 5,000, about 6,000, about 7,500, about 10,000, about 15,000, about 20,000, about 25,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, about 100,000, or any range including and/or in between any two of the preceding values. Additionally or alternatively, in some embodiments, the collagen may have a weight- average molecular weight of about 5,000 to about 20,000, about 10,000 to about 25,000, about 20,000 to about 40,000, about 30,000 to about 50,000, about 40,000 to about 80,000, about 60,000 to about 100,000, or any range including and/or in between any two of these values.
[0015] In some embodiments, the formulation may include a solvent and an effective amount of at least one agent selected from the group consisting of a growth factor, an antimicrobial agent, a peptide, a biopolymer, and any combination thereof. Additionally or alternatively, in some embodiments, the solvent may be an aqueous solvent or an organic solvent (e.g., water, citric acid, acetic acid etc.).
[0016] In some embodiments, the at least one agent may be included at about 0.01 wt.% to about 40 wt.%, or about 0.5 wt.% to about 5 wt.% in the formulation. Additionally or alternatively, in some embodiments, the at least one agent may be included at about 0.01 wt.%, about 0.025 wt.%, about 0.05 wt.%, about 0.1 wt.%, about 0.25 wt.%, about 0.5 wt.%, about 1 wt.%, about 5 wt.%, about 10 wt.%, about 15 wt.%, about 20 wt.%, about 25 wt.%, about 30 wt.%, about 35 wt.%, about 40 wt.% of the formulation, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the at least one agent may be included about 0.01 wt.% to about 0.1 wt.%, about 0.05 wt.% to about 0.5 wt.%, about 0.1 wt.% to about 1 wt.%, about 0.5 wt.% to about 5 wt.%, about 1 wt.% to about 10 wt.%, about 5 wt.% to about 25 wt.%, about 10 wt.% to about 40 wt.% of the formulation, or any range including and/or in between any two of these values.
[0017] Additionally or alternatively, in some embodiments, the formulation may include one or more of a binder, a colorant, a deodorant agent, a fdler, a plasticizer, a viscosity modifier, an anti microbial, or any combination thereof. The binder may include one or more of hyaluronic acid, chitosan, heparin, alginate, cellulose, fibrin, gelatin, chondroitin sulfate, agarose, dextran, carrageenan, silk, polyethylene glycol), poly(vinyl alcohol), polycaprolactone, polyphophazene, polyglycolic acid, rosin, lactose, sucrose, tapioca starch, polyvinylpyrrolidone, or any combination thereof. In some embodiments, the colorant comprises one or more of direct red 80, bromophenol blue, toluidine blue, a food coloring, Allura Red AC, Erythrosine, Tartrazine 5, Anthocyanins, Curcuma, Annatto, or any combination thereof. Additionally or alternatively, in some embodiments, the deodorant agent comprises one or more of zinc ricinoleate, triethyl citrate, Saccharomyces ferment, Arctium lappa root extract, Humulus lupulus extract, Thymus vulgaris, or any combination thereof. Additionally or alternatively, in certain embodiments, the filler comprises one or more of amorphous silica, mica, kaolin, titanium dioxide, or any combination thereof.
[0018] Additionally or alternatively, in some embodiments, the plasticizer may include one or more of an acetylated monoglyceride, an alkyl citrate, methyl ricinoleate, glycerol, or any combination thereof. In some embodiments, the alkyl citrate may be one or more of triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, trioctyl citrate, acetyl trioctyl citrate, trihexyl citrate, acetyl trihexyl citrate, butyryl trihexyl citrate, trimethyl citrate, or any combination thereof.
[0019] In some embodiments, the viscosity modifier may include one or more of sodium polyacrylate, acrylates/alkyl methacrylate block copolymers, polyacrylic acid, cellulose gum, hydroxyethylcellulose, stearyl alcohol, carbomer, or any combination thereof.
[0020] In some embodiments, the growth factor may include one or more of epidermal growth factor (EGF), hepatocyte growth factor (HGF), fibroblast growth factors (FGFs), platelet-derived
growth factor (PDGF), or any combination thereof. Additionally or alternatively, in some embodiments, the fibroblast growth factors comprise one or more of fibroblast growth factor 1 (FGF1), fibroblast growth factor 2 (FGF2), fibroblast growth factor 3 (FGF3), fibroblast growth factor 4 (FGF4), fibroblast growth factor 5 (FGF5), fibroblast growth factor 6 (FGF6), fibroblast growth factor 7 / keratinocyte growth factor (FGF7/KGF), fibroblast growth factor 8 (FGF8), fibroblast growth factor 9 (FGF9), fibroblast growth factor 10 / keratinocyte growth factor 2 (FGF10/KGF2), fibroblast growth factor 11 (FGF11), fibroblast growth factor 12 (FGF12), fibroblast growth factor 13 (FGF13), fibroblast growth factor 14 (FGF14), fibroblast growth factor 15 (FGF15), fibroblast growth factor 16 (FGF16), fibroblast growth factor 17 (FGF17), fibroblast growth factor 18 (FGF18), fibroblast growth factor 19 (FGF19), fibroblast growth factor 20 (FGF20), fibroblast growth factor 21 (FGF21), fibroblast growth factor 22 (FGF22), fibroblast growth factor 23 (FGF23), or any combination thereof.
[0021] In some embodiments, the antimicrobial agent may include one or more of polyhexamethylene biguanide, acetic acid, benzoic acid, povidone iodine, natamycin, nisin, citric acid, sorbic acid, propionic acid, honey, sulfites, or any combination thereof.
[0022] In some embodiments, the peptide may include one or more of defensins, histatins, cathebcidin LL-37, or any combination thereof.
[0023] In some embodiments, the biopolymer may include one or more of hyaluronic acid, fibrinogen, a chitosan, a polysaccharide, a gelatin, a collagen, an oxidized cellulose, an oxidized regenerated cellulose (ORC), or any combination thereof.
[0024] In another aspect, the present disclosure provides a method for making a wound dressing composition of any embodiment disclosed herein, the method comprising, heating a formulation to about 40 °C to about 80 °C, depositing the formulation onto a layer comprising a collagen and an oxidized cellulose to form a coated layer, and freezing the coated layer, wherein the coated layer has an average thickness of about 0.1 pm to about 1,000 pm. Additionally or alternatively, in some embodiments, the method further comprises drying the coated layer.
[0025] Additionally or alternatively, in some embodiments, the coated layer has an average thickness of about 0.1 pm, about 0.3 pm, about 0.6 pm, about 1 pm, about 2 pm, about 5 pm, about 10 pm, about 15 pm, about 30 pm, about 50 pm, about 75 pm, about 100 pm, about 150 pm, about 200 pm, about 300 pm, about 400 pm, about 500 pm, about 600 pm, about 800 pm, or about 1,000 pm, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the coated layer has an average thickness of about 0.1 pm to about 1 pm, about 0.3 pm to about 3 pm, about 1 pm to about 10 pm, about 3 pm to about 30 pm, about 10 pm to about 100 pm, about 30 pm to about 300 pm, or about 100 pm to about 1000 pm.
[0026] In some embodiments, the method comprises heating the formulation to about 40 °C, about 45 °C, about 50 °C, about 55 °C, about 60 °C, about 65 °C, about 70 °C, about 75 °C, about 80 °C, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the method comprises heating the formulation to about 40 °C to about 50 °C, about 45
°C to about 55 °C, about 50 °C to about 60 °C, about 55 °C to about 65 °C, about 60 °C to about 70 °C, about 65 °C to about 75 °C, about 70 °C to about 80 °C, or any range including and/or in between any two of these values.
[0027] In some embodiments, the formulation is heated for a period between about 0.5 min to about 240 min. Additionally or alternatively, in some embodiments, the formulation is heated for a period between about 0.5 min, about 1 min, about 2.5 min, about 5 min, about 7.5 min, about 10 min, about 15 min, about 30 min, about 45 min, about 60 min, about 90 min, about 120 min, about 150 min, about 180 min, about 210 min, about 240 min, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the formulation is heated for a period between about 0.5 min to about 5 min, about 2 min to about 20 min, about 5 min to about 50 min, about 20 min to about 90 min, about 45 min to about 180 min, about 60 min to about 240 min, or any range including and/or in between any two of these values.
[0028] In some embodiments, the first layer may be frozen to form a frozen layer prior to deposition of the formulation, wherein the frozen layer optionally comprises a first surface.
[0029] In some embodiments, the first surface of the frozen layer may be melted prior to deposition of the formulation.
[0030] In some embodiments, the formulation may be deposited by a spray process or a thin layer application. Additionally or alternatively, in some embodiments, the thin layer application may be carried out by means of a brush.
[0031] In some embodiments, the coated layer is frozen at a temperature between about 0 °C to about -80 °C. Additionally or alternatively, in some embodiments, the coated layer is frozen at a temperature of about 0 °C, about -5 °C, about -10 °C, about -15 °C, about -20 °C, about -30 °C, about -40 °C, about -50 °C, about -60 °C, about -70 °C, about -80 °C, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the coated layer is frozen at a temperature between about 0 °C to about -20 °C, about -10 °C to about -30 °C, about -20 °C to about -40 °C, about -30 °C to about -50 °C, about -40 °C to about -60 °C, about -50 °C to about -70 °C, about -60 °C to about -80 °C, or any range including and/or in between any two of these values.
[0032] In some embodiments, the coated layer may be frozen and/or freeze-dried for a period between about 0.1 min to about 10,000 min. Additionally or alternatively, in some embodiments, the coated layer may be frozen and/or freeze-dried for a period between about 0.1 min, about 0.5 min, about 1 min, about 5 min, about 15 min, about 30 min, about 60 min, about 90 min, about 120 min, about 200 min, about 500 min, about 750 min, about 1000 min, about 2000 min, about 4000 min, about 6000 min, about 8000 min, about 10,000 min, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the coated layer may be frozen and/or freeze-dried for a period between about 0.1 min to about 1 min, about 0.5 min to about 5 min, about 2 min to about 20 min, about 5 min to about 50 min, about 20 min to about 200 min, about 50 min to about 500 min, about 200 min to about 2000 min, about 500 min to about 5000 min, about 1000 min to about 10000
min, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the coated layer may be frozen and/or freeze-dried for at least 30 minutes.
[0033] In some embodiments, the present disclosure provides for a wound dressing composition generated by any method disclosed herein.
[0034] In one aspect, the present disclosure provides a method for treating a wound in a subject in need thereof, the method including administering to the wound a wound dressing composition of any embodiment disclosed herein. Additionally or alternatively in some embodiments, the wound dressing composition induces, enhances, or promotes healing in the subject. Additionally or alternatively, in some embodiments, the subject is human.
[0035] In one aspect, the present disclosure provides a method for preventing or reducing the risk of wound infection in a subject in need thereof, the method including administering to the wound a wound dressing composition of any embodiment disclosed herein. Additionally or alternatively in some embodiments, the wound dressing composition induces, enhances, or promotes healing in the subject. Additionally or alternatively, in some embodiments, the subject is human. Additionally or alternatively, in some embodiments, the method further comprises performing negative pressure wound therapy to the wound prior to, concurrently with or after applying the wound dressing.
[0036] Also provided herein are kits comprising the wound dressing compositions of any embodiment described herein and instructions for use. Additionally or alternatively, in some embodiments, the kit, further comprises negative pressure wound therapy device.
[0037] In one aspect, the present disclosure provides an apparatus comprising a layer with a wound facing surface and an environmental-facing surface, wherein the freeze-dried layer comprises a first layer comprising a combination of collagen and an oxidized cellulose; and a coating forming a coated layer on the first layer, the coated layer comprising a formulation comprising an effective amount of at least one biologically active agent wherein the wound dressing composition does not visually appear to be wrinkled. Additionally or alternatively, in some embodiments, the formulation is applied to the first layer before freeze drying the first layer. Additionally or alternatively, in some embodiments, the coated layer has an average thickness of about 0.1 pm to about 1,000 pm. Additionally or alternatively, in some embodiments, the formulation is applied at a temperature of about 40 °C to about 80 °C. Additionally or alternatively, in some embodiments, the apparatus is resistant to structural changes compared to a control apparatus that includes a collagen and an oxidized cellulose that has been freeze- dried before coating with the same formulation.
[0038] In one aspect, the present disclosure provides a device for the treatment of wound comprising a layer a layer with a wound-facing surface and an environmental-facing surface, wherein the freeze-dried layer comprises a first layer comprising a combination of collagen and an oxidized cellulose; and a coating forming a coated layer on the first layer, the coated layer comprising a formulation comprising an effective amount of at least one biologically active agent wherein the wound dressing composition does not visually appear to be wrinkled. Additionally or alternatively, in some
embodiments, the formulation is applied to the first layer before freeze drying the first layer. Additionally or alternatively, in some embodiments, the coated layer has an average thickness of about 0.1 pm to about 1,000 pm. Additionally or alternatively, in some embodiments, the formulation is applied at a temperature of about 40 °C to about 80 °C. Additionally or alternatively, in some embodiments, the device is resistant to structural changes compared to a device dressing that includes a collagen and an oxidized cellulose that has been freeze-dried before coating with the same formulation.
[0039] In one aspect, the present disclosure provides a method of the treatment of a wound in a subject in need thereof, the method comprising administering to the subject the apparatus disclosed herein or the device for the treatment of wound of any embodiment. Additionally or alternatively, in some embodiments, the method further comprises performing negative pressure wound therapy to the wound prior to, concurrently with or after applying the wound dressing.
[0040] In one aspect, the present disclosure provides a method for preventing or reducing the risk of wound infection in a subject in need thereof, the method comprising administering to the subject the apparatus disclosed herein or the device for the treatment of wound of any embodiment.
BRIEF DESCRIPTION OF THE DRAWINGS
[0041] FIG. l shows a flow diagram of exemplary methods to manufacture the wound dressing compositions of the present technology.
[0042] FIG. 2 shows non-limiting representations of specific embodiments of a wound dressing composition of the present technology.
[0043] FIG. 3 shows decreased wrinkle formation in the wound dressing composition of the present technology (right panel), compared to a wound dressing composition that has been initially freeze-dried prior to applying the citric acid coating (left panel).
DETAILED DESCRIPTION
[0044] It is to be appreciated that certain aspects, modes, embodiments, variations and features of the present methods are described below in various levels of detail in order to provide a substantial understanding of the present technology.
[0045] The present disclosure is directed to wound dressing compositions which have been coated with a formulation to incorporate functional molecules onto the surface of the wound dressing compositions, and methods for making the same. In some instances, the wound dressing compositions of the present technology do not comprise any wrinkles after coating with the formulation, which can be beneficial for ease of use, product packaging and handling, and can decrease the rate of degradation of the wound dressing upon application to a wound (see Kharkar, P.M. et al. Chemical Society Reviews 42:7335-7372 (2013)).
[0046] In one aspect, the present disclosure provides a wound dressing composition comprising a freeze-dried layer with a wound-facing surface and an environmental-facing surface; wherein the freeze-dried layer comprises a first layer comprising a combination of collagen and an oxidized cellulose; and a coating forming a coated layer on the first layer, the coated layer comprising a formulation comprising an effective amount of at least one biologically active agent wherein the wound dressing composition does not visually appear to be wrinkled. Additionally or alternatively, in some embodiments, the formulation the formulation is applied at a temperature of about 40 °C to about 80 °C. Additionally or alternatively, in some embodiments, the formulation is applied to the first layer before freeze drying the first layer. Additionally or alternatively, in some embodiments, the formulation the coated layer has an average thickness of about 0.1 pm to about 1,000 pm. Additionally or alternatively, in some embodiments, the formulation the wound dressing is resistant to structural changes compared to a control dressing that includes a collagen and an oxidized cellulose that has been freeze-dried and has been coated with the same formulation. In some embodiments, the control dressing is coated with the formulation via spray coating or continuous coating with a brush.
[0047] In another aspect, the present disclosure is directed to methods for making a wound dressing composition, the method comprising, heating a formulation to about 40 °C to about 80 °C, depositing the formulation onto a layer comprising a collagen and an oxidized cellulose to form a coated layer, and freezing the coated layer; wherein the coated layer has an average thickness of about 0.1 pm to about 1,000 pm.
[0048] FIG. 1 provides a representative, non-limiting flow diagram of an exemplary method for making the wound dressing compositions of the present technology. FIG. 2 provides representative, non-limiting illustrations of embodiments of the wound dressing compositions of the present technology. FIG. 3 demonstrates that the wound dressing compositions of the present technology feature decreased wrinkle formation compared to the wound dressing compositions which undergo freeze-drying prior to the application of the coating.
Definitions
[0049] The definitions of certain terms as used in this specification are provided below. Unless defined otherwise, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this present technology belongs.
[0050] The following terms are used throughout as defined below.
[0051] As used herein and in the appended claims, singular articles such as“a”,“an”, and“the” and similar referents in the context of describing the elements (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were
individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein, is intended merely to better illuminate the embodiments and does not pose a limitation on the scope of the claims unless otherwise stated. No language in the specification should be construed as indicating any non-claimed element as essential.
[0052] As used herein,“about” will be understood by persons of ordinary skill in the art and will vary to some extent depending upon the context in which it is used. If there are uses of the term which are not clear to persons of ordinary skill in the art, given the context in which it is used,“about” will mean up to plus or minus 10% of the particular term.
[0053] As used herein, the“administration” of a wound dressing composition to a subject includes any route of introducing or delivering to a subject a wound dressing composition to perform its intended function. Administration can be carried out by any suitable route, including but not limited to, topical administration. Administration includes self-administration and the administration by another.
[0054] As used herein, the terms“contain”,“contains”, or“containing” in the context of describing the elements (especially in the context of the following claims) are to be construed as comprising or including the elements being described herein.
[0055] As used herein, the term“effective amount” refers to a quantity sufficient to achieve a desired therapeutic effect and/or prophylactic effect, e.g., an amount which results in the decrease in a wound described herein or one or more signs or symptoms associated with a wound described herein. In the context of therapeutic or prophylactic applications, the wound dressing composition administered to the subject will vary depending on the composition, the degree, type, and severity of the wound and on the characteristics of the individual.
[0056] As used herein, the terms“individual”,“patient”, or“subject” can be an individual organism, a vertebrate, a mammal, or a human. In some embodiments, the individual, patient or subject is a human.
[0057] As understood by one of ordinary skill in the art,“molecular weight” (also known as “relative molar mass”) is a dimensionless quantity that can be converted to molar mass by multiplying by 1 gram/mole - for example, collagen with a weight-average molecular weight of 5,000 has a weight- average molar mass of 5,000 g/mol.
[0058] As used herein, the term“solid content” refers to the density of a material and/or fdm of the wound dressing composition of the present technology, which is its mass per unit volume.
[0059] “Treating” or“treatment” as used herein covers the treatment of a wound described herein, in a subject, such as a human, and includes: (i) inhibiting a wound, i.e., arresting its development; (ii) relieving a wound, i.e., causing regression of the wound; (iii) slowing progression of the wound; and/or (iv) inhibiting, relieving, or slowing progression of one or more symptoms of the wound. In some
embodiments, treatment means that the symptoms associated with the wound are, e.g., alleviated, reduced, cured, or placed in a state of remission.
[0060] As used herein, the term“% w/v” refers to the percent of weight of the solution in the total volume of the solution, i.e., the number of grams of solute in 100 mL of solution.
[0061] It is also to be appreciated that the various modes of treatment of wounds as described herein are intended to mean“substantial,” which includes total but also less than total treatment, and wherein some biologically or medically relevant result is achieved. The treatment may be a continuous prolonged treatment for a chronic wound or a single, or several administrations for the treatment of an acute wound.
The Wound Dressing Compositions of the Present Technology
[0062] The present disclosure provides a wound dressing composition comprising a layer with a wound-facing surface and an environmental-facing surface, wherein the first layer comprises a collagen and an oxidized cellulose, and wherein the first layer is coated with a formulation on the wound-facing surface to form a coated layer on the first layer; wherein the coated layer has an average thickness of about 0.1 pm to about 1,000 pm, the formulation is applied at a temperature of about 40 °C to about 80 °C, and the wound dressing is resistant to structural changes compared to a control dressing that includes a collagen and an oxidized cellulose, and has been freeze-dried and then coated with the same formulation. In any embodiment disclosed herein, the method further comprises drying the coated layer.
[0063] Additionally or alternatively, in some embodiments, the coated layer has an average thickness of about 0.1 pm, about 0.3 pm, about 0.6 pm, about 1 pm, about 2 pm, about 5 pm, about 10 pm, about 15 pm, about 30 pm, about 50 pm, about 75 pm, about 100 pm, about 150 pm, about 200 pm, about 300 pm, about 400 pm, about 500 pm, about 600 pm, about 800 pm, or about 1,000 pm, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the coated layer has an average thickness of about 0.1 pm to about 1 pm, about 0.3 pm to about 3 pm, about 1 pm to about 10 pm, about 3 pm to about 30 pm, about 10 pm to about 100 pm, about 30 pm to about 300 pm, or about 100 pm to about 1000 pm.
[0064] In any embodiment disclosed herein, the formulation is applied at a temperature of about 40 °C to about 80 °C. In any embodiment disclosed herein, the formulation is applied at a temperature of about 40 °C, about 45 °C, about 50 °C, about 55 °C, about 60 °C, about 65 °C, about 70 °C, about 75 °C, about 80 °C, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the formulation is applied at a temperature of about 40 °C to about 50 °C, about 45 °C to about 55 °C, about 50 °C to about 60 °C, about 55 °C to about 65 °C, about 60 °C to about 70 °C, about 65 °C to about 75 °C, about 70 °C to about 80 °C, or any range including and/or in between any two of these values.
[0065] In any embodiment disclosed herein, the collagen may be recombinant or naturally occurring. Additionally or alternatively, in some embodiments, the collagen may be a mammalian collagen, an avian collagen, a reptilian collagen, an amphibian collagen, or any combination thereof. Additionally or alternatively, in some embodiments, the collagen may be mammalian collagen. Additionally or alternatively, in some embodiments, the collagen may be a human collagen. Additionally or alternatively, in some embodiments, the human collagen may be human collagen type I, human collagen type III, or any combination thereof. Additionally or alternatively, in some embodiments, the collagen may be a bovine collagen. Additionally or alternatively, in some embodiments, the collagen may be bovine collagen type I, bovine collagen type II, bovine collagen type III, bovine collagen type IV, or any combination thereof. Additionally or alternatively, in some embodiments, the collagen may be bovine collagen type I and bovine collagen type III.
[0066] In any embodiment disclosed herein, the collagen may be provided by any manner known in the art. Additionally or alternatively, in some embodiments, the collagen may be provided by a tissue sample or recombinantly manufactured. Additionally or alternatively, in some embodiments, mammalian recombinant collagen may be provided by any suitable method known in the art. Additionally or alternatively, in some embodiments, human recombinant collagen may be provided by any suitable method known in the art. For example, the step of providing human recombinant collagen may comprise following the protocol described in U.S. Pat. No. 5,962,648, the entire content of which is incorporated herein by reference. Further recombinant processes are set forth in U.S. Pat. No. 5,593,859 and W02004/078120, which are also incorporated herein by reference. Additionally or alternatively, in some embodiments, collagen will be recombinantly manufactured by culturing a cell which has been transfected with at least one gene encoding a polypeptide comprising collagen and genes encoding oxidized cellulose and subunits of the post-translational enzyme prolyl 4-hydroxylase, and purifying the resultant collagen monomer therefrom. Additionally or alternatively, in some embodiments, collagen will be recombinantly manufactured by a plant (e.g., CollPlant, CollPlant Holdings Ltd., Ness Ziona, Israel) such as tobacco, or in yeast. The human recombinant collagen solution may be subsequently subjected to polymerization or cross-linking conditions to produce an insoluble fibrous collagen.
[0067] In any embodiment disclosed herein, the collagen may be a type I collagen, a type II collagen, or a type III collagen. Additionally or alternatively, in some embodiments, the collagen may be obtained from any natural source, may be chemically-modified collagen (e.g., an atelocollagen obtained by removing the immunogenic telopeptides from natural collagen), or may be any combination thereof. For example, the collagen may include collagen obtained from bovine corium that has been rendered largely free of non-collagenous components, for example, including fat, non-collagenous proteins, polysaccharides, and other carbohydrates, such as by procedures described in U.S. Pat. Nos. 4,614,794 and 4,320,201, the entire contents of which are incorporated by reference.
[0068] In any embodiment disclosed herein, the first layer may include about 1 wt.% to about 95 wt.% collagen. Additionally or alternatively, in some embodiments, the first layer may include about 1 wt.%, about 2 wt.%, about 5 wt.%, about 10 wt.%, about 15 wt.%, about 20 wt.%, about 25 wt.% about 30 wt.%, about 35 wt.%, about 40 wt.%, about 45 wt.%, about 50 wt.%, about 55 wt.%, about 60 wt.%, about 65 wt.%, about 70 wt.%, about 75 wt.%, about 80 wt.%, about 85 wt.%, about 90 wt.%, about 95 wt.%, or any range including and/or in between any two of the preceding values, of collagen. Additionally or alternatively, in some embodiments, the first layer may include about 1 wt.% to about 10 wt.%, about 5 wt.% to about 20 wt.%, 10 wt.% to about 40 wt.%, about 30 wt.% to about 45 wt.%, about 40 wt.% to about 55 wt.%, about 50 wt.% to about 65 wt.%, about 60 wt.% to about 75 wt.%, about 70 wt.% to about 85 wt.%, about 80 wt.% to about 95 wt.% collagen, or any range including and/or in between any two of the preceding values.
[0069] In some embodiments, the collagen may have a weight-average molecular weight of about 5,000 to about 100,000. Additionally or alternatively, in some embodiments, the collagen may have a weight-average molecular weight of about 5,000, about 6,000, about 7,500, about 10,000, about 15,000, about 20,000, about 25,000, about 30,000, about 40,000, about 50,000, about 60,000, about 70,000, about 80,000, about 90,000, about 100,000, or any range including and/or in between any two of the preceding values. Additionally or alternatively, in some embodiments, the collagen may have a weight- average molecular weight of about 5,000 to about 20,000, about 10,000 to about 25,000, about 20,000 to about 40,000, about 30,000 to about 50,000, about 40,000 to about 80,000, about 60,000 to about 100,000, or any range including and/or in between any two of these values.
[0070] In any embodiment disclosed herein, the oxidized cellulose comprises cellulose or a modified form of cellulose such as oxidized regenerated cellulose (ORC). Additionally or alternatively in some embodiments, the oxidized cellulose comprises ORC. In any embodiment disclosed herein, ORC may be produced by the oxidation of cellulose, for example with dinitrogen tetroxide and/or as described in U.S. Pat. No. 3,122,479 (incorporated herein by reference). Without wishing to be bound by theory, it is believed that this process may convert primary alcohol groups on the saccharide residues of the cellulose to carboxylic acid groups, for example, forming uronic acid residues within the cellulose chain. The oxidation need not proceed with complete selectivity, and as a result hydroxyl groups on carbons 2 and 3 of the saccharide residue may be converted to the keto form. These ketone units may introduce an alkali labile link, which at pH 7 or higher initiates the decomposition of the polymer via formation of a lactone and sugar ring cleavage. As a result, oxidized regenerated cellulose is biodegradable and bioresorbable under physiological conditions. ORC is available with a variety of degrees of oxidation and hence rates of degradation.
[0071] In any embodiment disclosed herein, the first layer may include about 30 wt.% to about 70 wt.% oxidized cellulose. In any embodiment disclosed herein, the first layer may include about 30 wt.%, about 35 wt.%, about 40 wt.%, about 45 wt.%, about 50 wt.%, about 55 wt.%, about 60 wt.%, about 65 wt.%, about 70 wt.%, or any range including and/or in between any two of the preceding
values, of oxidized cellulose. In any embodiment disclosed herein, the first layer may include about 30 wt.% to about 40 wt.%, about 35 wt.% to about 45 wt.%, about 40 wt.% to about 50 wt.%, about 45 wt.% to about 55 wt.%, about 50 wt.% to about 60 wt.%, about 55 wt.% to about 65 wt.%, about 60 wt.% to about 70 wt.% oxidized cellulose, or any range including and/or in between any two of these values.
[0072] Additionally or alternatively, in some embodiments, the oxidized cellulose and/or ORC may comprise a weight-average molecular weight of about 50,000 to about 1,000,000. Additionally or alternatively, in some embodiments, the oxidized cellulose may have a weight-average molecular weight of about 50,000, about 60,000, about 75,000, about 100,000, about 150,000, about 200,000, about 250,000, about 300,000, about 400,000, about 500,000, about 600,000, about 700,000, about 800,000, about 900,000, about 1,000,000, or any range including and/or in between any two of the preceding values. Additionally or alternatively, in some embodiments, the oxidized cellulose may have a weight-average molecular weight of about 50,000 to about 200,000, about 100,000 to about 250,000, about 200,000 to about 400,000, about 300,000 to about 500,000, about 400,000 to about 800,000, about 600,000 to about 1,000,000, or any range including and/or in between any two of these values.
[0073] In any embodiment disclosed herein, the ORC may include particles, fibers, or both; in any embodiment disclosed herein, the ORC may be in the form of particles, such as fiber particles or powder particles. In embodiments that include ORC fibers, the ORC fibers may have a volume fraction such that at least 80% of the fibers have lengths in the range from about 5 pm to about 1,000 pm. Additionally or alternatively, in some embodiments, the ORC may include fiber lengths of about 5 pm, about 10 pm, about 20 pm, about 50 pm, about 75 pm, about 100 pm, about 150 pm, about 200 pm, about 300 pm, about 400 pm, about 500 pm, about 600 pm, about 800 pm, about 1,000 pm, or any range including and/or in between any two of the preceding values. Additionally or alternatively, in some embodiments, the ORC may include fiber lengths of about 5 pm to about 50 pm, about 10 pm to about 100 pm, about 50 pm to about 250 pm, about 100 pm to about 500 pm, about 200 pm to about 600 pm, about 500 pm to about 1000 pm, or any range including and/or in between any two of the preceding values.
[0074] In any embodiment disclosed herein, the wound dressing compositions of the present technology may comprise about 30 wt.% to about 90 wt.% of the mixture of collagen and oxidized cellulose. Additionally or alternatively, in some embodiments, the collagen and oxidized cellulose mixture may be comprised at about 30 wt.%, about 40 wt.%, about 50 wt.%, about 60 wt.%, about 70 wt.%, about 80 wt.%, about 90 wt.%, or any range including and/or in between any two of the preceding values. In any embodiment disclosed herein, the mixture of collagen and oxidized cellulose can be included within the wound dressing compositions of the present technology at about 30 wt.% to about 40 wt.%, about 35 wt.% to about 45 wt.%, about 40 wt.% to about 50 wt.%, about 45 wt.% to about 55 wt.%, about 50 wt.% to about 60 wt.%, about 55 wt.% to about 65 wt.%, about 60 wt.% to about 70 wt.% about 65 wt.% to about 75 wt.%, about 70 wt.% to about 80 wt.%, about 75 wt.% to about 85
wt.%, about 80 wt.% to about 90 wt.%, or any range including and/or in between any two of these values.
[0075] In any embodiment disclosed herein, the first layer may be frozen at a temperature between about 0 °C to about -80 °C. Additionally or alternatively, in some embodiments, the first layer is frozen at a temperature of about 0 °C, about -5 °C, about -10 °C, about -15 °C, about -20 °C, about -30 °C, about -40 °C, about -50 °C, about -60 °C, about -70 °C, about -80 °C, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the first layer is frozen at a temperature between about 0 °C to about -20 °C, about -10 °C to about -30 °C, about -20 °C to about -40 °C, about -30 °C to about -50 °C, about -40 °C to about -60 °C, about -50 °C to about -70 °C, about -60 °C to about -80 °C, or any range including and/or in between any two of these values.
[0076] In any embodiment disclosed herein, the formulation may include a solvent and an effective amount of at least one agent selected from the group consisting of a growth factor, an antimicrobial agent, a peptide, a biopolymer, and any combination thereof. Additionally or alternatively, in some embodiments, the solvent may be an aqueous solvent or an organic solvent. Additionally or alternatively, in some embodiments, the aqueous solvent may include a dilute organic acid, for example, acetic acid, citric acid, or a combination thereof.
[0077] In any embodiment disclosed herein, the formulation may include one or more of a binder, a colorant, a deodorant agent, a filler, a plasticizer, a viscosity modifier, an anti-microbial, or any combination thereof.
[0078] In any embodiment disclosed herein, the binder may be one or more of hyaluronic acid, chitosan, heparin, alginate, cellulose, fibrin, gelatin, chondroitin sulfate, agarose, dextran, carrageenan, silk, poly(ethylene glycol), poly(vinyl alcohol), polycaprolactone, polyphosphazene, polyglycolic acid, rosin, lactose, sucrose, tapioca starch, polyvinylpyrrolidone, or any combination thereof. Additionally or alternatively, in some embodiments, the formulation may include about 1 % w/v to about 10 % w/v of the binder. Additionally or alternatively, in some embodiments, the formulation may include about 1.0 % w/v, about 2.0 % w/v, about 3.0 % w/v, about 4.0 % w/v, about 5.0 % w/v, about 6.0 % w/v, about 7.0 % w/v, about 8.0 % w/v, about 9.0 % w/v, about 10 % w/v, or any range including and/or in between any two of the preceding values, of the binder. Additionally or alternatively, in some embodiments, the formulation may include about 1.0 % w/v to about 2.5 % w/v, about 2.0 % w/v to about 4 % w/v, 3.0 % w/v to about 5.0 % w/v, about 4.0 % w/v to about 6 % w/v, 5.0 % w/v to about 7.0 % w/v, about 6.0 % w/v to about 8 % w/v, 7.0 % w/v to about 9.0 % w/v, about 8.0 % w/v to about 10 % w/v, or any range including and/or in between any two of the preceding values, of the binder.
[0079] In any embodiment disclosed herein, the colorant may be one or more of direct red 80, bromophenol blue, toluidine blue, a food coloring, Allura Red AC, Erythrosine, Tartrazine 5, Anthocyanins, Curcuma, Annatto, or any combination thereof. Additionally or alternatively, in some embodiments, the formulation may include about 0.1 % w/v to about 5 % w/v of the colorant. Additionally or alternatively, in some embodiments, the formulation may include about 1 % w/v to
about 10 % w/v of the colorant. Additionally or alternatively, in some embodiments, the formulation may include about 0.1 % w/v, about 0.15 % w/v, about 0.20 % w/v, about 0.30 % w/v, about 0.50 % w/v, about 0.75 % w/v, about 1.0 % w/v, about 2.0 % w/v, about 2.5 % w/v, about 3.0 % w/v, about 4.0 % w/v, about 5.0 % w/v, or any range including and/or in between any two of the preceding values, of the colorant. Additionally or alternatively, in some embodiments, the formulation may include about 0.1 % w/v to about 0.5 % w/v, about 0.25 % w/v to about 1.25 % w/v, about 1 % w/v to about 3 % w/v, about 2.0 % w/v to about 4.0 % w/v, about 2.5 % w/v to about 5.0 % w/v, or any range including and/or in between any two of the preceding values, of the colorant.
[0080] In any embodiment disclosed herein, the deodorant agent may be one or more of zinc ricinoleate, triethyl citrate, Saccharomyces ferment, Arctium lappa root extract, Humulus lupulus extract, Thymus vulgaris, or any combination thereof. Additionally or alternatively, in some embodiments, the formulation may include about 0.01 % w/v to about 5 % w/v of the deodorant agent. Additionally or alternatively, in some embodiments, the formulation may include about 0.01 % w/v, about 0.025 % w/v, about 0.05 % w/v, about 0.075 % w/v, 0.1 % w/v, about 0.20 % w/v, about 0.30 % w/v, about 0.50 % w/v, about 0.75 % w/v, about 1.0 % w/v, about 2.0 % w/v, about 2.5 % w/v, about 3.0 % w/v, about 4.0 % w/v, about 5.0 % w/v, or any range including and/or in between any two of the preceding values, of the deodorant agent. Additionally or alternatively, in some embodiments, the formulation may include about 0.01 % w/v to about 0.05 % w/v, about 0.025 % w/v to about 0.125 % w/v, 0.1 % w/v to about 0.5 % w/v, about 0.25 % w/v to about 1.25 % w/v, about 1 % w/v to about 3 % w/v, about 2.0 % w/v to about 4.0 % w/v, about 2.5 % w/v to about 5.0 % w/v, or any range including and/or in between any two of the preceding values, of the deodorant agent.
[0081] In any embodiment disclosed herein, the fdler may be one or more of amorphous silica, mica, kaolin, titanium dioxide, or any combination thereof. Additionally or alternatively, in some embodiments, the formulation may include about 0.01 % w/v to about 10 % w/v of the fdler. Additionally or alternatively, in some embodiments, the formulation may include about 0.01 % w/v, about 0.025 % w/v, about 0.05 % w/v, about 0.075 % w/v, 0.1 % w/v, about 0.20 % w/v, about 0.30 % w/v, about 0.50 % w/v, about 0.75 % w/v, about 1.0 % w/v, about 2.0 % w/v, about 2.5 % w/v, about 3.0 % w/v, about 4.0 % w/v, about 5.0 % w/v, about 6.0 % w/v, about 7.0 % w/v, about 8.0 % w/v, about 9.0 % w/v, about 10.0 % w/v, or any range including and/or in between any two of the preceding values, of the fdler. Additionally or alternatively, in some embodiments, the formulation may include about 0.01 % w/v to about 0.05 % w/v, about 0.025 % w/v to about 0.125 % w/v, 0.1 % w/v to about 0.5 % w/v, about 0.25 % w/v to about 1.25 % w/v, about 1 % w/v to about 3 % w/v, about 2.0 % w/v to about 4.0 % w/v, about 2.5 % w/v to about 7.5 % w/v, about 3.0 % w/v to about 10.0 % w/v, or any range including and/or in between any two of the preceding values, of the fdler.
[0082] In any embodiment disclosed herein, the plasticizer may include at least one component selected from the group consisting of an acetylated monoglyceride, an alkyl citrate, methyl ricinoleate, and glycerol. Additionally or alternatively, in some embodiments, the alkyl citrate may be triethyl
citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, trioctyl citrate, acetyl trioctyl citrate, trihexyl citrate, acetyl trihexyl citrate, butyryl trihexyl citrate, trimethyl citrate, or any combination thereof. Additionally or alternatively, in some embodiments, the formulation may include about 1 % w/v to about 10 % w/v of the at least one plasticizer. Thus, the at least one plasticizer may be included in an amount of about 0.01 % w/v, about 0.025 % w/v, about 0.05 % w/v, about 0.075 % w/v, 0.1 % w/v, about 0.20 % w/v, about 0.30 % w/v, about 0.50 % w/v, about 0.75 % w/v, about 1.0 % w/v, about 2.0 % w/v, about 2.5 % w/v, about 3.0 % w/v, about 4.0 % w/v, about 5.0 % w/v, about 6.0 % w/v, about 7.0 % w/v, about 8.0 % w/v, about 9.0 % w/v, about 10.0 % w/v, or any range including and/or in between any two of the preceding values, of the at least one plasticizer. Additionally or alternatively, in some embodiments, the formulation may include about 0.01 % w/v to about 0.05 % w/v, about 0.025 % w/v to about 0.125 % w/v, 0.1 % w/v to about 0.5 % w/v, about 0.25 % w/v to about 1.25 % w/v, about 1 % w/v to about 3 % w/v, about 2.0 % w/v to about 4.0 % w/v, about 2.5 % w/v to about 7.5 % w/v, about 3.0 % w/v to about 10.0 % w/v, or any range including and/or in between any two of the preceding values, of at least one plasticizer.
[0083] In any embodiment disclosed herein, the viscosity modifier may be one or more of sodium polyacrylate, acrylates/alkyl methacrylate block copolymers, polyacrylic acid, cellulose gum, hydroxyethylcellulose, stearyl alcohol, carbomer, or any combination thereof. Additionally or alternatively, in some embodiments, the formulation may include about 0.1 % w/v to about 10 % w/v of the viscosity modifier. Additionally or alternatively, in some embodiments, the formulation may include an amount of about 0.01 % w/v, about 0.025 % w/v, about 0.05 % w/v, about 0.075 % w/v, 0.1 % w/v, about 0.20 % w/v, about 0.30 % w/v, about 0.50 % w/v, about 0.75 % w/v, about 1.0 % w/v, about 2.0 % w/v, about 2.5 % w/v, about 3.0 % w/v, about 4.0 % w/v, about 5.0 % w/v, about 6.0 % w/v, about 7.0 % w/v, about 8.0 % w/v, about 9.0 % w/v, about 10.0 % w/v, or any range including and/or in between any two of the preceding values, of the viscosity modifier. Additionally or alternatively, in some embodiments, the formulation may include about 0.01 % w/v to about 0.05 % w/v, about 0.025 % w/v to about 0.125 % w/v, 0.1 % w/v to about 0.5 % w/v, about 0.25 % w/v to about 1.25 % w/v, about 1 % w/v to about 3 % w/v, about 2.0 % w/v to about 4.0 % w/v, about 2.5 % w/v to about 7.5 % w/v, about 3.0 % w/v to about 10.0 % w/v, or any range including and/or in between any two of the preceding values, of the viscosity modifier.
[0084] In any embodiment disclosed herein, the formulation may include about 0.01 wt.% to about 40 wt.%, or about 0.5 wt.% to about 5 wt.% of the at least one agent. Additionally or alternatively, in some embodiments, the formulation may include at least one agent at about 0.01 wt.%, about 0.025 wt.%, about 0.05 wt.%, about 0.1 wt.%, about 0.25 wt.%, about 0.5 wt.%, about 1 wt.%, about 5 wt.%, about 10 wt.%, about 15 wt.%, about 20 wt.%, about 25 wt.%, about 30 wt.%, about 35 wt.%, about 40 wt.%, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the at least one agent may be included at about 0.01 wt.% to about 0.1 wt.%, about 0.05 wt.% to about 0.5 wt.%, about 0.1 wt.% to about 1 wt.%, about 0.5 wt.% to about 5 wt.%,
about 1 wt.% to about 10 wt.%, about 5 wt.% to about 25 wt.%, about 10 wt.% to about 40 wt.% of the formulation, or any range including and/or in between any two of these values.
[0085] In any embodiment disclosed herein, the growth factor may include one or more of epidermal growth factor (EGF), hepatocyte growth factor (HGF), fibroblast growth factors (FGFs), or platelet-derived growth factor (PDGF). Additionally or alternatively, in some embodiments, the fibroblast growth factors comprise one or more of fibroblast growth factor 1 (FGF1), fibroblast growth factor 2 (FGF2), fibroblast growth factor 3 (FGF3), fibroblast growth factor 4 (FGF4), fibroblast growth factor 5 (FGF5), fibroblast growth factor 6 (FGF6), fibroblast growth factor 7 / keratinocyte growth factor (FGF7/KGF), fibroblast growth factor 8 (FGF8), fibroblast growth factor 9 (FGF9), fibroblast growth factor 10 / keratinocyte growth factor 2 (FGF10/KGF2), fibroblast growth factor 11 (FGF11), fibroblast growth factor 12 (FGF12), fibroblast growth factor 13 (FGF13), fibroblast growth factor 14 (FGF14), fibroblast growth factor 15 (FGF15), fibroblast growth factor 16 (FGF16), fibroblast growth factor 17 (FGF17), fibroblast growth factor 18 (FGF18), fibroblast growth factor 19 (FGF19), fibroblast growth factor 20 (FGF20), fibroblast growth factor 21 (FGF21), fibroblast growth factor 22 (FGF22), fibroblast growth factor 23 (FGF23), or any combination thereof.
[0086] In any embodiment disclosed herein, the antimicrobial agent may include one or more of polyhexamethylene biguanide, povidone-iodine, acetic acid, benzoic acid, povidone iodine, natamycin, nisin, citric acid, sorbic acid, propionic acid, honey, a silver compound, sulfites, or any combination thereof.
[0087] In any embodiment disclosed herein, the peptide may be one or more of defensins, histatins, cathelicidin FF-37, or any combination thereof.
[0088] In any embodiment disclosed herein, the biopolymer may be one or more of hyaluronic acid, fibrinogen, a chitosan, a polysaccharide, a gelatin, an oxidized cellulose, an oxidized regenerated cellulose (ORC), or any combination thereof. Additionally or alternatively, in some embodiments, the wound dressing composition of the present technology may include one or more synthetic polymers including, but not limited to, polyethylene glycol), poly(lactic acid), poly(vinyl alcohol) and polycaprolactone .
[0089] In any embodiment disclosed herein, the first layer has a thickness of about 1 mm to about 15 mm, or about 3 mm to about 8 mm. Additionally or alternatively, in some embodiments of the wound dressing disclosed herein, the first layer may have a thickness of about 1 mm, about 1.5 mm, about 2 mm, about 2.5 mm, about 3 mm, about 4 mm, about 5 mm, about 6 mm, about 7 mm, about 8 mm, about 9 mm, about 10 mm, about 11 mm, about 12 mm, about 13 mm, about 14 mm, about 15 mm, or any range including and/or in between any two of the preceding values. Additionally or alternatively, in some embodiments of the wound dressing disclosed herein, the first layer may have a thickness of about 1 mm to about 3 mm, about 2 mm to about 4 mm, about 3 mm to about 5 mm, about 4 mm to about 6 mm, about 5 mm to about 7 mm, about 6 mm to about 8 mm, about 7 mm to about 9
mm, about 8 mm to about 10 mm, about 9 mm to about 11 mm, about 10 mm to about 13 mm, about 12 mm to about 15 mm, or any range including and/or in between any two of the preceding values.
[0090] In any embodiment disclosed herein, the first layer and/or coated layer may optionally include a silver compound. Additionally or alternatively, in some embodiments, the first layer and/or coated layer may comprise about 0.1 wt.% to about 3 wt.% of a silver compound. Additionally or alternatively, in some embodiments, the first layer and/or coated layer may comprise about 0.1 wt.%, about 0. 25 wt.%, about 0.5 wt.%, about 0.75 wt.%, about 1 wt.%, about 1.5 wt.%, about 2 wt.%, about 2.5 wt.%, about 3 wt.%, or any range including and/or in between any two of the preceding values, of the silver compound. Additionally or alternatively, in some embodiments, the first layer and/or coated layer may comprise 0.1 wt.%, to about 0.3 wt.%, about 0.25 wt.% to about 0.75 wt.%, about 0.5 wt.% to about 1.5 wt.%, about 1 wt.% to about 2 wt.%, about 1.5 wt.% to about 3 wt.%, or any range including and/or in between any two of the preceding values, of the silver compound.
[0091] In any embodiment disclosed herein, the silver compound of the first and/or coated layer may include one or more pharmaceutically acceptable silver salts. Exemplary sources of the one or more pharmaceutically acceptable silver salts include, but are not limited to, silver oxide, silver chromate, silver allantoinate, silver borate, silver glycerolate, silver nitrate, silver acetate, silver chloride, silver sulfate, silver lactate, silver bromide, silver iodide, silver carbonate, silver citrate, silver laurate, silver deoxycholate, silver salicylate, silver p-aminobenzoate, silver p-aminosalicylate, nanocrystalline silver, any pharmaceutically acceptable salt thereof, or any combination thereof. Additionally or alternatively, in some embodiments of the wound dressing disclosed herein, the silver compound comprises a silver (II) oxide, silver (III) oxide, a silver oxy-salt, or any combination thereof. Additionally or alternatively, in some embodiments of the wound dressing disclosed herein, the silver oxy-salt may comprise a general formula of Ag(Ag30a)X, wherein X can include, but is not limited to, one or more acid anions such as sulfates, chlorides, phosphates, carbonates, citrates, tartrates, or oxalates; and wherein a is at least two.
[0092] In any embodiment disclosed herein, the first layer may include about 1 wt.% to about 15 wt.% of at least one plasticizer. Additionally or alternatively, in some embodiments, the at least one plasticizer of the first layer may be include at about 1 wt.%, about 2 wt.%, about 3 wt.%, about 4 wt.%, about 5 wt.%, about 6 wt.%, about 8 wt.%, about 10 wt.%, about 12.5 wt.%, about 15 wt.%, or any range including and/or in between any two of the preceding values. Additionally or alternatively, in some embodiments, the at least one plasticizer of the first layer may be include at about 1 wt.% to about 3 wt.%, about 2 wt.% to about 4 wt.%, about 3 wt.% to about 5 wt.%, about 4 wt.% to about 6 wt.%, about 5 wt. % to about 10 wt. %, about 8 wt. % to about 15 wt. %, or any range including and/or in between any two of the preceding values. Additionally or alternatively, in some embodiments, the at least one plasticizer may be an acetylated monoglyceride, an alkyl citrate, methyl ricinoleate, glycerol, polyvinylpyrrolidone, and any combination thereof. Additionally or alternatively, in some embodiments, the alkyl citrate may be triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl
tributyl citrate, trioctyl citrate, acetyl trioctyl citrate, trihexyl citrate, acetyl trihexyl citrate, butyryl trihexyl citrate, trimethyl citrate, and any combination thereof.
[0093] In any embodiment of the wound dressing disclosed herein, the anthocyanins are selected from the group consisting of cyanidin, delphinidin, malvidin, pelargonidin, peonidin, petunidin, and mixtures thereof.
[0094] In any embodiment of the wound dressing disclosed herein, the flavanols are selected from the group consisting of catechin, epicatechin, theaflavin, thearubigins, gallocatechin, epigallocatechin, or any gallate ester thereof, and mixtures thereof.
[0095] In any embodiment of the wound dressing disclosed herein, the flavanones are selected from the group consisting of eriodictyol, hesperetin, naringenin, and mixtures thereof.
[0096] In any embodiment of the wound dressing disclosed herein, the flavones are selected from the group consisting of apigenin, luteolin, tangeritin, and mixtures thereof.
[0097] In any embodiment of the wound dressing disclosed herein, the flavonols are selected from the group consisting of isorhamnetin, kaempferol, myricetin, proanthocyanidins, quercetin, rutin, and mixtures thereof.
[0098] In any embodiment of the wound dressing disclosed herein, the isoflavone phytoestrogens are selected from the group consisting of daidzein, genistein, glycitein, and any combination thereof.
[0099] In any embodiment of the wound dressing disclosed herein, the phenolic acids are selected from the group consisting of chicoric acid, chlorogenic acid, cinnamic acid, ellagic acid, ellagitannins, gallic acid, gallotannins, rosmarinic acid, salicylic acid, or any ester thereof, and any combination thereof.
[00100] In any embodiment of the wound dressing disclosed herein, the stillbenoids are selected from the group consisting of resveratrol, pterostilbene, and any combination thereof.
[00101] In any embodiment disclosed herein, the solid content of the first layer may be comprised at about 0.1 wt.%to about 10 wt.%. Additionally or alternatively, in some embodiments, the solid content of the first layer may be comprised at about 0.1 wt.%, about 0. 25 wt.%, about 0.5 wt.%, about 0.75 wt.%, about 1 wt.%, about 1.5 wt.%, about 2 wt.%, about 2.5 wt.%, about 3 wt.%, about 5 wt.%, about 7.5 wt.%, about 10 wt.%, or any range including and/or in between any two of the preceding values. Additionally or alternatively, in some embodiments, the solid content of the first layer may be comprised at about 0.1 wt.%, to about 0.3 wt.%, about 0.25 wt.% to about 0.75 wt.%, about 0.5 wt.% to about 1.5 wt.%, about 1 wt.% to about 3 wt.%, about 2 wt.% to about 6 wt.%, about 3 wt.% to about 10 wt.%, or any range including and/or in between any two of the preceding values.
[00102] In one aspect, the present disclosure provides an apparatus comprising a layer with a wound facing surface and an environmental-facing surface, wherein the freeze-dried layer comprises a first layer comprising a combination of collagen and an oxidized cellulose; and a coating forming a coated layer on the first layer, the coated layer comprising a formulation comprising an effective amount of at least one biologically active agent wherein the wound dressing composition does not visually appear to
be wrinkled. Additionally or alternatively, in some embodiments, the formulation is applied to the first layer before freeze drying the first layer. Additionally or alternatively, in some embodiments, the coated layer has an average thickness of about 0.1 pm to about 1,000 pm. Additionally or alternatively, in some embodiments, the formulation is applied at a temperature of about 40 °C to about 80 °C. Additionally or alternatively, in some embodiments, the apparatus is resistant to structural changes compared to a control apparatus dressing that includes a collagen and an oxidized cellulose that has been freeze-dried before coating with the same formulation.
[00103] In one aspect, the present disclosure provides a device for the treatment of wound comprising a layer a layer with a wound-facing surface and an environmental-facing surface, wherein the freeze-dried layer comprises a first layer comprising a combination of collagen and an oxidized cellulose; and a coating forming a coated layer on the first layer, the coated layer comprising a formulation comprising an effective amount of at least one biologically active agent wherein the wound dressing composition does not visually appear to be wrinkled. Additionally or alternatively, in some embodiments, the formulation is applied to the first layer before freeze drying the first layer. Additionally or alternatively, in some embodiments, the coated layer has an average thickness of about 0.1 pm to about 1,000 pm. Additionally or alternatively, in some embodiments, the formulation is applied at a temperature of about 40 °C to about 80 °C. Additionally or alternatively, in some embodiments, the device is resistant to structural changes compared to a control device that includes a collagen and an oxidized cellulose that has been freeze-dried before coating with the same formulation.
Therapeutic and Prophylactic Methods of the Present Technology
[00104] In one aspect, the present disclosure provides a method for treating a wound in a subject in need thereof, the method including administering to the wound a wound dressing composition, apparatus, device, and/or layer of any embodiment disclosed herein. Additionally or alternatively in some embodiments, the wound dressing composition, apparatus, device, and/or layer induces, enhances, or promotes healing in the subject. Additionally or alternatively, in some embodiments, the subject is human.
[00105] In another related aspect, the present disclosure provides a method for preventing or reducing the risk of wound infection in a subject in need thereof, the method including administering to the wound a wound dressing composition, apparatus, device, and/or layer of any embodiment disclosed herein. Additionally or alternatively in some embodiments, the wound dressing composition, apparatus, device, and/or layer induces, enhances, or promotes healing in the subject. Additionally or alternatively, in some embodiments, the subject is human.
[00106] In any embodiment disclosed herein, the wound is an acute wound selected from the group consisting of bums, skin grafts, and dehisced surgical wounds. Additionally or alternatively, in some embodiments of the methods disclosed herein, the wound is a chronic wound selected from the group consisting of infectious wounds, venous ulcers, arterial ulcers, decubitis ulcers and diabetic ulcers.
[00107] Any method known to those in the art for administering a wound dressing composition, apparatus, device, and/or layer to an acute wound or a chronic wound disclosed herein may be employed. Suitable methods include in vitro or in vivo methods. In vivo methods typically include the administration of one or more wound dressing compositions, apparatuses, devices, and/or layers to a subject in need thereof, suitably a human. In some embodiments, the wound dressing composition, apparatus, device, and/or layer is applied directly to the wound. When used in vivo for therapy, the one or more wound dressing compositions, apparatus, device, and/or layer described herein are administered to the subject in effective amounts (i.e., amounts that have desired therapeutic effect). The dose and dosage regimen will depend upon the state of the wound of the subject, and the characteristics of the particular wound dressing, apparatus, device, and/or layer used.
[00108] The effective amount may be determined during pre-clinical trials and clinical trials by methods familiar to physicians and clinicians. An effective amount of one or more wound dressing compositions, apparatus, device, and/or layer useful in the methods may be administered to a subject in need thereof by any number of well-known methods for administering wound dressings, apparatuses, devices, and/or layers.
[00109] In any embodiment disclosed herein, the wound dressing compositions, apparatuses, devices, and/or layers are administered daily for 1 hour or more, for 2 hours or more, for 3 hours or more, for 4 hours or more, for 5 hours or more, for 6 hours or more, for 12 hours or more. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered one, two, three, four, or five times per day. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered daily for one, two, three, four or five weeks. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered daily for less than 6 weeks. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered daily for 6 weeks or more. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered daily for 12 weeks or more. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered every day, every other day, every third day, every fourth day, every fifth day, or every sixth day. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered weekly, bi-weekly, tri-weekly, or monthly. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered for a period of one, two, three, four, or five weeks. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered for six weeks or more. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered for twelve weeks or more. Additionally or alternatively, in some embodiments, the wound dressing compositions,
apparatuses, devices, and/or layers are administered for a period of less than one year. Additionally or alternatively, in some embodiments, the wound dressing compositions, apparatuses, devices, and/or layers are administered for a period of more than one year.
[00110] In some embodiments, the wound dressing compositions apparatuses, devices, and/or layers can be changed for a chronic wound as appropriate. Additionally or alternatively, in some embodiments, the wound is a chronic wound selected from the group consisting of infectious wounds, venous ulcers, arterial ulcers, decubitis ulcers and diabetic ulcers.
[00111] In one aspect, the present disclosure provides a method of the treatment of a wound in a subject in need thereof, the method comprising administering to the subject the apparatus, wound dressings, device, and/or layer disclosed herein of any embodiment disclosed herein.
[00112] In one aspect, the present disclosure provides a method for preventing or reducing the risk of wound infection in a subject in need thereof, the method comprising administering to the subject the apparatus any embodiment disclosed herein.
Methods of Making the Wound Dressings of the Present Technology
[00113] Also disclosed herein are methods for making the wound dressings, apparatuses, devices, and/or layers of the present technology. In one aspect, the present disclosure provides a method for making a wound dressing composition, apparatus, and/or device of any embodiment disclosed herein, the method comprising, heating a formulation to about 40 °C to about 80 °C, depositing the formulation onto a first layer comprising a collagen and an oxidized cellulose to form a coated layer on the first layer, and freezing the coated layer; wherein the coated layer has an average thickness of about 0.1 pm to about 1,000 pm. Additionally or alternatively, in some embodiments, the method further comprises drying the coated layer, wound dressing composition, apparatus, and/or device.
[00114] In any embodiment disclosed herein, the method comprises heating the formulation to about 40 °C, about 45 °C, about 50 °C, about 55 °C, about 60 °C, about 65 °C, about 70 °C, about 75 °C, about 80 °C, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the method comprises heating the formulation to about 40 °C to about 50 °C, about 45 °C to about 55 °C, about 50 °C to about 60 °C, about 55 °C to about 65 °C, about 60 °C to about 70 °C, about 65 °C to about 75 °C, about 70 °C to about 80 °C, or any range including and/or in between any two of these values.
[00115] In any embodiment disclosed herein, the formulation is heated for a period of time between about 0.5 min to about 240 min. Additionally or alternatively, in some embodiments, the formulation is heated for a period between about 0.5 min, about 1 min, about 2.5 min, about 5 min, about 7.5 min, about 10 min, about 15 min, about 30 min, about 45 min, about 60 min, about 90 min, about 120 min, about 150 min, about 180 min, about 210 min, about 240 min, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the formulation is heated for a period between about 0.5 min to about 5 min, about 2 min to about 20 min, about 5 min to about
50 min, about 20 min to about 90 min, about 45 min to about 180 min, about 60 min to about 240 min, or any range including and/or in between any two of these values.
[00116] In any embodiment disclosed herein, the first layer may be frozen to form a frozen layer prior to deposition of the formulation, wherein the frozen layer optionally comprises a first surface. Additionally or alternatively, in some embodiments, the first surface of the frozen layer may be melted prior to deposition of the formulation.
[00117] In any embodiment disclosed herein, the first layer may be frozen at a temperature between about 0 °C to about -80 °C. Additionally or alternatively, in some embodiments, the first layer is frozen at a temperature of about 0 °C, about -5 °C, about -10 °C, about -15 °C, about -20 °C, about -30 °C, about -40 °C, about -50 °C, about -60 °C, about -70 °C, about -80 °C, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the first layer is frozen at a temperature between about 0 °C to about -20 °C, about -10 °C to about -30 °C, about -20 °C to about -40 °C, about -30 °C to about -50 °C, about -40 °C to about -60 °C, about -50 °C to about -70 °C, about -60 °C to about -80 °C, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the first layer may be frozen at a temperature lower than -80 °C. Additionally or alternatively, in some embodiments, the first layer may be frozen at or below the freezing temp of the mixture.
[00118] In any embodiment disclosed herein, the formulation may be deposited by a spray process or a thin layer application. Additionally or alternatively, in some embodiments, the thin layer application may be carried out by means of a brush.
[00119] In any embodiment disclosed herein, the coated layer may be frozen and/or freeze-dried for a period between about 0.1 min to about 10,000 min. Additionally or alternatively, in some embodiments, the coated layer may be frozen and/or freeze-dried for a period between about 0.1 min, about 0.5 min, about 1 min, about 5 min, about 15 min, about 30 min, about 60 min, about 90 min, about 120 min, about 200 min, about 500 min, about 750 min, about 1000 min, about 2000 min, about 4000 min, about 6000 min, about 8000 min, about 10,000 min, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the coated layer may be frozen and/or freeze-dried for a period between about 0.1 min to about 1 min, about 0.5 min to about 5 min, about 2 min to about 20 min, about 5 min to about 50 min, about 20 min to about 200 min, about 50 min to about 500 min, about 200 min to about 2000 min, about 500 min to about 5000 min, about 1000 min to about 10000 min, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the coated layer may be frozen and/or freeze-dried for at least 30 minutes. Additionally or alternatively, in some embodiments, the coated layer may be frozen and/or freeze-dried for at least 30 minutes.
[00120] In any embodiment disclosed herein, the coated layer is further dried and/or freeze-dried at a temperature above the temperature of the first drying and/or freeze drying of the coated fertilizer to facilitate removal of water.
[00121] In some embodiments, the coated layer is freeze-dried for at least 30 min., 1 hour, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 20 hours, or 24 hours.
[00122] For example, in some embodiments, the first layer may include a combination of a collagen and an oxidized regenerated cellulose (ORC) in a ratio of about 70 wt.%:30 wt.%, about 65 wt.%:35 wt.%, about 60 wt.%:40 wt.%, about 55 wt.%:45 wt.%, about 50 wt.%:50 wt.%, about 45 wt.%:55 wt.%, about 40 wt.%:60 wt.%, about 35 wt.%:65 wt.%, about 30 wt.%:70 wt.%, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the first layer may include a combination of a collagen and an oxidized regenerated cellulose (ORC) in a ratio of about 55 wt.%: 45 wt.%. The first layer may be produced by adding a collagen (either in paste or powder form) to an acidic solution e.g., in order to swell the collagen. Examples of suitable acid solutions include, but are not limited to acetic acid and/or ascorbic acid. For example, the collagen may be contacted with the acid solution prior to forming an intermediate slurry with the ORC or an ORC- silver complex. In some embodiments, a slurry material may be generated with a solid content of about 0.1%, about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 8%, about 10%, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, a slurry material may be generated with a solid content of about 0.1% to about 0.5%, about 0.4% to about 2%, about 1% to about 4%, about 3% to about 6%, about 4% to about 10%, or any range including and/or in between any two of these values. The resulting slurry is then frozen. In some embodiments, the resulting slurry may be flash frozen in a freezer at a temperature between about 0 °C, about -1 °C, about -5 °C, about -10 °C, about -15 °C, about -20 °C, about -30 °C, about -40 °C, about -50 °C, about -60 °C, about -70 °C, about -80 °C, or any range including and/or in between any two of these values. Additionally or alternatively, in some embodiments, the resulting slurry may be flash frozen in a freezer at a temperature between about 0 °C to about -10 °C, about -5 °C to about - 20 °C, about -10 °C to about -30 °C, about -20 °C to about -40 °C, about -30 °C to about -60 °C, about -50 °C to about -80 °C, or any range including and/or in between any two of these values. The first layer can then be coated with a thin layer application of a formulation at a temperature of about 40 °C, about 45 °C, about 50 °C, about 55 °C, about 60 °C, about 65 °C, about 70 °C, about 75 °C, about 80 °C, or any range including a temperature and/or range in between any two of these values. Additionally or alternatively, in some embodiments, the formulation may be applied at a temperature of about 40 °C to about 60 °C, about 50 °C to about 70 °C, about 60 °C to about 80 °C, or any range including a temperature and/or range in between any two of these values. The coated layer will then be freeze- dried at a reduced pressure to produce a wound dressing of the present technology.
[00123] In one aspect, the present disclosure provides a method of the treatment of a wound in a subject in need thereof, the method comprising administering to the subject the device for the treatment of wound of any embodiment. In one aspect, the present disclosure provides a method for preventing or reducing the risk of wound infection in a subject in need thereof, the method comprising administering to the subject the device for the treatment of wound of any embodiment. Additionally or
alternatively, in some embodiments, the method further comprises performing negative pressure wound therapy to the wound prior to, concurrently with or after applying the wound dressing.
Kits Comprising the Wound Dressings of the Present Technology
[00124] In a further related aspect, the present disclosure provides kits that include a wound dressing composition of any embodiment described herein and instructions for use. The kits of the present technology may also include instructions for treating a wound in a subject in need thereof. The kit may optionally comprise components such as antiseptic wipes, ointment, adhesive tape, tweezers, or scissors.
[00125] Additionally or alternatively, in some embodiments, the kit, further comprises negative pressure wound therapy device. Additionally or alternatively, in some embodiments, the kit includes a patch, the patch comprising: a patch layer configured to prevent leaks, the patch layer comprising an opening, a patch backing layer adhered to the patch layer, and a patch delivery layer adhered to the patch layer, wherein the patch delivery layer comprises a slit, wherein the slit extends between an opening in the patch delivery layer and an exterior edge of the patch delivery layer; wherein placing the patch comprises positioning the opening in the patch layer over a vacuum port in the dressing layer and securing the patch layer to the dressing layer; and removing the patch delivery layer from the patch layer, wherein the slit permits the patch delivery layer to be removed when a fluid conduit is coupled to the vacuum port.
EXAMPLES
[00126] The present technology is further illustrated by the following Example, which should not be construed as limiting in any way. The examples herein are provided to illustrate advantages of the present technology and to further assist a person of ordinary skill in the art with preparing or using the compositions and systems of the present technology. The examples should in no way be construed as limiting the scope of the present technology, as defined by the appended claims. The examples can include or incorporate any of the variations, aspects, or embodiments of the present technology described above. The variations, aspects, or embodiments described above may also further each include or incorporate the variations of any or all other variations, aspects or embodiments of the present technology.
Example 1: Making the Wound Pres sins Compositions of the Present Technology
[00127] FIG. 1 provides a flow chart for making a wound dressing composition, device, layer, and/or apparatus, of the present technology. Briefly, a wound dressing composition, device, layer, and/or apparatus, of the present technology is made by freezing a slurry comprising collagen and oxidized regenerated cellulose (ORC), coating with a functional molecule, followed by freeze-drying (FIG. 1). The wound dressing composition, device, layer, and/or apparatus of the present technology may
comprise a layer with a wound-facing surface and an environmental-facing surface, wherein the first layer comprises a collagen and an oxidized cellulose, and is coated with a formulation on the wound facing surface to form a coated layer on the first layer; wherein the coated layer has an average thickness of about 0.1 pm to about 1,000 pm, and wherein the formulation is applied at a temperature of about 40 °C to about 80 °C (FIG. 1), and wherein the wound dressing, device, layer, and/or apparatus is resistant to structural changes compared to a control dressing, device, layer, and/or apparatus that includes a collagen and an oxidized cellulose, and has been freeze-dried and then coated with the same formulation (FIGs. 1 and 3).
[00128] In a non-limiting example, the first layer comprises a combination of a collagen and an oxidized regenerated cellulose (ORC) at a ratio of 55 wt.%:45 wt.%. The first layer was produced by adding and homogenising oxidized regenerated cellulose (ORC), and collagen (either in paste or powder form) to an acidic solution (e.g., in order to swell the collagen), resulting in a slurry with 0.55 g solid collagen weight per 100 mL acid solution and 0.45 g ORC per 100 mL slurry. The slurry was then degassed and flash frozen in at -80°C in a freezer to form a block. After freezing a thin layer of a formulation or droplets of a formulation were applied to the wound-facing surface of the block by means of a brush or spraying, respectively, at a temperature of about 40°C. The resulting coated block was subsequently freeze-dried. FIG. 2 shows two non-limiting examples of wound dressings, devices, layers, and/or apparatuses made by this method (left panel shows a uniform coating of citric acid, right panel shows povidone -iodine dots coated on the first layer). The panels also show that surprisingly there is no visually apparent wrinkling of the surface due to the application of the formulation when compared to the uncoated area.
Example 2: Decreased Wrinkle Formation in the Wound Dressing Compositions of the Present Technology
[00129] To understand the effect of the sequence of (1) coating a dressing with a formulation, and (2) freeze drying on the texture of a wound dressing composition, the following two wound dressing compositions were prepared and compared with each other. In the first wound dressing composition, which is shown in FIG. 3 (left panel), the first layer was initially freeze-dried prior to applying a coating of a citric acid formulation. In the second wound dressing composition, which is shown FIG. 3 (right panel), the first layer was first coated with the citric acid formulation and then subjected to freeze- drying. As shown in FIG. 3 (left panel), the first wound dressing composition exhibited wrinkle formation and distortion. Surprisingly, the second wound dressing composition exhibited no visually detectable wrinkle formation or distortion, compared to the first wound dressing composition (FIG. 3 (right panel)). The second wound dressing is desirable because it allows close contact of the formulation with skin and/ or wound surface, ease of handling, ease of packaging, and a uniform dissolution rate. These data demonstrate that the sequence of (1) coating a dressing with a formulation, and (2) freeze can be used to obtain a desirable texture for a wound dressing composition.
[00130] Accordingly, the wound dressing compositions of the present technology show reduced wrinkling and distortion, and are thus useful in the methods disclosed herein.
[00131] As shown in FIG. 2 the methods of making the wound dressing compositions of the present technology allow either uniform coating of formulations, or dotted/ patterned coating of formulations. The methods of making the wound dressing compositions of the present technology are amenable to coating the dressing with a formulation using processes such as soaking, imbibition, layering using an applicator, spray coating or continuous coating with a brush prior to freeze drying the wound dressing composition. This versatility enables coating of the wound dressing compositions of the present technology with a wider variety of formulations, including liquid, powder, semisolid or paste formulations. Likewise, aqueous or non-aqueous formulations can be easily applied.
[00132] Accordingly, the wound dressing compositions of the present technology are more versatile to make, and are thus useful in the methods disclosed herein.
Example 3: Improved Collagen Synthesis Upon Application of the Wound Dressing. Compositions of the Present Technology
[00133] A collagen synthesis assay with dermal fibroblasts is performed. This is a standard assay which shows the amount of collagen synthesized by fibroblasts after stimulation with the active agents in the wound dressing compositions, devices, layers, and/or apparatuses of the present technology. Briefly, 8.4* 104 human fibroblasts (per well) are plated into 24-well plates, and then incubated at 37° C, 5% C02, in 10% FBS-DMEM. Once the cells are confluent (within 24 hours of plating), the 10% FBS-DMEM is removed, and the cells are washed 3 c with serum-free DMEM (SF-DMEM), before the test samples of the present technology or a collagen/ORC alone dressing is added to the cells. Cells are then incubated for 72 hours after which time the media is collected and analyzed for the levels of the C-terminal propeptide of Type- 1 Collagen (CICP) present in the cell culture media. The level of CICP in the media, which is released by the fibroblasts as a by-product of collagen synthesis, is proportional to the level of collagen synthesis and so its level will be used to determine the level of collagen synthesis. It is anticipated that the wound dressing compositions, devices, layers, and/or apparatuses of the present technology will exhibit increased collagen synthesis and improved wound healing of chronic or acute wounds compared to a standard collagen/ORC dressing.
[00134] Further, the collagen synthesis assay with dermal fibroblasts is performed with the wound dressing compositions devices, layers, and/or apparatuses of the present technology as well as a conventional coated wound dressing (e.g., a wound dressing that includes a collagen and an oxidized cellulose that has been freeze-dried first and then has been coated with the same formulation). Following the incubation of dermal fibroblast cells with SF-DMEM extracts of the samples, it is anticipated that the wound dressing compositions devices, layers, and/or apparatuses of the present technology exhibit increased collagen synthesis and improved wound healing of chronic or acute wounds compared to a conventional coated wound dressing.
[00135] Accordingly, the dressings, devices, layers, and/or apparatuses of the present technology are useful in methods for treating a wound in a subject in need thereof, wherein the method comprises administering to the wound a dressing, device, layer, and/or apparatuse of any embodiment disclosed herein.
Example 4: Wound Dressing. Compositions of the Present Technology Decrease Protease Activity
[00136] A fluorometric assay is utilized to determine residual protease activities after incubation with the test wound dressing, device, layer, and/or apparatuse samples. Briefly, samples of the present technology, a standard collagen/ORC dressing, or a conventional coated wound dressing are incubated either in a solution of simulated wound fluid (SWF) containing human neutrophil elastase (HNE, 273 mU/mL) for 24 hours at 37° C, or in a solution of SWF containing matrix metalloproteinase-9 (MMP- 9, 1 pg/mL) for 2 hours at 37° C.
[00137] Following incubation, samples of the protease containing SWF are then evaluated by fluorometric assay to quantify residual protease activities. It is anticipated that the wound dressing compositions, devices, layers, and/or apparatuses of the present technology exhibit reduced protease levels and improved wound healing of chronic or acute wounds compared to standard collagen/ORC dressings and/or conventional coated wound dressings (e.g., a wound dressing that includes a collagen and an oxidized cellulose that has been freeze-dried first and then has been coated with the same formulation).
[00138] Accordingly, the wound dressing compositions, devices, layers, and/or apparatuses of the present technology are useful in methods for treating a wound in a subject in need thereof, wherein the method comprises administering to the wound a dressing, device, layer, and/or apparatus of any embodiment disclosed herein.
EQUIVALENTS
[00139] The present technology is not to be limited in terms of the particular embodiments described in this application, which are intended as single illustrations of individual aspects of the present technology. Many modifications and variations of this present technology can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. Functionally equivalent methods and apparatuses within the scope of the present technology, in addition to those enumerated herein, will be apparent to those skilled in the art from the foregoing descriptions. Such modifications and variations are intended to fall within the scope of the present technology. It is to be understood that this present technology is not limited to particular methods, reagents, compounds, compositions, or biological systems, which can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.
[00140] In addition, where features or aspects of the disclosure are described in terms of Markush groups, those skilled in the art will recognize that the disclosure is also thereby described in terms of any individual member or subgroup of members of the Markush group.
[00141] As will be understood by one skilled in the art, for any and all purposes, particularly in terms of providing a written description, all ranges disclosed herein also encompass any and all possible subranges and combinations of subranges thereof. Any listed range can be easily recognized as sufficiently describing and enabling the same range being broken down into at least equal halves, thirds, quarters, fifths, tenths, etc. As a non-limiting example, each range discussed herein can be readily broken down into a lower third, middle third, and upper third, etc. As will also be understood by one skilled in the art all language such as“up to,”“at least,” and the like include the number recited and refer to ranges which can be subsequently broken down into subranges as discussed above. As will also be understood by one skilled in the art all language such as“greater than,”“less than,” and the like refer to ranges which can be subsequently broken down into subranges as discussed above. Finally, as will be understood by one skilled in the art, a range includes each individual member. Thus, for example, a group having 1-3 cells refers to groups having 1, 2, or 3 cells. Similarly, a group having 1-5 cells refers to groups having 1, 2, 3, 4, or 5 cells, and so forth.
[00142] All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety, including all figures and tables, to the extent they are not inconsistent with the explicit teachings of this specification.
Claims
1. A wound dressing composition comprising a freeze-dried layer with a wound -facing surface and an environmental-facing surface;
wherein the freeze-dried layer comprises
(i) a first layer comprising a combination of collagen and an oxidized cellulose; and
(ii) a coating forming a coated layer on the first layer, the coated layer comprising a formulation comprising an effective amount of at least one biologically active agent
wherein the wound dressing composition does not visually appear to be wrinkled.
2. The wound dressing composition of claim 1, the coated layer has an average thickness of about 0.1 pm to about 1,000 pm.
3. The wound dressing composition of claim 1 or claim 2, wherein the oxidized cellulose comprises oxidized regenerated cellulose (ORC).
4. The wound dressing composition of any one of claims 1-3, wherein the collagen is recombinant or naturally occurring.
5. The wound dressing composition of any one of claims 1-4, wherein the collagen is a mammalian collagen.
6. The wound dressing composition of claim 5, wherein the mammalian collagen comprises a
bovine collagen, a human collagen, or any combination thereof.
7. The wound dressing composition of any one of claims 1-6, wherein the collagen comprises one or more of type I human recombinant collagen, type III human recombinant collagen, type I bovine collagen, type III bovine collagen, or any combination thereof.
8. The wound dressing composition of any one of claims 1-7, wherein the freeze-dried layer
comprises about 30 wt.% to about 95 wt.% collagen.
9. The wound dressing composition of any one of claims 1-8, wherein the collagen has a weight- average molecular weight of about 5,000 to about 100,000.
10. The wound dressing composition of any one of claims 1-9, wherein the freeze-dried layer
comprises about 30 wt.% to about 70 wt.% oxidized cellulose.
11. The wound dressing composition of any one of claims 1-10, wherein the oxidized cellulose has a weight-average molecular weight of about 50,000 to about 1,000,000.
12. The wound dressing composition of any one of claims 1-11, wherein the formulation comprises a solvent before freeze-drying.
13. The wound dressing composition of claim 12, wherein the solvent is an aqueous solvent or an organic solvent.
14. The wound dressing composition of any one of claim 12 or claim 13, wherein the formulation comprised, before freeze-drying, the at least one biologically active agent at about 0.01 wt.% to about 40 wt.%, or about 0.5 wt.% to about 5 wt.%, of the formulation.
15. The wound dressing composition of any one of claims 1-14, wherein the formulation comprises one or more of a binder, a colorant, a deodorant agent, a filler, a plasticizer, a viscosity modifier, or any combination thereof.
16. The wound dressing composition of claim 15, wherein the binder comprises one or more of hyaluronic acid, chitosan, heparin, alginate, cellulose, fibrin, gelatin, chondroitin sulfate, agarose, dextran, carrageenan, silk, poly(ethylene glycol), poly(vinyl alcohol), polycaprolactone, polyphosphazene, polyglycolic acid, rosin, lactose, sucrose, tapioca starch, polyvinylpyrrolidone, or any combination thereof.
17. The wound dressing composition of claim 15 or claim 16, wherein the colorant comprises one or more of direct red 80, bromophenol blue, toluidine blue, a food coloring, Allura Red AC, Erythrosine, Tartrazine 5, Anthocyanins, Curcuma, Annatto, or any combination thereof.
18. The wound dressing composition of any one of claims 15-17, wherein the deodorant agent
comprises one or more of zinc ricinoleate, triethyl citrate, Saccharomyces ferment, Arctium lappa root extract, Humulus lupulus extract, Thymus vulgaris, or any combination thereof.
19. The wound dressing composition of any one of claims 15-18, wherein the filler comprises one or more of amorphous silica, mica, kaolin, titanium dioxide, or any combination thereof.
20. The wound dressing composition of any one of claims 15-19, wherein the plasticizer comprises one or more of an acetylated monoglyceride, an alkyl citrate, methyl ricinoleate, glycerol, or any combination thereof.
21. The wound dressing composition of claim 20, wherein the alkyl citrate is one or more of triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, trioctyl citrate, acetyl trioctyl
citrate, trihexyl citrate, acetyl trihexyl citrate, butyryl trihexyl citrate, trimethyl citrate, or any combination thereof.
22. The wound dressing composition of any one of claims 15-21, wherein the viscosity modifier comprises one or more of sodium polyacrylate, acrylates/alkyl methacrylate block copolymers, polyacrylic acid, cellulose gum, hydroxyethylcellulose, stearyl alcohol, carbomer, or any combination thereof.
23. The wound dressing composition of any one of claims 1-22, wherein the biologically active agent is selected from the group consisting of a growth factor, an antimicrobial agent, a peptide, a biopolymer, and any combination thereof.
24. The wound dressing composition of claim 23, wherein the growth factor comprises one or more of epidermal growth factor (EGF), hepatocyte growth factor (HGF), fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), or any combination thereof.
25. The wound dressing composition of claim 24, wherein the fibroblast growth factors comprise one or more of fibroblast growth factor 1 (FGF1), fibroblast growth factor 2 (FGF2), fibroblast growth factor 3 (FGF3), fibroblast growth factor 4 (FGF4), fibroblast growth factor 5 (FGF5), fibroblast growth factor 6 (FGF6), fibroblast growth factor 7 / keratinocyte growth factor (FGF7/KGF), fibroblast growth factor 8 (FGF8), fibroblast growth factor 9 (FGF9), fibroblast growth factor 10 / keratinocyte growth factor 2 (FGF10/KGF2), fibroblast growth factor 11 (FGF11), fibroblast growth factor 12 (FGF12), fibroblast growth factor 13 (FGF13), fibroblast growth factor 14 (FGF14), fibroblast growth factor 15 (FGF15), fibroblast growth factor 16 (FGF16), fibroblast growth factor 17 (FGF17), fibroblast growth factor 18 (FGF18), fibroblast growth factor 19 (FGF19), fibroblast growth factor 20 (FGF20), fibroblast growth factor 21 (FGF21), fibroblast growth factor 22 (FGF22), fibroblast growth factor 23 (FGF23), or any combination thereof.
26. The wound dressing composition of any one of claims 23-25, wherein the antimicrobial agent comprises one or more of polyhexamethylene biguanide, acetic acid, benzoic acid, povidone iodine, natamycin, nisin, citric acid, sorbic acid, propionic acid, honey, sulfites, or any combination thereof.
27. The wound dressing composition of any one of claims 23-26, wherein the peptide comprises one or more of defensins, histatins, cathelicidin LL-37, or any combination thereof.
28. The wound dressing composition of any one of claims 23-27, wherein the biopolymer comprises one or more of hyaluronic acid, fibrinogen, a chitosan, a polysaccharide, a gelatin, a collagen, an
oxidized cellulose, an oxidized regenerated cellulose (ORC), poly(ethylene glycol), poly(lactic acid), poly(vinyl alcohol), polycaprolactone, or any combination thereof.
29. The wound dressing composition of any one of claims 1-28, wherein the formulation is applied to the first layer before freeze drying the first layer.
30. The wound dressing composition of any one of claims 1-29, wherein the formulation is applied to the a first layer at a temperature of about 40 °C to about 80 °C
31. A method for making a wound dressing composition comprising:
(a) heating a formulation comprising at least one biologically active agent;
(b) depositing the formulation onto a first layer comprising a combination of collagen and an oxidized cellulose to form a coated layer on the first layer; and
(c) freeze-drying the first layer and coated layer.
32. The method of claim 31, wherein the coated layer has an average thickness of about 0.1 pm to about 1,000 pm.
33. The method of claim 31 or claim 32, wherein at least one biologically active agent is selected from the group consisting of a growth factor, an antimicrobial agent, a peptide, a biopolymer, and any combination thereof.
34. The method of any one of claims 31-33, wherein the formulation comprises a solvent.
35. The method of claim 34, wherein the solvent is an aqueous solvent.
36. The method of claim 34 or claim 35, wherein the formulation comprises about 0.01 wt.% to about 40 wt.%, or about 0.5 wt.% to about 5 wt.% of the at least one biologically active agent.
37. The method of any one of claims 34-36, wherein the formulation comprises one or more of a binder, a colorant, a deodorant agent, a filler, a plasticizer, a viscosity modifier, or any combination thereof.
38. The method of claim 37, wherein the binder comprises one or more of hyaluronic acid, chitosan, heparin, alginate, cellulose, fibrin, gelatin, chondroitin sulfate, agarose, dextran, carrageenan, silk, poly(ethylene glycol), poly(vinyl alcohol), polycaprolactone, polyphosphazene, polyglycolic acid, rosin, lactose, sucrose, tapioca starch, polyvinylpyrrolidone, or any combination thereof.
39. The method of claim 37 or claim 38, wherein the colorant comprises one or more of direct red 80, bromophenol blue, toluidine blue, a food coloring, Allura Red AC, Erythrosine, Tartrazine 5, Anthocyanins, Curcuma, Annatto, or any combination thereof.
40. The method of any one of claims 37-39, wherein the deodorant agent comprises one or more of zinc ricinoleate, triethyl citrate, Saccharomyces ferment, Arctium lappa root extract, Humulus lupulus extract, Thymus vulgaris, or any combination thereof.
41. The method of any one of claims 37-40, wherein the filler comprises one or more of amorphous silica, mica, kaolin, titanium dioxide, or any combination thereof.
42. The method of any one of claims 37-41, wherein the plasticizer comprises one or more of an acetylated monoglyceride, an alkyl citrate, methyl ricinoleate, glycerol, or any combination thereof.
43. The method of claim 42, wherein the alkyl citrate is one or more of triethyl citrate, acetyl triethyl citrate, tributyl citrate, acetyl tributyl citrate, trioctyl citrate, acetyl trioctyl citrate, trihexyl citrate, acetyl trihexyl citrate, butyryl trihexyl citrate, trimethyl citrate, or any combination thereof.
44. The method of any one of claims 37-43, wherein the viscosity modifier comprises one or more of sodium polyacrylate, acrylates/alkyl methacrylate block copolymers, polyacrylic acid, cellulose gum, hydroxyethylcellulose, stearyl alcohol, carbomer, or any combination thereof.
45. The method of any one of claims 33-44, wherein the growth factor comprises one or more of epidermal growth factor (EGF), hepatocyte growth factor (HGF), fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), or any combination thereof.
46. The method of claim 45, wherein the fibroblast growth factors comprise one or more of fibroblast growth factor 1 (FGF1), fibroblast growth factor 2 (FGF2), fibroblast growth factor 3 (FGF3), fibroblast growth factor 4 (FGF4), fibroblast growth factor 5 (FGF5), fibroblast growth factor 6 (FGF6), fibroblast growth factor 7 / keratinocyte growth factor (FGF7/KGF), fibroblast growth factor 8 (FGF8), fibroblast growth factor 9 (FGF9), fibroblast growth factor 10 / keratinocyte growth factor 2 (FGF10/KGF2), fibroblast growth factor 11 (FGF11), fibroblast growth factor 12 (FGF12), fibroblast growth factor 13 (FGF13), fibroblast growth factor 14 (FGF14), fibroblast growth factor 15 (FGF15), fibroblast growth factor 16 (FGF16), fibroblast growth factor 17 (FGF17), fibroblast growth factor 18 (FGF18), fibroblast growth factor 19 (FGF19), fibroblast growth factor 20 (FGF20), fibroblast growth factor 21 (FGF21), fibroblast growth factor 22 (FGF22), fibroblast growth factor 23 (FGF23), or any combination thereof.
47. The method of any one of claims 33-46, wherein the antimicrobial agent comprises one or more of polyhexamethylene biguanide, acetic acid, benzoic acid, povidone iodine, natamycin, nisin, citric acid, sorbic acid, propionic acid, honey, sulfites, or any combination thereof.
48. The method of any one of claims 33-47, wherein the peptide comprises one or more of defensins, histatins, cathelicidin LL-37, or any combination thereof.
49. The method of any one of claims 33-48, wherein the biopolymer comprises one or more of
hyaluronic acid, fibrinogen, a chitosan, a polysaccharide, a gelatin, a collagen, an oxidized cellulose, an oxidized regenerated cellulose (ORC), poly(ethylene glycol), poly(lactic acid), poly(vinyl alcohol), polycaprolactone, or any combination thereof.
50. The method of any one of claims 31-49, wherein the first layer is frozen to form a frozen first layer prior to deposition of the formulation.
51. The method of claim 50, wherein the frozen first layer comprises a first surface, wherein the first surface is melted prior to deposition of the formulation.
52. The method of any one of claims 31-51, wherein the formulation is heated to about 40 °C to about 80 °C.
53. The method of any one of claims 31-52, wherein the formulation is heated for a period between about 0.5 min to about 240 min.
54. The method of any one of claims 31-53, wherein the formulation is deposited on the first layer to form a coated layer.
55. The method of claim 54, wherein the formulation is deposited on the first surface to form the coated layer.
56. The method of claim 54 or claim 55, wherein the formulation is deposited by a spray process or a thin layer application.
57. The method of claim 56, wherein the thin layer application is carried out by means of a brush.
58. The method of any one of claims 54-57, wherein the first layer and the coated layer are frozen at a temperature between about 0 °C to about -80 °C.
59. The method of any one of claims 54-58, wherein the first layer and coated layer are freeze-dried for a period between about 0.1 min to about 10,000 min.
60. The method of claim 59, wherein the first layer and coated layer are freeze-dried for at least 6 hours.
61. A wound dressing composition generated by the method of any one of claims 31-60.
62. The wound dressing composition of claim 61, wherein the wound dressing composition does not visually appear to be wrinkled.
63. A method for treating a wound in a subject in need thereof, comprising administering to the wound a wound dressing composition of any one of claims 1-30 or 61-62.
64. A method for preventing or reducing the risk of wound infection in a subject in need thereof, comprising administering to the wound a wound dressing composition of any one of claims 1-30 or 61-62.
65. The method of claim 63 or claim 64, wherein the wound dressing composition induces, enhances, or promotes healing in the subject.
66. The method of any one of claims 63-65, wherein the subject is human.
67. The method of any one of claims 63-65, further comprising performing negative pressure wound therapy to the wound prior to, concurrently with or after applying the wound dressing.
68. A kit comprising the wound dressing composition of any one of claims 1-30 or 61-62 and
instructions for use.
69. The kit of claim 68, further comprising negative pressure wound therapy device.
70. An apparatus comprising a layer with a wound-facing surface and an environmental-facing
surface;
wherein a layer
(i) comprises a first layer comprising a combination of collagen and an oxidized
cellulose; and
(ii) is coating forming a coated layer on the first layer, the coated layer comprising a formulation comprising an effective amount of at least one biologically active agent
wherein the wound dressing composition does not visually appear to be wrinkled.
71. The apparatus of claim 70, wherein the formulation is applied to the first layer before freeze drying the first layer.
72. A device for the treatment of wound comprising a layer with a wound-facing surface and an environmental-facing surface;
wherein the layer
(i) comprises matrix comprising a collagen and an oxidized cellulose; and
(ii) is coated with a formulation on the wound-facing surface to form a coated layer on the matrix;
wherein the layer does not visually appear to be wrinkled.
73. The device of claim 72, wherein the formulation is applied to the first layer before freeze drying the first layer.
74. A method of the treatment of a wound in a subject in need thereof, the method comprising
administering to the subject the apparatus of claim 70 or claim 71 or the device of claim 72 or claim 73.
75. A method for preventing or reducing the risk of wound infection in a subject in need thereof, the method comprising administering to the subject the apparatus of claim 70 or claim 71 or the device of claim 72 or claim 73.
76. The method of claim 74 or claim 75, further comprising performing negative pressure wound therapy to the wound prior to, concurrently with or after applying the wound dressing.
77. The method of any one of claims 74-76, wherein the wound dressing composition induces, enhances, or promotes healing in the subject.
78. The method of any one of claims 74-77, wherein the subject is human.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962875670P | 2019-07-18 | 2019-07-18 | |
US62/875,670 | 2019-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021009713A1 true WO2021009713A1 (en) | 2021-01-21 |
Family
ID=71784347
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2020/056710 WO2021009713A1 (en) | 2019-07-18 | 2020-07-16 | Process of incorporation of functional molecules within freeze-dried dressing |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2021009713A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112717193A (en) * | 2021-02-02 | 2021-04-30 | 孙明侠 | Novel environment-friendly enzyme medical dressing and preparation method thereof |
CN113456878A (en) * | 2021-07-09 | 2021-10-01 | 蓝科医美科学技术(吉林)有限公司 | Plant extract combined dressing based on ginseng extract and preparation method thereof |
CN116019963A (en) * | 2022-12-02 | 2023-04-28 | 江苏弘生生物工程有限公司 | Preparation method of medical silica gel foam dressing |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3122479A (en) | 1957-11-14 | 1964-02-25 | David F Smith | Hemostatic surgical dressings |
US4320201A (en) | 1979-10-27 | 1982-03-16 | Firma Carl Freudenberg | Method for making collagen sponge for medical and cosmetic uses |
US4407787A (en) * | 1980-10-03 | 1983-10-04 | Dr. Ruhland Nachf. Gmbh | Collagenous dressing |
US4614794A (en) | 1983-10-04 | 1986-09-30 | Johnson & Johnson | Protein/polysaccharide complexes |
US5593859A (en) | 1991-10-23 | 1997-01-14 | Thomas Jefferson University | Synthesis of human procollagens and collagens in recombinant DNA systems |
US5962648A (en) | 1993-01-28 | 1999-10-05 | Cohesion Technologies, Inc. | Production of human recombinant collagen in the milk of transgenic mammals |
EP1053029A1 (en) * | 1998-12-07 | 2000-11-22 | Johnson & Johnson Medical Ltd. | Sterile complex of therapeutic peptide bond to a polysaccharide |
WO2004078120A2 (en) | 2003-02-28 | 2004-09-16 | Fibrogen, Inc. | Collagen compositions and biomaterials |
WO2019126368A1 (en) * | 2017-12-20 | 2019-06-27 | Kci Usa, Inc. | Dressing including dehydrated placental tissue for wound healing |
-
2020
- 2020-07-16 WO PCT/IB2020/056710 patent/WO2021009713A1/en active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3122479A (en) | 1957-11-14 | 1964-02-25 | David F Smith | Hemostatic surgical dressings |
US4320201A (en) | 1979-10-27 | 1982-03-16 | Firma Carl Freudenberg | Method for making collagen sponge for medical and cosmetic uses |
US4407787A (en) * | 1980-10-03 | 1983-10-04 | Dr. Ruhland Nachf. Gmbh | Collagenous dressing |
US4614794A (en) | 1983-10-04 | 1986-09-30 | Johnson & Johnson | Protein/polysaccharide complexes |
US5593859A (en) | 1991-10-23 | 1997-01-14 | Thomas Jefferson University | Synthesis of human procollagens and collagens in recombinant DNA systems |
US5962648A (en) | 1993-01-28 | 1999-10-05 | Cohesion Technologies, Inc. | Production of human recombinant collagen in the milk of transgenic mammals |
EP1053029A1 (en) * | 1998-12-07 | 2000-11-22 | Johnson & Johnson Medical Ltd. | Sterile complex of therapeutic peptide bond to a polysaccharide |
WO2004078120A2 (en) | 2003-02-28 | 2004-09-16 | Fibrogen, Inc. | Collagen compositions and biomaterials |
WO2019126368A1 (en) * | 2017-12-20 | 2019-06-27 | Kci Usa, Inc. | Dressing including dehydrated placental tissue for wound healing |
Non-Patent Citations (1)
Title |
---|
KHARKAR, P.M. ET AL., CHEMICAL SOCIETY REVIEWS, vol. 42, 2013, pages 7335 - 7372 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112717193A (en) * | 2021-02-02 | 2021-04-30 | 孙明侠 | Novel environment-friendly enzyme medical dressing and preparation method thereof |
CN113456878A (en) * | 2021-07-09 | 2021-10-01 | 蓝科医美科学技术(吉林)有限公司 | Plant extract combined dressing based on ginseng extract and preparation method thereof |
CN113456878B (en) * | 2021-07-09 | 2022-06-28 | 蓝科医美科学技术(吉林)有限公司 | Plant extract combined dressing based on ginseng extract and preparation method thereof |
CN116019963A (en) * | 2022-12-02 | 2023-04-28 | 江苏弘生生物工程有限公司 | Preparation method of medical silica gel foam dressing |
CN116019963B (en) * | 2022-12-02 | 2023-09-22 | 江苏弘生生物工程有限公司 | Preparation method of medical silica gel foam dressing |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021009713A1 (en) | Process of incorporation of functional molecules within freeze-dried dressing | |
US20200337904A1 (en) | Dressing including dehydrated placental tissue for wound healing | |
EP1325754B1 (en) | Wound dressing materials comprising collagen and oxidized cellulose | |
Kaur et al. | Biomaterials-based regenerative strategies for skin tissue wound healing | |
RU2468129C2 (en) | Biopolymeric fibre, composition of forming solution for its obtaining, method of forming solution preparation, linen of biomedical purpose, biological bandage and method of wound treatment | |
Obara et al. | Photocrosslinkable chitosan hydrogel containing fibroblast growth factor-2 stimulates wound healing in healing-impaired db/db mice | |
Murakami et al. | Hydrogel blends of chitin/chitosan, fucoidan and alginate as healing-impaired wound dressings | |
EP0986408B1 (en) | New medicaments based on polymers composed of methacrylamide-modified gelatin | |
RU2455995C2 (en) | Preparation for wound healing and prevention of bandage adhesion to wound, containing chitosan-glucan complex | |
Yanagibayashi et al. | Novel hydrocolloid-sheet as wound dressing to stimulate healing-impaired wound healing in diabetic db/db mice | |
Sikka et al. | The role of biopolymers and biodegradable polymeric dressings in managing chronic wounds | |
Kratz et al. | Immobilised heparin accelerates the healing of human wounds in vivo | |
CN102727926B (en) | The preparation method of the composite wound dressing of a kind of polysaccharide and nanometer bacteria cellulose | |
CN1887358A (en) | Medical chitosan dressing and its application | |
WO2021240271A1 (en) | Encapsulation of antimicrobial agents for advanced wound dressings | |
CN104623718A (en) | Chitosan petrolatum gauze and preparation method thereof | |
Hasan et al. | Biopolymers in diabetic wound care management: A potential substitute to traditional dressings | |
Yaşayan et al. | Natural polymers for wound dressing applications | |
Abudula et al. | Latest progress in electrospun nanofibers for wound healing applications | |
CN113599391A (en) | Application of carboxymethyl chitosan in promoting skin wound healing and repairing skin barrier | |
EP3823680B1 (en) | Nitric oxide producing collagen/orc dressing | |
Jin et al. | Multifunctional self-healing peptide hydrogel for wound healing | |
Zehra et al. | Electrospun bilayer membranes carrying bearberry/licorice extract to ameliorate wound healing | |
CN115737887A (en) | Skin wound dressing and preparation method thereof | |
WO2020261189A1 (en) | Collagen polysaccharide wound dressing |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20745303 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20745303 Country of ref document: EP Kind code of ref document: A1 |